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ABSIRAQI
TOWELLjA. BEHAVIOURAL ASSAYS OF THE EFFECTS OF ANTIDEPRESSANT 
DRUG TREATMENT ON THE FUNCTIONING OF CATECHOLAMINE SYSTEMS.
The e-ffects of antidepressant drugs on central beta-adrenergic 
and dopaminergic receptor function were investigated using the 
anorexic effects of low doses of amphetamine and apomorphine as 
assays of beta-adrenergic function and presynaptic dopamine 
function respectively. Anorexia was typically examined using a 
microstructural analysis of feeding, which was validated 
observationally.
Amphetamine anorexia was characterized by a decrease in eating 
time and an increase in eating rate. At 0.5 mg/kg both beta- 
adrenergic and dopaminergic antagonists reversed anorexic 
effects, whilst anorexia at 1.0 mg/kg was reversed by 
dopaminergic antagonists only. An enhancement of amphetamine 
anorexia was seen following acute desmethylimipramine treatment! 
this effect was exactly compensated for over chronic treatment, 
implying no net change at beta-adrenergic synapses. However, 
applying amphetamine intracranial 1 y showed that approximately 757. 
of the acute enhancement of amphetamine anorexia was mediated 
peripheral1y, suggesting an attenuation of beta—receptor function 
during chronic antidepressant drug treatment. Some further data 
suggested that an alpha-adrenergic change could also have 
contributed to the antidepressant drug-induced attenuation of 
anorex i a.
Low doses of apomorphine, specific for presynaptic dopamine 
receptors, induced an anorexia characterized by decreases in both 
eating time and eating rate. The dopamine receptor antagonists 
haloperidol and thioridazine reversed apomorphine anorexia by 
reversing eating time but not eating rate. Administration of 
apomorphine into nuclei A9 and AlO reduced total food intake and 
eating time but not eating rate. These findings imply that 
presynaptic dopamine receptors mediate the effects of apomorphine 
on eating time. Acute treatment with desmethylimipramine, 
enhanced apomorphine anorexia. During chronic treatment the 
apomorphine-induced reduction in eating time was sometimes 
attenuated, suggesting a presynaptic dopamine receptor 
subsensitivity. Anorexia was also enhanced following acute 
desmethylimipramine treatment with intracranial administration of 
apomorphine. Again, there was no clear evidence of 
subsensitivity following chronic treatment, but some evidence for 
subsensitivity in nucleus AlO during withdrawal.
The significance of a reduced beta-receptor function and an 
increased dopamine function following chronic antidepressant 
drug treatment are discussed in relation to the biological basis 
of depression.
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CHAPTER ONE
MONOAMINES AND DEPRESSION
1.1. INIBQDyÇîiON
In the 1950s, a biological orientation to depression was adopted 
by many, which was based on the observations that drugs used to 
treat other medical conditions such as tuberculosis and 
hypertension could either elevate or depress mood. The first 
clinical trials of the tricyclic anti depressant drug (TAD), 
imipramine, were reported in 1957 (Crane 1957; Loomer et al 1957) 
after which many new TADs were synthesized and made available for 
prescription. TADs are now amongst the most prescribed treatments 
for depression. However, despite the immense research initiative 
into the psychobiology of depression, there is still uncertainty 
over the exact mechanism by which TADs and other antidepressant 
drug (AD) treatments work.
The incidence of depressive disorders is known to have increased 
in western society over the past few decades (Uorld Health 
Organisation figures). This increase has been attributed 
partially to socio-economic factors, such as increased 
industrialization and the subsequent stresses it makes on our 
lives, and has also been partially attributed to the acceptance 
and acknowledgement of a role for medicine in psychological 
problems and mood disorders in our society. However, it is also 
clear that reports of an increase in the depressive disorders are 
at least in part dependent on the definition of depressive 
illness and the subsequent criteria used to diagnose such 
states.
1,2. DEFINIIIONS ANg CLASSIFICAIIONS
Clinically, the term depression can refer not just to a state of 
depressed or lowered mood, but to a syndrome which comprises mood 
disorder, psychomotor changes, and a variety of somatic and 
vegetative distirbances. These changes may all be present, but 
none, including depressed mood, is essential. In fact, according 
to DSM III, the third edition of the American Psychiatric 
Associations Diagnostic and Statistical Manual (1980), the only 
essential criterion to diagnose a major depression is that the 
syndrome be present for at least two weeks. This system therefore 
encompasses 'masked depressions' where the patient often 
satisfies certain criteria but will not admit to being unhappy. 
It has been claimed that the DSM III system is a classification 
system which describes the clinical features of affective 
disorders (and other psychiatric disorders) comprehensively and 
at "the lowest order of inference necessary to identify the 
disorder in a reliable way" (U, Malt 1983) thereby avoiding the 
criticism of diagnostic invalidity due to overcomplexity. Even 
at this level though, depression can be seen to take a variety of 
forms.
For the purposes of both treatment and research, it is necessary 
to decide when the emotional state of feeling depressed (which we 
all feel from time to time) changes into an abnormal clinical 
symptom. It is clear that internationally acceptable 
criteria are needed to diagnose depression and in so doing, to 
further classify the depressions into specific sub-groups.
categories or dimensions- reflecting its heterogenous nature. 
Some clinical taxonomies relevent to the scope of this thesis,
i.e. to the psychobiology of depression, will be discussed 
briefly. Such forms or subgroups of depression are based on 
symptomatic, familial and genetic characteristies, on biological 
measures or the therapeutic response or on outcome. It is worth 
noting that genetic, biological and outcome data are mainly used 
for research purposes and are not used routinely in clinical 
di agnosi s.
1.2.1. BIPÜLAR-UNIPOLAR
Two such subgroups characterized by these criteria are bipolar 
and unipolar depressions. These data are summarized in table 1. 
More recently, further subdivisions have been defined in bipolar 
illness (bipolar I, II and III) based on family history and the 
neccesity for hospitalization (Depue and Monroe 1979). The 
usefulness of this latter system has yet to be assessed 
clinically. It must be mentioned though that the unipolar—  
bipolar distinction does not necessarily reflect a dichotomy. 
The problem is that, unlike bipolar depressions, unipolar 
depressions are extremely heterogenous, and it may be possible 
that there are some unipolar diseases (endogenous, retarded; see 
1.2.3) which are not phenomenologically distinguishable from 
bipolar disease. However, the diagnostic criteria used by the 
bipolar-unipolar taxonomy yield a high degree of concordance 
amongst clinicians; these criteria, unfortunately, do not 
encompass all the syndromes of affective disease, rendering the 
unipolar-bipolar distinction ineffective as a global taxonomy.
S à B S J L
SONS MAJOR BIFTBLBKES REPORTED BBTWEQf BIPOLAR ASD URIPOLAR BEFRES8I0RS
BIPOLAR TJHIPOLAR AXnSOR
H isto x y  o f  B o n ia P o a l t i r o H o gatloo P a z z ia  ( 1 9 ^ )
F am ily  h ia to z y P o altiT O HogatiTO T a y lo r and ibzam a ( i9 6 0 )
Ago o f  o o o o t Tonngor O ldo r T a y lo r and ibzam a ( i9 6 0 )
Sox d lo tz ilm tlo n M alovFm aalo H alo  F o o m I o T a y lo r and Abzama ( i9 6 0 )
Hypomanio zosponoo to  
tx le y e l lo  a n tld o p M o sa n t 
dmiT ond l-4 o p a
P o aitlT O HogatiTO Bonnoy (1976) 
Itarp iiy  o t  111 ( 19 71)
A ntidopiroooaB t d zn ^  
rooponso to  U t h i i a  
ca rb o n a to
Good P oor T a y lo r and A brasa ( i9 6 0 )
P la to lo t  monoamiTio 
o z id aao  a o t i o l i y
B ooroaaod Hozmal G o z ^  o t  a l  ( 1979)
P ayehon o to r a e t l o i t y  
d o z in g  doptroaalT o op iaodo
HogatiTO P o aitiT O E o p fo r o t  a l  ( 1974)
1.2.2. PRIMARY-SECONDARY
This classi-f ication is based on the existence of a prior 
psychiatric history and was developed by Robins and Guze (1972) 
to define depression for research purposes. A primary depressive 
is a patient with an affective disorder who has had no pre­
existing diagnosable psychiatric illness other than depression or 
mania. In contrast, a secondary depressive is a patient with an 
affective disorder who has previously had or currently has 
another diagnosable psychiatric illness. As this system is based 
on chronology and not on clinical features of the depression, it 
does not necessarily follow that primary and secondary 
depressions differ. In fact they do not? patterns of symptoms do 
not differ between the two groups (Mood et al 1977). This system 
does not appear to be consistent with other systems (e.g. Spitzer 
et al 1980), the exception being that secondary depression is 
rarely seen in bipolar patients (Akiskal et al 1979).
1.2.3. ENDOGENOUS-REACTIVE
The endogenous-reactive distinction is based primarily on 
aetiology. Reactive depressions are associated with attributable 
environmental and psychological précipitants whilst endogenous 
depressions have no clear psychological precipitant.
Multivariate statistical procedures have consistently provided 
evidence in support of endogenous depression as a distinct 
diagnostic category (Charney and Nelson 1981). Endogenous 
depression corresponds to the DSM III diagnosis of major
depression with melancholia, which is defined as the inability to 
experience pleasure, together with three of the followings 
distinct quality of mood, excessive or inappropriate guilt, 
marked psychomotor change, anorexia, early morning awakening and 
having more severe symptoms in the morning.
In addition to producing evidence to isolate endogenous 
depression as a diagnostic category, a number of different 
multivariate techniques have also shown that the symptom most 
strongly associated with endogenous depression is psychomotor 
change, in particular retardation, rather than severity of 
depressed mood or lack of reactivity (Nelson and Charney 1981).
Biological markers also provide some support for the 
endogenous/non—endogenous distinction. The most widely used of 
these is the dexamethasone suppression test. Depressed people 
have elevated cortisol levels in plasma and cerebral spinal fluid 
(CSF), due to the failure of the brain to inhibit
adr enocor t i cotrophi c hormone release. Dexameth£|sone is a
synthetic corticosteroid, which suppresses adrenocorticotrophic 
hormone release. When dexamethasone is given to endogenously 
depressed patients, they usually show normal suppression of blood 
cortisol level. However, in depressed people, dexamethosone 
suppression of cortisol does not last as long as it does in 
normal controls. Depressed people therefore escape from 
suppression significantly earlier than normal. Escape from 
dexamethosone supprssion was seen in 43% of endogenous 
depressions, but only in 4% of non-endogenous depressions
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(Carroll 1982).
A second biological marker of importance is a decreased rapid eye 
movement sleep latency, defined as the latency from the onset of 
sleep to the first period of rapid eye movement sleep. Like the 
dexamethasone suppression test, this change also appears to be 
specific for endogenous depression (Akiskal 1980).
It is noteworthy that the term 'reactive’ was originally used in 
the context of depressions being 'reactive to treatment', as 
opposed to depressions being 'reactive to stress'; in this 
thesis the latter and more recent definition has been used. The 
endogenous-reactive distinction has also been used to encompass 
the psychotic/neurotic distinction which refers to clinical 
symptomatology, and the autonomous/reactive distinction which 
refers to the course of the depression (see Wiliner 1984, for a 
discussion of the current status of these distinctions). 
Multivariate analysis of symptomology supports the concept of
a psychotic depression, but not a diagnostically homogenous 
neurotic depression. This is consistent with the view of some 
authors that neurotic depression is what endogenous depressions 
are not (e.g. Foulds 1975).
The distinction between endogenous and reactive depressions has 
been questioned as both types of depression are equally likely to 
be prec eded by pschosocial stressors (e.g. Brown and Harris
1978). The apparent presence of précipitants in one group and
their absence in the other, has been explained by two artefacts 
of reporting! endogenous dépressives tend to underreport serious 
events as précipitants, because to some extent they see 
themselves as having been responsible, whilst reactive 
dépressives tend to over-report events as précipitants, which may 
appear to an observer as being rather trivial inconveniences 
which are not related to their depression (Willner 1984c).
The previous discussion, which has reviewed some of the various 
taxonomies currently in use, emphasizes the heterogenous nature 
of affective illness. What is required, then, is a global 
taxonomy that can encompass the various classifications without 
losing diagnostic validity. DSM III, through its multiple axes 
or dimensions, provides the most comprehensive and up to date 
taxonomy available.
1.3. IHE CASE FOR A BIOLOGICAL APPROACH IQ JHE IBiAIMENI AND 
iiyDY OF DEPRESSION
With the recent onset of cognitive psychotherapies (Beck et al 
1980; Kovacs 1980) that in some cases have proved as effective as 
some antidepressant drugs in the treatment of depression, it has 
become increasingly necessary to justify a biological approach to 
the research and treatment of depression. The starting point for 
such a justification is that although psychological and 
environmental factors are known to precipitate depressions to a 
great extent, the course of endogenous depression is subsequently 
largely independent of such factors. The exception being the 
claimed therapeutic treatment success of the cognitive
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psychotherapies mentioned above. Furthermore, therapies which 
selectively change monoamine transmission are known to be 
clinically e-ffective in the treatment of some depressions and 
therefore support a biological orientation towards depression. 
This finding is classically exemplified by the study of Klein and 
Davis (1969) who reviewed 65 reports comparing a number of 
tricyclic antidepressant drug (TAD) treatments and concluded that 
in approximately 007. of these reports TADs were more effective 
than placebos. Efficacy of the monoamine oxidase inhibitors 
(MAOIs) has generally been found to be less than that of the 
TADs, but these drugs may have specific indications in groups of 
atypical or hysterical depressions with prominent apathy and 
di scouragement (mixed anxiety depression), (Paykel 197.i) . 
However, these drugs are not favoured over the TADs because of 
the risk of hypertensive crisis and convulsions induced by 
reactions to diets, such as the 'cheese reaction'. Another 
antidepressant treatment, electro-convulsive tratment (ECT), has 
been shown to be at least as effective as TAD treatment in the 
treatment of affective disease. The main disadvantages of ECT 
over TADs are the side effects it produces (e.g. retrograde 
amnesia); these iatrogenic symptoms which were thought to be 
transient are now thought to be more permanent (Kendall 1981).
Although a small literature implicates acetylcholine in 
depression, and an even smaller literature implicates other non- 
monoaminergic transmitters, by far the most work has concentrated 
on the monoamines- noradrenaline (NA), dopamine (DA) and 
serotonin (5-HT).
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1.4. MONOAMINE HYPQIHESES OF DEPRESSION
1.4.1. THE CATECHOLAMINE HYPOTHESIS
The CA hypothesis of depression can be summarized by the 
proposition that depression resulted from a deficiency of NA at 
certain functionally important synapses in the CNS and that the 
action of AD treatments was to increase NA activity at these 
synapses (Bunney and Davis 1965; Schildkraut 1965). The 
hypothesis was attractive in that it provided an explanation of 
the pathogenesis of depression together with a proposed mechanism 
of action of the clinically effective TADs. It incorporated 
several lines of evidence» amongst thems~
(i) Reserpine (0.5 mg/day), used in the treatment of 
hypertension, induced a severe depression in 15-20% of patients 
receiving this drug, that was thought at the time to be 
clinically indistinguishable from ”true' clinical depression 
(Bunney and Davis 1965). This drug was postulated to cause 
depression via a depletion of functionally active CA systems
(Carlsson 1961).
(ii) Around the same time, iproniazed and isoniazid, drugs used 
to treat tuberculosis, were found to produce an elevation in 
mood, contrasting with the lowering of mood often accompanying 
such a chronic illness (Loomer et al 1957). These drugs were 
postulated to act via the inhibition of monoamine oxidase, and 
were assumed to increase monoamine transmission in the brain.
(iii) Amphetamine, a drug acting primarily by increasing synaptic 
CA levels, was effective in elevating mood in normal subjects
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(Lasagna et al 1955) and was thought to be an e-f-fective AD.
(iv) TADs were demonstrated to inhibit NA re-uptake into the 
presynaptic terminal, thereby enhancing NA transmission 
(Glowinski and Axelrod 1964).
(v) A -few years later, 3-methoxy-4-hydroxyphenyglycol (MHPB) , was 
identified as the main metabolite of noradrenaline in rat brain 
and subsequently in human CSF (Schanberg et al 1968). On the 
basis of metabolite levels, taken from a heterogenous sample of 
depressives. Schildkraut later proposed a system of diagnosis 
that encompassed a variety of postulated depressions, some of 
them being linked with schizophreniform symptoms (^ Schi 1 dkraut et 
al 1978).
The CA hypothesis was valuable in two ways. First, it afforded a 
parsinomous explanation of the treatment and pathogenesis of 
depression in terms of the role of NA; and, secondly, it proved 
to have immense heuristic value in that it could be readily 
tested, permitting focused biochemical, pharmacological and
clinical research.
1.4.2. THE DOPAMINE HYPOTHESIS
The CA hypothesis of depression was centred primarily on NA. 
Adrenalin, which was known to be poorly represented in the CNS 
(although more recent evidence would suggest established 
adrenalin pathways, Hokfelt et al 1978) gained little attention. 
DA, the precursor of NA, was not at that time (1965) widely 
accepted as a transmitter in its own right, and also gained 
little attention until the identification of its cell bodies and
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pathways by Ungerstedt in 1971 (see chapter 2, section 2.3.1). 
Emphasis was therefore directed away from DA in the formulation 
of the CA hypothesis, although its neurotransmitter potential was 
well recognised in other clinical and laboratory contexts 
(Hornkiewicz 1966).
In fact a substantial amount of evidence cited in support of the 
CA hypothesis can be used in favour of a DA hypothesis 
reserpine depletes DA by interfering with its storage (Carlsson 
et al 1957), monoamine oxidase inhibitors also protect DA from 
metabolism (Molinoff and Axelrod 1971), and in animals, 
amphetamine stimulation is blocked by DA antagonists such as 
pimozide but not by NA antagonists. Additionally, some depressed 
patients showed evidence of reduced central DA function as 
determined by homovanillic acid (HVA) concentrâtion in the CSF 
(Goodwin et al 1973), though this was proposed to mediate the 
motor retardation often seen in depressed people, and was thought 
to be a secondary characteristic of depression (Praag et al 
1971). However, TADs appeared not to block synaptic re-uptake of 
DA, except at relatively high doses. In consequence, DA did not 
gain much attention until Randrup et al (1975) published a review 
promoting a DA hypothesis of depression. This review cited 
evidence from a number of sources that DA depletion in people was 
associated with depression.
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1.4.3. THE SEROTONIN HYPOTHESIS
The possibility that serotonin <5-HT) is involved in depression 
was raised following the observation that reserpine-induced 
sedation in rats was found to be associated not only with 
decreased levels of NA and DA but also 5-HT (Carlsson 1961). 
However, weighing against an involvement of 5-HT, was the finding 
that the precursor of NA (L-DOPA) reversed reserpine-induced 
sedation whilst the precursor of 5-HT (5-HTP) did not (Carlsson 
1967). However, the additional observations that MAOIs 
also elevate 5-HT (Spector et al 1963) and that TADs block the 
uptake of both NA and 5-HT (Carlsson et al 1969) supported a 5-HT
hypothesi s.
Other lines of evidence have also suggested a role for 5-HT in 
the affective disorders. The earliest of these was probably the 
observation by Woolley and Shaw (1954), that 5-HT and LSD were 
structurally similar? they therefore speculated a role for 5-HT 
in the regulation of mood and associated disorders. In addition, 
the 5-HT precursor, tryptophan, was also thought to possess AD 
properties (Coppen et al 1963) and a reduction in 5-HIAA (5- 
hydroxyindoleacetic acid) in CSF was also observed (Ashcroft et 
al 1966) in a proportion of depressed patients and has 
subsequently been shown to be a consistent finding (Willner
1984c).
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1.5. AN EVALyeilON OF JME MONOAMINE HYPQIHESES
1.5.1. BIOCHEMISTRY
Shortly a-fter the -formulation o-f the monoamine hypotheses o-f 
depression, evidence began to emerge that was contrary to the 
predictions made by the hypotheses. A substantial amount o-f such 
evidence arose from biochemical studies attempting to measure 
levels of biogenic amines and their metabolites in blood, urine 
and spinal fluid of depressed patients. It has become
increasingly apparent, that the measure of a single metabolite in 
a sample is dependent upon drug regime, age, sex, length of 
illness, time of testing, diet and many other variables. Worse, 
these metabolite levels may not reflect whole brain monoamine 
levels or activity.
1.5.1.1. NORADRENALINE
The original NA hypothesis of depression implies lower rates of 
generation and output of NA metabolites in depressed patients. 
MHPG is thought to be the major central metabolite of NA (Maas 
and Landis 1968, Schanberg et al 1968). Studies of CSF MHPG in 
depression have given largely negative results. A reduction of 
□5P MHPG has been reported in depressed patients (e.g.
Subrahmanyam 1975), but others have failed to replicate this 
result (e.g. Berger et al 1980). However, it is possible that 
CSF measures of NA turnover may give a poor estimate of NA 
turnover in the brain (Bertillson et al 1982), whilst some 
peripheral measures of NA turnover might reflect central NA 
function better than lumbar CSF measures (Peyrin and Pequignot
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1983).
The actual proportion of urinary MHPG originating in the human 
CNS is controversial ; estimates vary between 20"/. (Blomberg et al
1980) and 80*/. (Ebert et al 1975). The usual finding in 
undifferentiated groups of depressed patients, or patients 
diagnosed as suffering from endogenous depression or primary 
affective disorder is a reduced excretion of MHPG (e.g. Puzynski 
et al 1980). A return to normal MHPG levels in patients who 
recovered from depression, but not in those who did not, has also 
been reported (Pickar et al 1978). MHPG excretion appears to be 
reduced during depressive episodes in some, but not all, bipolar 
patients (e.g. Beckman and Goodwin 1980) and in some unipolar 
patients (e.g. Pickar et al 1978). There appears also to be a 
group of unipolars in whom MHPG is abnormally high (Schildkraut
et al 1981).
There is also some evidence that MHPG levels can predict 
responsiveness to different TADs. It has also been suggested that 
pretreatment urinary MHPG excretion may be predictive of TAD 
response (Maas et al 1972, Schildkraut 1971). Low levels of MHPG 
were found predictive of response to imipramine or desipramine in 
one study (Mass et al 1972), while higher levels of MHPG 
correlated with an antidepressant response to amitryptx1ine in 
another study (Schildkraut et al 1971). Furthermore, patients 
with low pretreatment MHPG responded to a challenge with 
amphetamine with a brightening of mood, and either no change or a 
slight increases in MHPG. Patients with normal or high
17
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pretreatment levels of MHPG, when challenged with amphetamine, 
show reduced MHPG and no change in mood. On the basis of these 
findings, Maas has proposed two subtypes of depression, type A 
correlating with low MHPG and type B correlating with high MHPG. 
The type B findings have not been consistently replicated (e.g. 
Maas et al 1982; Mendewicz et al 1982), whilst the type A 
findings have proven to be more robust (e.g. Maas et al 1982; 
Schatzberg et al 1980).
1.5.1.2. DOPAMINE
Biochemical studies of DA turnover seem to be more consistent in 
that decreased concentrations of HVA are usually found in the CSF 
of depressed patients (e.g. Banki 1977), although this has not 
always been reported (e.g. Berger 1980). Probenecid blocks the 
active transport of organic acid metabolites such as HVA out of 
the CSF and thereby raises relative concentrâtions. Use of this 
drug has yielded the more consistent finding of decreased CSF HVA 
accumulation in some or all depressed patients (e.g. Berger 
1980). Decreased post-probenecid CSF HVA accummulation is a 
particularly consistent finding in depressed patients with 
psychomotor retardation as a symptom (Banki 1977, Willner 1983ij .
1.5.1.3. SEROTONIN
There have been several studies on the concentration of the 5—HT 
metabolite 5-HIAA in the cerebro-spinal fluid. Although there is 
some argument as to the significance of cerebro—spinal fluid 5— 
HIAA levels (Curzon et al 1971, Ashcroft et al 1973), it is
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generally thought that decreased brain 5-HT turnover is indicated 
by low lumbar CSF concentrations of its metabolite, 5-HIAA, which 
have been reported in many studies (e«g> Curzon et al 1980) 
although a few disagree (e.g. Berger et al 1980). Low lumbar 
cerebr0“spinal fluid values probably indicate that 5~HT turnover 
is low in part of the nervous system only, as ventricular CSF 5- 
HIAA appears normal (Curzon 1980). The disagreements on lumbar 
5-HIAA values may derive from differences in patient selection as 
Asberg et al (1976) found that values were distributed bimodally. 
Low values correlate highly with suicidal and violent behaviour. 
This suggests that the abnormality of 5-HT metabolism could be 
causally related to symptomatology. These data therefore support 
a classical indoleamine hypothesis of depression in some 
patients.
1.5.2. PHARMACOLOGY - NORADRENALINE, DOPAMINE AND SEROTONIN 
Body fluid assessment and measuring of monoamine function are 
rather inconsistent, and in any case hard to interpret in terms 
of brain biochemistry. This is mainly due to methodological 
problems and to the fact that depression may be biochemically 
heterogenous. Therefore, it is difficult to evaluate the
original monoamine hypotheses from these studies, with the 
possible exception of the DA hypothesis. This hypothesis would 
tend to be supported from the biochemical studies reviewed, at 
least in the case of depressions with psychomotor retardation as
a symptom.
Extensive pharmacological studies have been carried out in both
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animals and man involving manipulations of biogenic amine levels 
in an effort to evaluate the original hypothesis. Drugs which 
increase functional monoamine levels in the brain should 
alleviate depression, whilst treatments which reduce monoamine 
levels should exacerbate depression.
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A major challenge to the monoamine hypothesis came from a re­
appraisal of the original reserpine results which concluded that 
the majority of cases of depression reported were actually a 
’pseudo—depress!on^ syndrome of sedation and lethargy. The 
actual incidence of true depressions during reserpine 
administration was thought to be around only 5/ to 9%, with the 
majority of these cases having a prior history to the disease 
(Goodwin et al 1972). Furthermore, reserpine given to animals 
induces a psychomotor retardation that can be reversed by 1-dopa; 
however, 1-dopa given to depressed patients induces psychomotor 
activation but seems to have no AD properties (Goodwin 1972).
■ i
Like reserpine, alpha—methyl—para—tyrosine (AMPT), which inhibits 
the rate-1imiting step in the synthesis of DA and NA, should also 
exacerbate depression if the CA hypothesis is correct, but no 
consistent findings have emerged from these studies (Mendels and 
Fraser 1974). Clearly, therefore, treatments which reduce CA 
levels do not necessarily cause depression in humans.
As stated earlier, it would be predicted that drugs which 
increase CA levels, such as amphetamine, should alleviate
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depression. Amphetamine has not been shown to be an effective 
AD> rather, it increases motor activity and by doing so 
alleviates some of the symptoms associated with depression. 
Furthermore, cocaine, another psychostimulant drug which acts in 
part via CA re-uptake blockade (the same supposed mechanism as 
TADs), also appears not to be an effective AD. Similar findings 
have also emerged from studies using 1—dopa as a drug therapy 
(Goodwin et al 1970). These studies therefore do not support the 
original hypothesis. More recent studies, though, using the 
directly acting DA receptor agonists bromocryptine and piribedil, 
have indicated that such drugs have AD properties (e.g. Waehrens 
et al 1981, Reus et al 1980).
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If brain 5-HT deficiency has a causal role in depression, then 
treatments which increase 5—HT synthesis or increase responses 
dependent on 5-HT should have a therapeutic effect. When 
tryptophan is given alone, varied results are obtained; though 
it is generally found that tryptophan potentiates other ADs, such 
as MAOIs (Coppen et al 1963) and the 5-HT re-uptake blocker 
clorimipramine (Walinder et al 1976). Tryptophan availability can 
be measured in at least two different ways, and it is generally 
thought that free rather than total tryptophan (free and albumin- 
bound) in plasma influences the availability of tryptophan to the 
brain. This in turn influences synthesis and, in some 
circumstances, functional activity of 5-HT (Kennett and Joseph
1981). Low levels of free tryptophan in plasma have been found 
in some groups of patients (e.g. Burns and MendelIs 1979) though 
not in others (e.g. Moller et al 1979).
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Studies wih the other 5-HT precursor, 5-hydroxy-L~trytophan (5- 
HTP) , at -first showed it to be ine-ffective as an AD treatment 
(e.g. Glassman 1969). However, more recent studies, using larger 
doses o-f 5-HTP have given more positive results (e.g. Van Praag 
1983) and would tend to support a classic indoleamine hypothesis 
o-f depression.
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The conventional ly assumed pharmacological mechanism o-f TADs 
(reuptake blockade) has also been questioned. This problem was 
highlighted with the introduction of two 'atypical' ADs, 
mianserin and iprindole, which were shown to possess therapeutic 
properties, but were relatively ineffective at uptake blockade at 
monoaminergic synapses (Gluckman and Baum 1969; Randrup and 
Braestrup 1977; Zis and Goodwin 1979). Moreover, as the clinical 
effects of TADs usually take between two to four weeks to become 
apparent, beginning in the mid~1970s, many workers suggested that 
amine uptake blockade, which occurs immediately, may not be the 
mechanism of clinical action of TADs. This viewpoint may be 
rather premature, as it has been claimed that intravenous (i.v.) 
administration of TADs can show a therapeutic response as early 
as the second day of treatment (e.g. Becker 1971). Nevertheless, 
the long latency in the therapeutic response during TAD therapy 
had a profound influence on research. Attention was shifted from 
acute to chronic studies.
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1.6. ÎHE REVISED NA HYPQIHESIS
When the shi-ft away -from acute towards chronic studies began, it 
became evident that chronic TAD treatment actually reduced some 
aspects o-f NA function, shown for example by the development of 
beta receptor sub^ensitivity at NA synapses. A reduction in NA 
function following chronic TAD treatmentis a finding inconsistent 
with the original NA hypothesis (Schildkraut et al 1970, Segal et 
al 1974). On the basis of these observâtions, Segal et al (1974) 
proposed an NA hypothesis of depression, which was diametrically 
opposed to the original hypothesis; i.e. that depression resulted 
from an overstimulation of NA receptors which was corrected by 
chronic TAD treatment. The fact that certain subpopulations of 
patients showed a reduced MHPG excretion, which was originally 
reported in support of the 'too little' hypothesis, was now 
explained in terms of postsynaptic supersensitivity at NA 
synapses. This resulting overstimulation brought into play a 
negative feedback mechanism, which reduced the activity of NA 
neurones, causing a decrease in NA synthesis, and the observed 
reduction in MHPG excretion. It was further postulated that this 
mechanism could only partially compensate for the supersensitive 
receptors, and the system still remained in a state of 
overstimulation. The effect of tricyclics would be to increase 
receptor stimulation once more, which would further activate the 
negative feedback system, and, finally, reduce the activity of NA 
neurons sufficiently to compensate fully for abnormal receptor 
activity (Segal et al 1974, Mandel et al 1975). This proposed 
mechanism of TAD action accords with the adaptive processes of
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the brain and the role o-f receptors in mediating these processes. 
It. is therefore the effects of AD treatments on monoamine 
receptors which will now be reviewed with a view to gaining 
further insight into the psychobiology of depression.
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1.7. ANIIDEPRESSANI DRUGS AND NORADRENALINE 
1.7.1. ACUTE EFFECTS
One of the best documented effects of acute TAD treatment is to 
block NA re-uptake into the pre-synaptic cleft. Although all the 
tricyclic antidepressant drugs are very similar in structure, 
they can be usefully classified by the type of amine on their 
side chain (tertiary or secondary). Furthermore, secondary TADs 
(e.g. desethylimipramine) are more potent uptake blockers than 
the tertiary TADs (e.g. amitriptyline), (Maitre et al 1982). One 
cQnseguence of NA uptake blockade is the stimulation of 
inhibitory presynaptic alpha 2 autoreceptors, which results in a 
decrease in firing rate (McMillan et al 1980) and NA turnover 
(Rosloff and Davis 1978). Therefore, TADs have two opposing 
synaptic effects - inhibition of uptake and decreased turnover. 
The net result as revealed by electrophysiological recording is 
an increase in adrenergic transmission at post-synaptic beta 
receptor sites (e.g. Huang 1979). At alpha receptors, however, 
the picture is less clear, since in addition to the effects 
already described, TADs also act as post-synaptic alpha-receptor 
antagonists (Brown et al 1980). Secondary TADs tend to enhance 
alpha adrenergic transmission, as do with tertiary TADs at low 
doses; on the other hand, tertiary TADs at high doses tend to
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block transmission (Menkes and Aghajanian 1981).
=• Atypical' TADs, which do not block re-uptake, have nevertheless 
been shown to potentiate adrenergic transmission through a 
variety of mechanisms. For instance, mianserin is a potent 
antagonist at presynaptic alpha 2 receptors (Maggi et al 1980) 
and consequently increases NA turnover (Sugrue 1980). Iprindole, 
which is comparable to DMI and imipramine in clinical potency 
(Bradshpw et al 1974), seems to be devoid of effects on NA uptake 
or turnover (Rosloff and Davis 1974), but it has been shown to 
potentiate the electrophysiological effects of iontophoretical 1 y 
applied NA (Sevan et al 1975).
1.7.2. CHRONIC EFFECTS
The effect of chronic TAD treatment on presynaptic receptors has 
been assessed by observing concurrent changes in clonidine- 
induced sedation, a supposed index of presynaptic receptor 
function (Drew et al 1979). Desensitization of alpha-2 
autoreceptors following chronic TAD treatment is an effect 
observed with a number of AD treatments (Kostowski et al 1983) 
including ECT and REM sleep deprivation, although there are some 
exceptions (e.g. Bhavsar et al 1981, 1983). Presynaptic alpha-2
receptor desensitization has also been demonstrated in depressed 
patients receiving amitriptyline (Charney et al 1983). However, 
receptor binding studies do not confirm these findings. Binding 
measures of presynaptic adrenergic receptors are usually
increased or unchanged by chronic AD treatment (see Willner
1984c). The development of autoreceptor subsensitivity during
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chronic AD treatment results in an enhancement of NA turnover, as 
measured by the production of MHPG (e.g. Rof-fman et al 1977). 
The increase in release, together with the acute adrenergic 
facilitation effects of TADs result in an increased stimulation 
of post-synaptic recep*-ors.
Chronic TADs r.ave variable effects on post-synaptic alpha-2 
receptors, making it difficult to draw any conclusions (Willner 
1984c). In contrast, chronic TAD treatment increases the 
functional efficacy of the more numerous post-synaptic alpha-1 
receptors as indexed by clonidine stimulation of locomotor 
activity (Modigh 1975, Maj et al 1979). This effect has also 
been reported following repeated electroconvulsive shock (Ehlers 
et al 1983) and has been confirmed electrophysiological 1 y (e.g. 
Menkes and Aghajanian 1981). As before, receptor binding studies 
do not confirm an enhancement of alpha—1 transmission, probably 
due to difficulties inherent in binding methodology (Menkes et al 
1983).
The most widely reported effect of chronic TAD treatment and most 
other AD treatments, is a decrease in beta-receptor sensitivity, 
^2sessed by the ability of NA to stimulate cAMP production, a 
beta-receptor mediated response (Vetulani and Sulser 1975). This 
decrease in functional sensitivity of beta-receptors is 
accompanied, in most cases, by a reduction in cortical beta 
receptor binding (Banerjee et al 1977).
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In order for a 'too much' hypothesis of depression to work, it is 
insufficient that the changes at beta-receptors merely compensate 
for acute AD-induced increases in NA transmission, they must 
actually over-compensate. If they do not, the net result will 
still be an increase in NA transmission rather than a decrease. 
So a simple reduction in binding, for instance, cannot be used as 
evidence to support the 'too much' hypothesis. On the other 
hand, although, electrophysiological evidence was used to support 
a reduced beta—receptor function (Schultz et al 19B1), due to a 
shift in baseline firing rate this evidence is inconclusive. 
Without a steady baseline firing rate, it is impossible to 
interpret the effects of iontophoretical 1y applied NA. Evidence 
showing an increase in baseline firing rate following chronic DMI 
treatment, in support of a decrease in beta—adrenergic function 
is therefore controversial. In fact, only one study shows an 
increase (Huang 1979) and most others show no change, with a 
variety of AD treatments (e.g. De Montigny et al 1981; see 
section 5.1.). A major focus of this thesis will be to assess 
beta—receptor subsensitivity using behavioural technigues.
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1.8. ANIIDEPRESSANI DRUGS AND DOPAMINE 
1.8.1. ACUTE EFFECTS
Although originally believed not to affect DA, it now appears 
that ADs do block DA uptake, although less potently than that of 
NA and 5-HT (Hytell 1978). However, many TADs are also DA 
receptor antagonists. Therefore, depending on which of these two 
effects predominate, some TADs enhance DA function, others 
decrease DA function, whilst a third group show no consistent
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change (Carlsson and Lindquist 1978).
1.8.2. CHRONIC EFFECTS
Behavioural studies point to a -functional increase in DA activity 
following chronic AD treatment. In particular, the mesolimbic DA 
system has been found to be sensitive to TAD induced
facilitation, as indexed by an enhancement of the locomotor 
stimulant effects of apomorphine (e.g. Green et al 1981), 
amphetamine (Wielosz 1981), and a number of other
psychostimulants -all known to reflect mesolimbic activity at 
the moderate doses used (e.g. Kelly et al 1975» Pijnenberg et al 
1973). The addition of the striato-nigral feedback loop in the 
nigrostriatal DA system, which provides a homeostatic regulation 
to this system, may well be reflected in the relative lack of 
enhancement of psychostimulant-induced stereotypy following 
chronic AD treatment (Willner 1983c).
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Biochemical studies do not provide evidence tor an increased 
responsiveness to post-synaptic DA receptors following chronic AD 
treatments. Binding of spiroperidol, assumed to label post- 
synaptic DA receptors, shows no change following chronic AD 
treatments (e.g. Bergstrom et al 1979, Rosenblatt et al 1979). 
However, as mentioned earlier, the relevance of binding 
techniques to measure physiological properties of receptors has 
been questioned (Menkes et al 1983). Electrophysiological 
studies have not yet been carried out which directly address this 
question. So if one were to reach a conclusion solely from 
biochemical evidence, it would have to be that chronic AD
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treatment does not increase the sensitivity of post-synaptic DA
receptors. However, DA receptor agonists, including apomorphine,
when injected into the nucleus accumbens following chronic TAD
treatment, do enhance DA activity (indexed by locomotor 
H€a I et 0.1activity^. This would suggest that behavioural stimulation by 
the action of apomorphine following TAD treatment is mediated 
postsynaptically.
It is, however, also possible that the TAD-induced increase in 
DA responsiveness has a presynaptic contribution. Chronic 
treatment with TADs does not appear to affect DA synthesis or 
turnover, measured by accummul ation of the DA metabolites 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) 
(Sugrue 1980). However, evidence is accumulating that chronic AD 
treatments may desensitize DA autoreceptors. The sedative
effects of low doses of apomorphine are thought to be dependent 
on DA autoreceptor stimulation. Serra et al (1979) first 
demonstrated that apomorphine-induced sedation was reversed by 
chronic amitriptyline, imipramine and mianserin <10 days) 
treatment but not by acute treatment with these drugs. This 
autoreceptor desensitization effect has been demonstrated with a 
range of other TAD treatments (Zebrowska-Lupina et al 1980) as 
well as treatment with MAOIs, ECS (Serra et al 1981) and lithium
(Harrison-Read 1980).
The effect has also been demonstrated electrophysiologically as 
shown by a reduction of the inhibitory effect of a low dose of
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apomorphine on DA cell -firing (Chiodo and Antelman 1980a,b>. It 
has also been shown biochemically by blocking the apomorphine- 
induced inhibition of DA release as measured by the accumulation 
of the DA metabolite DOPAC (Serra et al 1979). In fact Chiodo 
and Antelman (1980b) observed more than a reduction in
apomorphine-induced inhibition of DA cell firings following 
chronic imipramine or amitriptyline treatment, they observed 
excitation/(in approximately 25-50% of the cells they studied. It 
was suggested that this progressive switch in cell firing effect 
might potentially explain the shift from hypomania to mania, 
sometimes seen in bipolar depressed patients receiving TAD
treatment. In support of DA autoreceptor subsensitivity are the 
findings that the actual number of active DA cells in A9 and AlO 
areas increased following chronic DMI treatment (Chiodo and 
Bunney 1982). In addition, autoreceptor subsensitivity appears 
to depend simply on the passage of time, as opposed to repeated 
drug treatment: a similar degree of autoreceptor subsensitivity
was seen 10 days after 2 days of imipramine treatment as compared 
to 2 days after 10 days of treatment (Chiodo and Antelman 1980c). 
Similar results were also obtained with ECS (Antelman et al
1982).
However, subsequent studies have shown that autoreceptor 
subsensitivity is not as robust an effect as it first seemed.
Spyraki and Fibiger (1981) and Chiodo et al (1983) were unable to
demonstrate attenuation of apomorphine-induced sedation after 
chronic TAD treatment. No change in apomorphine-induced
inhibition of DA synthesis has also been reported following
chronic TAD treatment (Holcombe et al 1982). These findings do 
not support the hypothesis of a DA autoreceptor mediation of TAD 
therapy. This topic, which is the second major issue addressed 
in this thesis, will be examined in chapters 6, 7 and 8.
1.9. ANIIDEPRESSANI DRUGS AND SEROIQNIN 
1.9.1. ACUTE
Acute tricyclics have generally been found to block 5-HT uptake, 
with the exception of the atypical AD and some typical tricyclics 
such as DMI, which are relatively weak at uptake blockade (Maitre 
et al 1982). In addition, firing rate of 5-HT containing cells 
in the raphe nuclei, and rate of synthesis and turnover are 
reduced following acute AD treatment. These effects are
proportional to the blockade of 5-HT uptake and are therefore 
probably mediated by autoreceptors (Carlsson and Lindquist 1978, 
De Montigny et al 1981). Post-synaptic receptor blockade is also 
a property of many TADs. Post-synaptic function appears to be 
enhanced by zimelidine (a specific 5-HT uptake inhibitor with AD 
properties) on a variety of measures including potentiation of 5- 
HTP stimulation of locomotor activity (Buus Lassen 1978). 
Mianserin, on the other hand, appears to have the reverse effect 
- showing an attenuation of post-synaptic function, as measured 
by a reduction of 5-HTP induced behavioural arousal (Gold et al
1980) for example.
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ySuppression of 5-HTP~induced arousal following mianserin appears 
to be mediated by blockade of post-synaptic 5-HT receptors, in 
particular the 5-HT2 receptors, which bind mianserin with high 
affinity (Barbacchia et al 1983). Therefore, in considering the 
net effect of acute AD on 5—HT transmission, blockade of post 
synaptic receptors must be set against the increase in receptor 
bombardment brought about by uptake blockade. The fact that many 
ADs show some degree of blockade of 5-HT receptors, which seem to 
predominate over their 5-HT enhancing effects, has been used as 
evidence to support the hypothesis that some depressions may be a 
reflection of hyperactive 5-HT mechanisms - a 'too little' 
hypothesis <Aprison et al 1982). However, the affinity of AD for 
5_HT2 receptors is less than that of traditional 5-HT blockers 
(Peroutka and Snyder 1982)5 furthermore, spiroperidol, which has 
the highest affinity for 5-HT2 receptors, seems to have no AD 
properties. Therefore, blockade of post-synaptic 5-HT2 receptors 
cannot be used as evidence for the 'too little' hypothesis, as 
this mechanism does not seem to mediate the therapeutic response
of AD.
1.9.2. CHRONIC EFFECTS
Chronic AD treatment seems to have no effect on autoreceptor 
desensitization as measured electrophysioiogically (e.g. Svensson 
1980). A single unit recording study did however find a recovery 
on the number of normally active raphe cells following chronic 
zimelidine treatment; this change was associated with a decrease 
in autoreceptor sensitivity to LSD (which is a selective 5-HT
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}autoreceptor agonist at low doses) (Blier and Demontigny 1982).
A decrease in 5—HT uptake in rat brain has been reported
following chronic ECT (Minchin et al 1983), though no change was
seen with a variety of other AD (Segawa et al 1982). Chronic TADs
and ECT (e.g. Langer et al 1981) decrease imipramine
binding. Imipramine is thought to bind to a site closely
associated with 5-HT specific uptake sites. Mianserin and
iprindole do not produce these changes in imipramine binding.
The effects of chronic TAD treatment on turnover seem to be
sr/»a|A/to their acute effects, i.e. DMI has no effect on 
turnover, whilst zimelidine decreases turnover (e.g. Sugrue 1980, 
see section 1.9.1). To summarize, most treatments enhance 
presynaptic 5-HT function by reducing 5-HT uptake, the exception 
being mianserin and iprindole.
The post-synaptic response to iontophoretical 1y applied 5-HT 
following chronic TADs, iprindole and ECT is enhanced in 
subcortical structures only (Willner 19840. Behavioural evidence 
also indicates an increased responsiveness of 5-HT receptors 
following chronic AD treatment. In particular ECT, as indicated, 
for example, by an increase in 5-HTP induced head twitches 
(Lebrecht and Nowak 1980). Evidence from studies employing other 
AD is less clear, mainly due to methodological inconsistencies 
such as the dose of drug used, the duration of treatment and the 
latency to testing following treatment. Powerful inhibitors of 
uptake such as zimelidine have been found in different studies to 
reduce and to enhance 5-HTP-induced behaviours over chronic
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treatment. TADs and atypical AD are usually reported to enhance 
5-HT receptor -function (e.g. De Montigny and Aghajamian 1978). 
The enhancement of 5-HT transmission observed with the uptake 
inhibitors and TADs is time dependent, becoming apparent several 
hours after treatment (withdrawal). This finding would seem to 
have important implications for the clinical setting and would 
merit further investigation.
Binding studies show that chronic AD treatments do not, in 
general, change 5-HTl receptor binding (Lucki and Frazer 1902). 
In contrast, chronic AD treatments reduce the binding of 3H- 
spiroperidol to 5-HT2 receptors, although some regional 
differences have been reported (Fuxe et al 1982). This effect of 
ADs on 5-HT2 binding seems quite specific (e.g. Peroutka and 
Snyder 1980) although amphetamine shares this effect, a 
treatment which has no AD potential when administered chronically 
(Nielsen et al 1980). However, ECS has the opposite effect, i.e. 
It increases the number of 5-HT2 receptors (Vetulani et al 1981). 
This finding makes it extremely unlikely that changes in 5-HT2 
receptor binding mediate the clinical effects of AD - a 
conclusion reached earlier in this review.
In summary, the evidence reviewed in this section would,^support 
the original indoleamine hypothesis of depression, that 
depression arises from ’too little’ S-HT and that AD treatments
increase 5-HT function.
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1.10. DISCUSSION
From th© previous sections on AD and monoamines, it will be 
apparent that the results o-f receptor binding studies are 
generally inconsistent with those obtained by 
electrophysiological and behavioural methods. Given that binding 
studies represent a 'static=' assessment o-F any one aspect o-f 
synaptic function, these generally discrepant data will be 
disregarded and emphasis will be directed towards functional 
measures of synaptic function i.e. electrophysiological, 
neuroendocrine and behavioural measures.
The problem that arises, is to decide in which direction the 
overall -functioning of a system changes following chronic AD 
treatment, and to relate this increase or decrease in potentially 
multi-synaptic functioning to a particular monoamine hypothesis 
of depression. This thesis addresses these problems in relation 
to NA- and DA- mediated mechanisms.
1•11• an ex ce ss noradrenaline hypqihesis
For a 'too much’ hypothesis of depression to be plausible. beta- 
receptor subsensitivity must not merely compensate for acute AD- 
induced increases in NA transmission, but it must actually over­
compensate. The net result will then be a decrease in NA 
transmission. Evidence for a reduction of beta-receptor function 
to overcompensate for the acute AD-induced enhancement of beta- 
receptor function is controversial. Receptor binding studies 
cannot provide evidence to answer this question. whilst only one 
electrophysiological study supports an overcompensation of beta-
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receptor function following chronic AD treatment (see section
5.1. for a more detailed discussion of this evidence).
Attempts to assess beta—adrenergic function via behavioural 
methods have been hampered by the fact that there are no models 
which precisely reflect beta-adrenergic receptor stimulation. 
One such attempt to model beta-receptor function utilized the 
dorsal bundle extinction effect (DBEE), which is thought to 
reflect a decrease in beta-adrenergic function during resistance 
to extinction. During chronic DMI treatment, in three different 
behavioural paradigms, no increase in resistance to extinction 
was seen except when the animals were tested during withdrawal 
(Montgomery and Wiliner 1980, Wiliner et al 1981). These results 
would suggest that beta-receptor subsensitivity is unmasked by 
withdrawing DMI, and simply compensates for the acute NA 
enhancing effects of the drug. However, resistance to extinction 
only appears when dorsal bundle lesions are made prior to 
acquisition (Mason and Fibiger 1979). It follows that if chronic 
DMI treatment- is mimicking a functional lesion of the dorsal NA 
bundle, resistance to extinction should be observed only when 
animals are treated during acquisition.
We carried out an experiment to test this hypothesis (Willner and 
Towell 1902a). Rats were trained to press a lever -for -food 
rewards, then given a five-week break. Animals which received 14 
daily DMI injections, ending 4 days before the extinction 
session, showed resistance to extinction! but no effect was seen
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in animals which received DMI during acquisition. These results 
show that resistance to extinction induced by DMI is probably not 
mediated by changes in the e-fiicacy of the dorsal NA bundle, and 
this behaviour cannot therefore be used with confidence to assay 
NA function.
A second behavioural assay approach relies on the anorexic 
effects of small doses of amphetamine on food intake; an effect 
known to have a beta-adrenergic component (e.g. Leibowitz 1975, 
see chapter 2, section 2.7.). As in the DBEE experiments, 
attenuation of amphetamine anorexia was only observed during 
withdrawal from DMI or iprindole, but not during the course of 
chronic treatment (Willner and Montgomery 1980, 1981, Willner, 
Towell and Montgomery 1984). Taken together, the simplest 
conclusion to be drawn from the biochemical, electrophysiological 
and behavioural studies of beta-adrenergic function during 
chronic antidepressant treatment is that changes in receptor 
function simply act to restore NA systems to pre-drug levels
rather than to decrease them.
Interpretation of these behavioural 
results is complicated by the fact that some ADs inhibit the 
metabolism of amphetamine <see chapter 5, experiment S). 
However, mianserin, which does not have this effect did attenuate 
amphetamine anorexia during the course of chronic treatment 
(Willner, Towel! and Montgomery 19B4), suggesting a decrease in
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beta-adrenergic function. However, since an alpha—adrenergic 
system stimulates feeding (see chapter 2, section 2.5.2.1), 
changes in amphetamine anorexia might equally well represent an 
increase in alpha-adrenergic function. This problem forms the 
subject of chapter 5, experiment 6.
1.12. A DOPAMINE DEFIQII HYPQIHESIS
The hypothesis that chronic AD treatments increase DA 
transmission has been reviewed in section 1.8.2. and would 
appear to be supported by the behavioural evidence. However, the 
mechanism of this enhancement of transmission is uncertain. 
Furthermore, although primarily the mesolimbic pathway has been 
implicated in depression, controversy has developed over which DA 
pathways are affected by AD, and whether these changes are 
mediated pre- or post—synaptical 1y.
Low doses of apomorphine have been shown to be selective for 
presynaptic DA receptors and to produce behavioural sedation. We 
have observed that low doses of apomorphine (0.05 mg/kg) produce 
a marked and reliable anorexia (chapter 6). Apomorphine anorexia 
was therefore used as a model to index autoreceptor function 
(chapter 6), and the effects of chronic DMI treatment on this 
model were also tested (chapter 7). Furthermore, the 
contribution of nigrostriatal and mesolimbic pathways towards 
mediating autoreceptor function were assessed in studies using 
central administration of apomorphine (chapter 7).
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CHAPTER TWO
QAIEChqlamines and feeding
2.1. INIRQDUCIIQN
To understand the mechanism o-f action o-f drugs which cause loss 
of appetite, such as amphetamine, it is necessary to understand 
how the brain produces hunger and satiety, and how the 
experiential and psychological states that follow such changes 
relate to feeding behaviour. This analysis of anorexic drug 
action spans across several domains of explanation such as the 
biochemical, physiological, cognitive and experiential. As the 
main thrust of this thesis is to develop behavioural assays of 
synaptic function in rodents through the use of pharmacological 
probes, such as amphetamine or apomorphine, it is possible to 
ignore the cognitive and experiential levels of explanation and 
concentrate on the biochemical and physiological levels.
2.2. IHE EARLY WORK
The earlier studies concerned with elucidating the mechanisms 
involved in feeding behaviour correlated gross electrolytic 
lesions with changes in food intake. Hetherington and Ranson 
(1940) demonstrated that electrolytical 1y induced ventromedial 
hypothalamic (VMH) lesions produced hyperphagia and obesity; 
Anand and Brobeck (1951) showed that lesions to the lateral 
hypothalamus (LH) produced aphagia and adipsia. These studies 
have been successfully replicated and have received further 
support from electrical brain stimulation investigations: 
electrical stimulation in the LH elicits feeding or drinking 
(Miller 1960), whereas electrical stimulation of the VMH blocks
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ongoing ingestive behaviour in deprived animals (e.g. Scla-fani 
and Maul 1974).
At the onset o-f the neurochemical era, Grossman and colleagues 
amongst others (in the 60's) set about to examine how the LH and 
^^|v||_| syndromes were mediated. This early work on the 
neurochemistry of feeding demonstrated that stimulation of 
adrenergic receptors within the hyothalamus resulted in feeding 
(e.g. Booth 1967). Briefly, this work eventually led to the 
hypothesis that alpha adrenergic stimulation in the
paraventricular nucleus (PON) led to feeding and beta-adrenergic 
stimulation in the perifornical hypothalamus (PFH) led to 
satiety. This literature is reviewed later in the chapter. 
However, the simplicity of this 'neurochemical' hypothesis has 
been questioned on anatomical as well as behavioural grounds. 
Therefore, in order to evaluate the 'neurochemical' hypothesis a 
brief review of CA neuroanatomy will follow. It should be noted 
that the neurochemical hypothesis of alpha adrenergic feeding in 
the PVN and beta adrenergic satiety in the FFH is distinct from 
the clasical two centre hypothesis of LH feeding and VMH satiety.
2.3. ANAIQMY OF CA SYSIEMS
The mapping oT CA pathways in the CNS was made possible by the 
development o-f histo-f luorescence techniques such as the 
formaldehyde (Falck et al 1962) and glyoxylic acid (Lindvall and 
Bjorklund 1974) methods, which have allowed cell bodies and 
terminal areas to be readily visualized in detail. These methods
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' Dn have been used in conjunction with potentially transmitter- 
speci-fic” neurochemical lesion techniques (such as 6-OHDA) to 
■further classify CA pathways.
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2.3.1. DOPAMINE
The CA axons arise from a series of cell bodies that were 
designated A1 to A12 by Dahlstrom and Fuxe (1964). Of these cell 
groups, AS, A9, AlO, and A12 are dopaminergic. They give rise to 
three major pathways as defined by Ungerstedt (1971): (1) the
nigro-striatal system (AS, A9) which terminates in the caudate 
nucleus, (2) the mesolimbic system (AlO) which terminates in the 
nucleus accumbens and (3) the tuberoinfundibular system (A12). 
Unlike the nigrostriatal and mesolimbic systems the
tuberoinfundibular system has not been directly implicated in 
behaviour. These systems have been re-classified by some to 
include the well established cortical projections of the DA 
systems - particularly the mesocortical system which emanates 
from AlO, passes through the nucleus accumbens and terminates in 
the frontal cortex (Lindvall and Bjorklund 1978).
2.3.2. NORADRENALINE
The anatomy of NA systems as identified by Ungerstedt (1971), 
sing the histof1uorescence method comprises two major pathways.u
(i) Ventral noradrenergic bundle(VNAB). This arises from cell 
groups Al, A2, AS and A7 in the medulla oblongata and pons and
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innervates the whole hypothalamus and several major terminal 
region of the mesencephalon.
(ii) Dorsal noradrenergic bundle (DNAB). This originates in the 
locus coeruleus (A6). The fibres ascend in the medial forebrain 
bundle to innervate the geniculate body, thalamic nuclei, the 
hippocampus and cortex. The cortical projections of the locus 
coeruleus have been found to have the highest fibre density in 
the medial cortex (Lindvall and Bjorklund 1978).
Additionally, a projection from the locus coeruleus to the 
hypothalamus has been identified (Lindvall and Bjorklund 1978). 
An adrenaline innervation of parts of the hypothalamus from cell 
bodies thought to lie closely in the region of A1 and A2 has also 
been shown (Hokfelt 1974). The hypothalamus is therefore heavily 
innervated by DA, NA and adrenalin pathways, together also with 
pathways, originating in the medial raphe nucleus (which
have not been reviewed).
2.4. LESION ilUDIES
Brobeck (1946) first speculated that the effects of VMM lesions 
(to increase food intake and body weight) might by caused by an 
interuption of pathways in the vicinity of the VMM rather than by 
destruction of the cell bodies of the VMM. Similar objections 
have also been raised about the notion that the aphagia from LH 
lesions arises from destruction of LH cell bodies, most notably 
by Morgans (1961). This is to cast doubt on the evidence in 
support for a 'centre’ concept, where a discrete region of the 
brain is supposed to carry out the integration necessary and
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su-f-ficent to organise behaviour such as appetite or satiation.
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2.4.1. LH APHAGIA - A RE-EXAMINATION
Speculation that LH aphagia is not in fact entirely mediated by 
destruction of LH cell bodies, arose from the general anatomical 
observations that the LH is relatively cell poor and is 
traversed by numerous diffuse fibre systems, some of which 
originate or terminate in the A9 and AlO cell bodies. Ungerstedt 
(1970, 1971) proposed that LH aphagia was mediated by
destruction of nigrostriatal DA connections, following his
finding that bilateral intra-ventricular injection of 6-OHDA 
(which was shown to destroy the nigrostriatal DA neurons, amongst 
others) produced marked aphagia and adipsia. Destruction of NA 
systems or the mesolimbic DA system produced no such effects. 
However, this nigrostriatal mediation of LH aphagia has been 
questioned on several grounds.
.0 1
First, 6-OHDA has considerable non-specific neurotoxic effects 
when used in the concentrâtions employed in these studies- these 
observations do not provide any evidence for a 
involvement of the nigrostriatal DA.
cruci al
Secondly, although the behavioural profiles consequent on 
nigrostriatal and LH destruction are similar, they differ in a 
number of details: nigrostriatal (NS) rats are not especially 
adverse to quinine adultered food as LH rats ares and less 
importantly as regards aphagia, NS rats are not somnolent (though
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they are akinetic) as LH rats are, and NS rats do not show 
certain gross autonomic changes as seen after LH lesions 
(Blundell et al 1979).
Ij-.
Thirdly, the reduction in striatal DA level is not proportional 
to the degree of aphagia shown, e.g. a 507. reduction in striatal 
DA following a LH lesion produces a complete disruption of 
ingestive behaviour (Zigmond and Strieker 1973), whereas a 907. 
reduction following other neurochemical treatments e.g. lesions 
with copper sulphate results in only mild aphagia (Grossman 
1976). It is therefore possible to conclude that striatal DA 
plays a role in LH aphagia but cannot wholly account for the 
behavioural effects of LH lesions. It is also probable that the 
reductions in striatal DA following both 6-OHDA and LH lesions 
are instrumental in producing aphagia as a consequence to some 
extent of gross sensory-motor impairment and lowered arousal 
(effects which are well documented e.g. Marshall et al 1974)5 
behavioural states which are incompatible with spontaneous 
ingestive behaviour but not specific to it.
Lesions in the dorsal midbrain tegmentum are known to produce a 
marked aphagia and adipsia, together with more persistent 
deficits (unlike aphagia which lasts up to a few weeks only). 
These deficits are in the rats’ feeding response to
glucoprivation, or to hydrational challenges, such as a decrease 
in the consumption of sucrose and saccharin solutions (Leibowitz 
et al 1980c, Grossman et al 1978). However, an interesting point 
in relation to LH aphagia, to emerge from the Leibowitz study is
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the report o-f a relatively 'normal’ neurological pro-file 
■following midbrain electrolytic lesions. Furthermore, 6-OHDA 
injected into the same area tailed to produce a marked aphagia or 
adipsia (Leibowitz et al 1980c) suggesting that the aphagia and 
adipsia observed after dorsal midbrain electrolytic lesions 
cannot be attributed to damage of the various ascending CA 
f i bres.
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Evidence against DA mediation of LH aphagia has also been 
obtained by Grossman et al (1978) who found that kainic acid 
lesions of the LH produced a small but significant aphagia and 
adipsia in the absence of neurological impairment. There was 
also no significant depletion of DA in the hypothalamus, striatum 
and telecephalon. These data therefore suggest that the LH 
syndrome may encompass a number of different syndromes mediated 
by different regional anatomy: dorsal midbrain tegmentum damage
(specifically related to the regulation of food and water intake), 
6-OHDA damage (related to sensory-motor disabilities), and 
kainic acid damage, involving specific destruction of neurons 
inherent to the LH, but not known to be related to any specific
component of aphagia.
It should be mentioned however, that although a wealth ot 
evidence fails to implicate nigrostriatal DA in aphagia, more 
recent evidence does suggest a role of AlO neurons in the feeding 
elicited by stimulation of the MFB at the level of the LH. 
Injections of spiroperidol into the nucleus accumbens,
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ipsilateral to the stimulating electrode, significantly 
attenuated the elicited feeding response; no change was seen on 
contralateral administration. These changes were also correlated 
with changes in the electrophysiological characteristics of cell 
bodies in the VTA (Mogenson 1982).
Another explanation of the aphagia seen following DA depletion is 
based on the idea that DA is implicated in the rewarding 
properties of food. DA depletion therefore renders food
unrewarding (Wise et al 1982). However, this view is not adopted 
by Beninger (1983), who sees DA as being implicated in the 
incentive value of food stimuli. In this model, DA neurons are 
seen in part to mediate reinforcing stimuli on learning. This 
may work by reinforcing stimuli increasing the incentive 
motivational properties of neutral stimuli that are associated 
with them. Normal DA functioning appears to be required for the 
establishment and maintenance of incentive learning in naive
ani mal s.
2.4.2. VtiH'HYPERPHAGIA - A RE-EXAMINATION
The classic VMH syndrome has also been criticised along similar 
lines. Firstly, the anatomical specificity of the lesion has 
been questioned. Discrete lesions of the VMH region e.g. within
the bounds of the VMN (ventromedial nucleus) produce no
hyperphagia, but larger lesions (e.g. those produced at
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1973). More sped-fical 1 y, damage to the tissue directly adjacent 
to the VMH skirting the -fornix produces hyperphagia. Also kni-fe 
cuts in that region are su-fficient to produce the classic VMH 
obesity syndrome (Bold 1973, Sclatani 1977). As mentioned 
earlier, this area is known to be heavily innervated by both NA 
and 5-HT pathways. An attempt to identi-fy the specific pathway 
involved in VMH hyperphagia was made through studies using 6-OHDA 
which indicated that destruction of the VNAB gave rise to a 
hyperphagic syndrome (Ahlskog 1974). Thus, it was possible that 
the original VMH lesion was identical to the VNAB lesion. This 
hypothesis received little support for a number of reasons.
Firstly, hyperphagia seen in VMH rats is more severe than in VNAB
rats. Secondly, VNAB rats overeat only at night whilst VMH rats 
overeat both day and night. Thirdly, hypophysectomy blocks 
hyperphagia in VNAB rats but not in VMH rats. Fourthly, VNAB 
rats show around a 507. attenuation of the anorexic effect of 
amphetamine whilst no such attenuation is seen in VMH rats. 
Fifthly, VMH rats are finicky, especially towards quinine
adulterated diets, VNAB rats are not. Sixthly, the hyperphagic 
effects of the two lesions are additive, arguing against them 
having the same mechanism. Finally, VNAB rats showed a 947. 
depletion of brain NA whereas VMH rats show no significant
depletion of NA (Ahlskog et al 1975).
.n
The anatomical specificity of the 6-OHDA-induced VNAB lesion has 
also been questioned. Selective lowering of NA by bilateral 6- 
□HDA injection produced a maximal effect on lowering brain NA at 
4 ug with no significant change in food intake. Only at 12 ug
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did increases in -food intake become apparent, suggesting that 
non-specitic damage around the injection site is responsible -for 
increases in -food intake (Oltmans et al 1977 i Lorden et al 
1976). However, this notion was contradicted by other studies 
which demonstrated normal -food intake with the same low and high 
doses <4 ug and 12 ug) oi 6-OHDA following DMI pretreatment 
(which was used to protect NA cells by its reuptake blockade 
action). These results support an interpretation in favour of NA 
mediation of 6-OHDA-induced hyperphagia (Hernandez and Hoebel 
1982). It is feasible that the ’non-specific’ damage which some 
claim to produce hyperphagia can be attributed to damage incurred 
by the adrenalin fibres of the central tegmental tract (CTT) and 
DA fibres of the A8 and A9 cells groups (see section 2.7.).
In summary, the LH and VMH lesions appear both to have a CA 
involvement. However, as 6-QHDA spares adrenalin fibres 
(Goldstein et al 1970), which innervate parts of the 
hypothalamus, it is possible that a component of both LH aphagia 
and VMH hyperphagia is mediated in part, by adrenergic activity 
of the hypothalamus! in particular the PVN and PFH. This 
hypothesis is addressed within the context of a review on 
neurochemical studies of feeding behaviour which follows.
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2.5. PHARMACGLOGICAL ilUDlES
2.5.1. FEEDING
Grossman (1962) -first demonstrated that the 1-isomer o-f NA (1-NA) 
injected into the hypothalamus of a fully satiated rat produced a 
feeding response. Adrenalin also produced this feeding response, 
with greater potency than NA (Booth 1968), whereas DA, 5-HT and 
the d-isomer of NA (d-NA) were ineffective (Booth 1968). Dose 
dependency of NA- and adrenalin-induced feeding were also shown 
(Miller et al 1964 and Booth 1968 respectively), together with 
facilitation of feeding by adrenalin and NA in hungry rats 
(Leibowitz 1970). The original site at which Grossman implanted 
and obtained the LH feeding has not been fully confirmed. 
Subsequent studies by Booth (1967) have shown sites medial to 
the fornix at the more rostral hypothalamic level to be more 
sensitive to NA elicited feeding. The sites identified by Booth 
were subsequently confirmed by Grossman (1968) in a re­
examination of his own histology. This particular area has been 
extensively studied by Leibowitz (1975, 1978a), amongst others,
who has identified the PVN within the anterior hypothalamus to be 
the site most sensitive to adrenergic feeding effects. This 
sensitivity is exemplified by the latency of NA to stimulate 
feeding at the PVN: in the region of 0.5 - 2.0 minutes at
exceptionally low threshold doses (1.0 - 4.2 ng)in satiated rats. 
But Mathews et al (1978) found that NA applied to the border of 
the PVN was the most sensitive site in eliciting NA-induced
■feeding.
, 1 ;aci=-i-fi f-ation o-f the NA-induced adrenergicPharmacological classi+ication ot
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effect was established in the earlier studies of Grossman (1960, 
1962). Booth (1968) and Slangen et al (1969) reaffirmed Grossmans 
finding that NA-induced feeding could be reduced by prior 
hypothalamic administration of phentolamine, an alpha-adrenergic 
blocker. This finding has been successfully replicated by 
Leibowits (1978a), amongst others, who found that administration 
of phentoleamine by i.c. and peripheral routes was also effective 
in blocking NA feeding. Compìementary to an alpha-adrenolytic 
disruption of NA feeding is the finding that alpha-agonists, such 
as clonidine and metaraminol, injected into the PVN, elicit a 
reliable sustained feeding response (Leibowitz 1975). The beta- 
agonist, isoproterenol, is ineffective in eliciting feeding at 
the PVN and similarly the beta-antagonist propranolol at 
relatively large doses is without effect in blocking NA feeding 
(Leibowitz et al 1980a).
Thus, evidence so far clearly supports the notion of an alpha- 
adrenergic mechanism mediating the feeding facilitatory effects 
of exogenously applied NA. However, this is far from 
establishing whether endogenous NA transmitter systems have a 
physiological role in the control of naturally motivated feeding. 
Attempts to answer this question utilize drug-induced release of 
endogenous transmitter to induce behavioural change. Slangen and 
Miller (1969) applied both tetrabenzine to deplete local CA 
stores and nialamide (a MAGI) to arrest breakdown of NA into the 
PFH, this drug conbimaton produced an eating response in satiated 
rats. Booth (1968) and Slangen et al (1969) showed that the TAD,
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DMI (NA re-uptake blocker) when injected into the LH showed some 
tendency to stimulate feeding. This result was more positively 
re-affirmed by Montgomery et al (1971), who showed that DMI 
potentiated feeding in hungry rats at a LH site but not in 
satiated rats. Amphetamine, a drug that increases synaptic 
concentrâtions of CAs, has also been shown to elicit a feeding 
response when injected into the VMH (Leibowits 1970b).
A more recent study by Leibowits (1978a) reported that the TAD 
DMI, protriptyline and amitriptyline injected into the PVN 
elicited feeding in satiated rats. This AD-induced feeding 
response was blocked in a dose—dependent fashion by phentol ami ne. 
AD-induced feeding was also blocked by PVN pretreatment with CA 
synthesis inhibitors, at doses which were shown to be without 
effect when administered together with exogenous NA. In 
conclusion, the AD facilitation of NA feeding at the PVN seems to 
depend on the integrity of the presynaptic uptake site and 
postsynaptic alpha-adrenergic receptors.
Biochemical support for the role of endogenous NA in feeding 
elicited from the PVN comes from a study by Martin and Myers 
(1975), who demonstrated that the PVN, particularly its 
dorsomedial and ventromedial areas, exhibited the most dramatic 
changes in indices of NA turnover or release as a function of 
changes in feeding behaviour. More solid evidence from van der 
Gugten et al (1977) demonstrated increased NA concentrât!ons in 
the PVN and certain other brain nuclei following feeding. These 
studies taken in isolation simply point to a correlation between
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changes in NA and -feeding, but taken in the context of 
pharmacology, they support the hypothesis of endogenous 
induced feeding within the FVN.
2.5.2. SATIETY
2.5.2.1. ADRENERGIC MEGHANISMS
LH sites have been implicated in the suppression of feeding 
behaviour. Adrenalin produces a marked anorexia when injected 
into the LH together with an alpha antagonist (phentolamine), 
(Leibowitz 1970a). The purpose of pretreatment with the alpha 
antagonist is to confirm that adrenalin acts at beta—adrenergic 
receptors, as stimulation of alpha—adrenergic receptors by 
adrenalin might mask any anorexia by inducing an increase in food 
intake. That the anorexic effect is beta-adrenergic is shown by 
an attenuation of food intake in food-deprived rats following a 
LH injection of the beta-adrenergic agonist isoproterenol.
Isoproterenol-induced suppression of food intake was reversed by 
prior administration with propranolol (beta blocker), but not by 
the alpha blocker phentolamine (Leibowitz 1973, Goldman et al 
1971). The assumption that this beta-adrenergic hypophagic 
effect has to do with natural satiety processes is speculative. 
It may be that the hypophagia is a consequence of
(un)palatabi1ity or a sickness artefact.
A controversy exists as to the beta-adrenergic specificity of 
feeding suppression, as it has also been reported that NA 
injected into a perifornical LH site elicits satiety instead of
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■feeding, whilst phentolamine injected into the same site elicits 
feeding (Margules 1970). In addition, Margules obtained evidence 
that NA suppressed feeding in the dark and facilitated feeding in 
the light (Margules et al 1972). However, Margules tested with 
milk rather than with solid food and his NA injections may have 
been affecting a system concerned with thirst rather than hunger. 
It seems uniikey that the water content of milk influenced the 
effects of NA on feeding, as it has been reported that NA 
injected into the dorsal perifornical region and the lateral 
aspect of the PVN elicited feeding irrespective of whether the 
rats' food was solid or liquid (Matthews et al 1978). As
Margules maintained his rats on solid food and presented milk
only during test periods, this factor could be responsible for 
the observed suppression of intake (Margules 1972). Matthews et 
al also reported a facilitation of feeding by NA in the light
with no effect on the amount of food eaten in the dark. This
result also differs from Margules and may possibly be explained 
in terms of dose of drug used, injection site and baseline food 
intake values.
It is apparent from the Margules work that the circadian cycle is 
variable in the expression of neurochemi cal 1 y-i nduced 
behavioural effects, and that the type of diet is also important 
when measuring a behaviour as complex as feeding. For example, 
Leibowits has proposed a carbohydrate specific preference to NA 
induced feeding, although a preliminary investigation failed to 
confirm this effect (Towell and Booth, unpublished data 1980).
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NA appears to be the endogenous neurotransmitter mediating alpha- 
adrenergic feeding effects (see section 2.5.1.). It is unclear 
which transmitter might mediate the beta-adrenergic 'satiety" 
effect. It is possible that NA could play a dual role in 
instigating feeding and satiety, but with the more recent finding 
that adrenalin innervates parts of the hypothalamus (see section
2.3.2.), it is plausible that adrenalin innervation might mediate 
beta-adrenergic satiety.
2.5.2.2. DOPAMINERGIC MECHANISMS
As mentioned earlier in section 2.4.1., Ungerstedt (1971) 
proposed that DA depletion was important in mediating aphagia. 
More specifical 1y, aphagia was presumed to be mediated by the 
depletions of DA in the nigro-striatal system (Ungerstedt 1974). 
Ihe resultant sensori-motor incapacitation following nigro- 
striatal DA depletion was thought to be incompatible with normal 
ingestive behaviour. Evidence in support of this hypothesis 
comes from studies showing that neuroleptics (especially the 
butyrophenones) injected peripherally cause aphagia, that is also 
presumed to result from lowering of striatal DA transmission 
(e.g. Blundell and Burridge 1979).
However, not all neuroleptics cause aphagia - the phenothiazine 
neuroleptics have been shown to increase feeding when injected 
peripheral1y, or centrally at an LH site, (Leibowitz 1976). This 
increase in feeding may possibly result from the stimulation of 
1^ pha-adrenergic receptors in the nearby PVN, or perhaps from a
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direct blockade o-f a group ot DA receptors in the PFH. This 
hypothalamic DA system, which is inhibitory to feeding, is 
thought to be located specifically in the lateral perifornical 
region of the hypothalamus (Leibowitz and Rossakis 1979b). Both 
DA and adrenalin in the PFH suppress feeding in a dose-dependent 
way. The effects of DA and adrenalin are selectively enhanced by 
the uptake inhibitors benzotropine and DMI respectively which 
indicates that there may be distinct presynaptic nerve endings 
for the release of DA and adrenalin.
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DA-induced suppression of feeding at the PFH is readily 
antagonized by intracranial (i.c.) pretreatment with a variety of 
neuroleptics but not with antagonists of alpha-adrenergic, beta- 
adrenergic, cholinergic and serotonergic receptors (Leibowitz 
1980). Adrenalin is also effective at the PFH in suppressing 
feeding, with a latency of between 1 and 2 minutes (Leibowitz and 
Rossakis 1979a). Leibowitz has used this short latency time for 
adrenalin as evidence to implicate the existence of a population 
of receptors close to the cannulae tip which mediate adrenal in■ s 
suppressive effects on feeding. Other evidence would suggest 
however, that after a latency of 1 minute or so, adrenalin is 
likely to be very widely diffused through the brain.
Adrenalin-induced feeding was blocked by pretreatment with beta- 
antagonists, more specifically those of the B2 subtype, but not 
by alpha-adrenergic, cholinergic and serotoninergic receptor 
antagonists. The receptor antagonism produced by propranolol was 
stereospecific and reversible by adrenalin. Neuroleptics were
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also found to be effective in reversing adrenalin's suppressive 
effect (Leibowitz and Rossakis 1979a). Taken together with the 
finding that beta—adrenergic blockers were ineffective at 
preventing DA—elicited suppression of feeding, these observations 
lead to the hypotheses that adrenalin and DA are actirig on two 
independent populations of hypothalamic receptors, and that the 
integrity of the DA receptors is necessary for even the beta- 
adrenergic suppression of feeding to occur.
2.6, DRUG-INDUCED ANOREXIA
2.6.1. PHARMACOLOGY
That suppression of feeding can be mediated by endogenous DA is 
indicated by the effects of amphetamine, a psychomotor stimulant 
which is known to amplify the release of endogenous NA and DA 
from presynaptic endings (Carlsson 1970). When amphetamine is 
injected into the PFH, as when injected i.p., it produces an 
anorexia which can be antagonized by CA synthesis inhibitors 
(Leibowitz 1976), DA blockers (see experiment 4), and beta 
blockers (see experiment 3). The evidence for beta-adrenergic 
blockade is controversial. However amphetamine anorexia is not 
mediated solely by DA release. Injection of beta—adrenergic 
receptor blocking drugs into the PFH attenuated the anorexic 
effect of centrally or peripherally administered amphetamine 
(e.g. Leibowitz et al 1980b). Furthermore, it has recently been 
reported that neuroleptics were ineffective in blocking low—dose 
amphetamine anorexia (0.5 mg/kg; Burridge and Blundell 1979) but
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that lesions to the VNAB did attenuate the hypophagic response to 
this low dose of amphetamine (Ahlskog 1974). Most studies 
however, fail to show attenuation of amphetamine anorexia with 
beta—b1ockers when the drugs are administered peripherally (e.g. 
Lehr et al 1973). This problem is addressed in experiment 3.
Other indirectly acting CA agonists (e.g. mazindol) have also 
been shown to produce an anorexia, which is selectively 
antagonized by DA blockade (see Leibowitz and Rossakis 1978 for 
details). Further evidence suggesting that endogenous DA 
mediates suppression of food intake, arises from studies using 1- 
dopa, a CA precursor. When injected peripherally (e.g. Sanghvi
et al 1975) or centrally (Leibowitz and Rossakis 1979c), 1-dopa 
has been shown to suppress food intake. The central effect at 
the PFH was totally antagonized by local administration of dopa 
decarboxylase inhibitors and by a combination of haloperidol and 
propranolol, but only partially attenuated when haloperidol and 
propranolol were used in isolation. This suggests that both DA
and NA at the PFH play some role in suppressing food intake in 
the rodent.
2 . 6 . 2 .  ANATOM Y
i^ A-, adrenalin- and NA-containing varicosities occur in the 
region of the PFH (Leibowitz 1979). Increased whole brain DA has 
been reported following satiety (Samanin and Garrantini 1981). 
The relationship between increased whole brain DA and
hypothalamic CA containing varicosities is obscure. However,
Dunnett (198%^ ) and Rolls (1983) have proposed that
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physiological ly identified DA cell bodies in the A9 region 
terminate in the hypothalamus. Although, a more thorough mapping 
of this proposed pathway is needed before any firm conclusions 
can be drawn, it might be that hypothalamic DA has a direct 
control over the physiological mechanisms controlling food intake 
and connections to substantia nigra provide the overriding and 
essential fine tuning and co-ordination of behaviour for this 
hypothalamic mediation to occur.
In support of this argument are the findings of Leibowitz et al
(1980) who suggest that the ventral midbrain may be a source of 
cell bodies, both DA (A8, A9) and NA (Al, Cl, A5) which project 
to the PFH and mediate satiety, (see section 2.7. for a more 
detailed discussion). However, a relevant question in all these 
types of studies is whether behavioural and neurochemical change 
resulting from lesions reflects a direct neuronal link between 
the midbrain and hypothalamus, as opposed to an indirect link due 
to damage of midbrain cells that have an impact upon the activity 
of hypothalamic CA neurons (Brownstein et al 1976).
These studies are consistent with the hypothesis that DA neurons 
contained within the PFH are not specific to the initiation of 
satiety, but rather through contact with other midbrain DA 
systems, serve as ■ regulators’ for the behavioural conditions 
wherebv eating and satiety occur. For example, a low level of 
hypothalamic DA activity might facilitate eating, by stimulating 
motor responses compatible with feeding; a high level of
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hypothalamic DA activity might hinder eating, by producing motor 
responses incompatible with eating, thereby indirectly initiating 
satiety or maybe an incompacity to eat.
2.7. AMPHEIAMINEa. QAIECHOLAMINESa. FEEDING AND SAIIEIY 
The behavioural e-f-fects o-f amphetamine can be used as evidence to 
support the dual-role DA hypothesis of feeding. Amphetamine 
potentiates central CA transmission (e.g. Fuxe and Ungerstedt 
1969); the predominant CA thought to mediate the behavioural 
effects of amphetamine is DA although there is some evidence for 
an NA mediation at lower doses (e.g. Ahlskog 1974). Low systemic 
doses of amphetamine (0.125—0.25 mg/kg) can produce feeding in 
hungry animals (Blundell and Latham 1979; Dobi^anski and Doggett 
1979), whereas higher doses (0.4 mg/kg upwards) produce a marked 
anorexia (Burridge and Blundell 1979). This enhancement of
feeding could represent a presynaptic action of amphetamine on DA 
receptors but this is unlikely as, when amphetamine is injected 
directly into the striatum at comparatively low doses, it
si gnificant1y increases food intake. This suggests that 
amphetamine exerts its facilitatory and inhibitory effects on 
food intake purely via a DA mechanism (as NA is not found in the 
corpus striatum). The concept of DA having a dual role in
feeding behaviour is consistent with the hypothesis of Lyons and 
Robbins (1976), who attempt to explain amphetamine action in 
terms of an increased tendency to respond to stimuli within a 
decreasing number of response categories.
That there is a beta-adrenergic component to the suppression of
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feeding is well established (see section 2.5.2.1.). It is 
difficult to determine whether amphetamine anorexia includes a 
beta-adrenergic component because of concommitant DA receptor 
stimulation. However, lesions to the VNAB attenuate the anorexic 
effect of a fairly low dose of amphetamine (0.5 mg/kg) by 
approximatel y 50X. This suggests that amphetamine-induced 
anorexia has an NA component.
A more detailed analysis of the behavioural consequences of the 
VNAB lesion (see section 2.4.2.) suggests that its facilitatory 
effects on feeding could either be attributed to other damage in 
the vicinity of the VNAB (eg Oltmans et al 1976) or conversely, 
to specific NA damage as reported by Ahlskog (1974) and more 
recently by Hernandez and Hoebel (1982). Around the VNAB lesion 
area, axons are highly col 1ateralized, therefore any damage aimed 
at a specific pathway is likely to be broadened by transsynaptic 
changes to other pathways. It is possible that Ahlskog's VNAB 
lesion also damaged ventral adrenergic fibres in the vicinity of 
the VNAB and DA fibres from the A8 and A9 cell groups. Lesions 
specifically aimed at the CTT (of which the VNAB is a component) 
in fact cause around a 40X reduction in the potency of 
amphetamine to induce anorexia, presumably arising from loss of 
the (beta) adrenergic component. That amphetamine anorexia is 
not totally abolished may be explained in terms of the DA 
receptor component to this behaviour (Leibowitz and Rossakis
1979b).
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Alternative explanations have been put forward to account for the 
effects of amphetamine on feeding behaviour. Tordoff et al (1982) 
present evidence suggesting that low—dose amphetamine anorexia is 
mediated by hepatic glycogenolysis: removal of the sympathetic 
nerves to the viscera attenuates the effects of amphetamine. 
This mechanism depends on stores of glycogen which are sustained 
during ad lib feeding, and so it is likely that free feeding 
animals do have a peripheral component which contributes to 
amphetamine anorexia. Food-deprived animals, on the other hand, 
have depleted stores of glycogen and therefore this peripheral 
component cannot account for amphetamine anorexia in most 
eAperiments. This is reflected by studies which show the anorexic 
effects of central amphetamine at doses ineffective peripherally 
(e.g. Hoebel 1977).
A recent binding study gave indication that amphetamine bound to 
two distinct sites in synaptosomal membrane preparations from 
the rat hypothalamus (Paul et al 1983). However, the fact that 
phenyl ethyl amine derivatives show affinity for specific binding 
sites, which was used as evidence to identify the "amphetamine 
receptor’, is probably merely a reflection of their similar 
chemical structure. The most likely explanation is that these 
two hypothalamic receptor binding sites represent NA and DA 
uptake sites respectively, or possibly pre- and post-synaptic NA 
sites, since amphetamine has been shown to have a direct action 
on post-synaptic sites at very high doses (Carlsson 1970).
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2.8. SUMMARY
in summary, therefore, the effects of amphetamine on food intake 
vary with site of action and dosage. However, evidence does 
support the hypothesis that low dose amphetamine anorexia (0.5 
mg/kg) can be used to index central beta-receptor activity (e.g. 
Ahlskog 1974). This position is confirmed in chapter 4, and this 
rationale underlies the use of low dose amphetamine anorexia to 
assess TAD function, as described in chapter 5. Futhermore, 
tf^®^tments which reduce midbrain DA levels also reduce feeding, 
though the exact behavioural mechanisms by which these different 
treatments reduce food intake differs markedly (see chapters 6 
and 7).
If drugs which suppress feeding are to be used to index TAD 
function, it is clear that a detailed understand!ng of their 
behavioural action as regards feeding is required. To this end, 
the next chapter will review some of the different behavioural 
mechanisms by which a drug can reduce food intake.
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CHAPTER THREE
MICROSIRyCTURAL ANALYSIS OF FEEDING BEHAVIOUR
3.1. INIRQDyCIION
Studies of food intake, have typically been concerned with the 
amount of food consumed within a fixed time period. As
illustrated in the previous chapter, amount eaten has proved 
useful as a dependent variable in analysing drug effects.
However, if one is interested in the behavioural mechanisms that 
produce drug effects, then this measurement procedure is clearly 
inadequate. The point is exemplified by the ambiguities that 
arise when a drug is shown to suppress food intake. A reduction
of weight of food consumed in a fixed time fails to indicate
whether a drug is acting to inhibit the onset of eating, to slow 
the process of eating, or to terminate an eating episode 
prematurely. For this reason, a more detailed behavioural 
analysis of feeding has been used by several 
psychopharmacologi sts.
M
■^2. MICROSIRyCiyRAL PARAMEIERS AND DRyG EFFECIS
Freely feeding and food deprived rats eat in discrete 'meals" 
(Richter 1927). Accordingly, it is possible to analyse feeding 
behaviour by measuring various parameters of meal patterns, such 
as the number of meals taken over a given period, meal sizes, 
ineal durations, inter-meal intervals, and the average rate of 
eatin during meals. Within meals, short bouts of eating are
separated by short episodes of other behaviours such as 
ambulation and rearing (Blundell 1981). So in addition, certain
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intra-meal parameters can be assessed, such as the number, size 
and duration o-f eating bouts. The relationship between bouts of 
eating and non—eating activities can also be assessed. Such data 
could demonstrate that a drug can suppress food intake 
independently of any process related to the control of food 
intake itself, either by enhancing non-nutritional behaviours 
between eating bouts or by disrupting feeding behaviour during a 
^®sl. The intrameal parameters are often called 
' mi crostructural ■' characteri stics of eating.
A number of experiments have in fact yielded demonstrations of 
the subtle differences that the actions of drugs can exert on 
feeding. For instance, Blundell and Latham (1978) selected doses 
of amphetamine (1.0 mg/kg), fenfluramine (3.0 mg/kg) and mazindol 
(5.0 mg/kg) which each produced an approximate SOX reduction in 
food intake measured over one hour and examined these drug 
effects on the microstructure of feeding. Trained and 
independently concordant observers recorded whether the animal 
was eating or not. Unlike the other drugs amphetamine increased 
the latency to begin eating. Mazindol reduced the frequency of 
bouts whilst not affecting the mean weight of food consumed per 
bout. Fenfluramine had the reverse effect of reducing the mean 
weight of food consumed per bout without affecting the frequency 
of bouts. All three drugs reduced the duration of bouts and 
therefore the time spent eating. The rate of eating per bout was 
lowered by fenfluramine, but paradoxically, despite their 
hypophagic effeccts the other drugs increased eating rate.
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Given that microstructural analysis of feeding behaviour can 
reveal variation among the actions of these anorectic drugs, it 
might be that the modifications in the microstructure of eating, 
may be related to the drugs' varying actions on particular 
neurochemical systems. Evidence for this hypothesis is that 
pimozide (a DA antagonist) reversed amphetamine's suppressant 
effect on food intake by increasing eating time, decreasing the 
latency to initiate feeding and decreasing the rate of eating. 
Fenfluramine, on the other hand, was antagonised by the 
serotoninergic receptor antagonist methergol ines the
fenf1uramine-induced increase in the latency to initiate feeding, 
decrease in the number of eating bouts, and decrease in rate of
eating, were all reversed by methergoline (Blundell and Latham
1 98 0 ) .
One of the most interesting results to emerge from the work of 
Blundell and Latham (1980), is the increase in eating rate 
brought about by amphetamine. This effect could explain why low 
doses of amphetamine are sometimes seen to increase food intake 
(see chapter 2, section 2.7.). However, Cooper et al (1979, 
1980a, 1980b) were unable to show an amphetamine-induced increase 
in eating rate. Spiroperidol and chiorodiazepoxide were found to 
antagonise amphetamine anorexia, mainly by reversing the 
amphetamine-induced reduction in eating time, and in the case of 
chlorodiazepoxide, also by reducing the increase in latency 
brought about by amphetamine. However, the procedures used in 
these studies differ from those used by Blundell and Latham
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(1980), in that feeding tests were of 10 minute duration instead 
of 1 hour. Given that both the Blundell and Latham <1980) and 
Cooper et al (1979, 1900a,b) studies employed similar feeding 
regimes (approximately 18 hours food-deprivation before the test 
session), and used the same dose of amphetamine (1.0 mg/kg), it 
is possible that the discrepancy arises from differences in the 
duration of the feeding test. In a 10 minute feeding test, 
following 18 hours food deprivation, it is unlikely that an 
animal would eat in discrete bouts; it is likely that an animal 
would eat virtually continuously throughout the 10 minute feeding 
test. However, this is impossible to calculate without relevant 
data taken from longer feeding sessions, which would enable one 
to calculate the mean length of the first bout of eating.
3.3. CRIlieISMS OF MICROSIRUCiyRE MEIHQDOLOGY
Studies such as the above have been criticised on several 
grounds. Feeding was observed over a period of only one hour, 
or indeed 10 minutes, excluding useful data that can be obtained 
from longer periods of access to food, which mimic the natural 
environment more closely. Animals are usually maintained on 
deprivation schedules and as such, given that increases in 
behavioural arousal modify brain neurotransmitter systems, data 
are obtained from ’abnormal’ rats. In addition, animals are 
relatively insensitive to suppressant effects of drugs as eating 
is so vigorous, especially when the animals have been adapted to 
a food dprivation cycle. Also, on a deprivation schedule, 
peripheral metabolism is ’abnormal’, affecting both eating and
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drug catabolism.
In an ef-fort to overcome criticisms of this kind, there has been 
a move to monitor food intake during much longer periods of 
access to food <e.g. 24 hours; Blundell and McArthur 1981). It
is clearly impractical to expect observers to monitor such 
sessions, although time-lapse video recording can provide some 
useful information. Instead, arbitary criteria are used to 
define whether an animal is eating or not. For instance, a
rodent meal has been defined as consuming 6 or more 45 mg food 
pellets, with a termination criterion of 10 minutes without 
taking a pellet (Hsiao et al 1979), or 5 or more pellets each 
separated from the last by less than 5 minutes (DeCastro 1981). 
It is apparent that these criteria do not take into account 
individual differences in eating patterns. Clearly, the criterion 
of what constitutes a meal is critical to every parameter 
calculated on the basis of such a decision. Therefore, drug 
effects may be distorted by artefacts of that decision.
Furthermore, the differences in the definition of a meal make it 
difficult to compare data across studies from different 
1aboratori es.
Probably the most important criticism of microstructural analysis 
of feeding behaviour - what exactly constitutes a 'meal' - can 
be countered by establishing meal-start and meal-end criterion 
for each animal. This can be (and has been) achieved by direct 
observation of one animal at a time, but this is both labour 
intensive and time consuming. An alternative is to use the method
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of log survivor analysis of the frequency distributions of inter­
response times (IRTs) to derive a meal criterion. The short half- 
life of many drugs and the need to increase the probability of 
eating within a short time, (so that sufficient data can be 
obtained for IRT analysis), make it necessary to use short test 
sessions with food deprived rats when carrying out experiments 
involving acute drug injections. However, the criticisms of 
brief feeding sessions outlined above do not apply when 
microstructural analysis of feeding behaviour is used as a tool 
for neuropharmacological analysis, as the purpose here is to 
study brain mechaAisms in their own right and not brain 
mechanisms in relation to naturalistic feeding behaviour.
3.4. MiCRDSIRUCIURAL ANALYSIS OF FEEDING BEHAVIOUR BY IHE IRJ 
dilHQP
A record of the time taken between successive responses to take 
food, (the inter— response time or IRT), during a feeding session 
can be plotted as an IRT frequency distribution. The theory 
behind IRT analysis is that this global distribution in fact 
constitutes a number of underlying Poisson distributions, each 
associated with a behaviour having a constant probability per 
opportunity during a feeding session, e.g. meal taking, 
exploratory activity and sleep. The problem in IRT analysis is to 
resolve these natural discontinuities reliably. This task is 
simplified and made more objective by transforming the IRT 
frequency distribution into a log survivor function, i.e. the log 
frequency of IRTs longer than any given time period. A straight
-i
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line on a log survivor -function represents a single Poisson 
■function and so any discontinuity can be visualised as changes in 
the slope o-f the log survivor function.
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This methodology has previously been applied to study drug 
effects on consumatory behaviour in rats over a 24 hour period 
(Booth 1972, Booth and Pain 1970). These authors identified 
breaks in survivor slope at less than 1 minute and at 7-10 
minutes, using intervals between photoelectrical 1y detected 
approaches to food in rats. Booth claimed that these findings 
established 'performance based' criteria for defining a meal, 
instead of the investigator using arbitary preconceptions. He 
interprets a pause of under 1 minute as being characteristic of 
consumatory control during a meal, 1-10 minutes as development of 
satiety during a meal, and pauses over 10 minute as ranging over 
intermeal intervals (Booth 1972). This criterion of what 
constitutes a meal was not computed for each individual animal 
however, but was observed from data aggregated over a sample of 
rats (n=6), thus obscuring possible differences between animals. 
So in the 24 hour IRT analysis of Booth, presumably pauses equal 
to or under 10 minutes represent the taking of a meal, and pauses 
of under 1 minute represent bouts during a meal.
In a 24 hour IRT analysis. Burton et al (1981) found no 
objective evidence to support a meal criterion from their data, 
but they were able to identify a bout-criterion from their log- 
survivor plot of each animal (n*8), which typically consisted of 
a cluster of feeding responses separated by less than 25 seconds.
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They adopted an arbitary meal criterion o-f 10 minutes as being 
representative of the literature (Kissileff 1970). Meals were 
typically composed of between 2 to 5 bouts.
3.5. MICROSIRUCIURAL ANALYSIS OF BRIEF FEEDING SESSIONS
The aim of the present work was to examine effects on feeding of 
drugs which at the doses used only suppress feeding for brief 
periods. An experiment was therefore carried out to determine 
whether log survivor analysis could be used to analyse feeding 
sessions brief enough to test such drugs i.e. 30 minutes. Before 
describing this validation exercise, some general features of the 
nilcrostructural method, as used in several of the experiments in 
this thesis, will first be outlined.
3.5.1. APPARATUS AND PROCEDURE
Operant chambers (Campden Instruments Ltd., London), from which 
the levers had been removed, were programmed to deliver a 45 mg 
food pellet (Campden Instruments Ltd., London), whenever the 
perspex food tray door was pressed, subject to the constraint 
that presses spaced less than one second apart were ineffective. 
The house light and tray light were illuminated continuously, and 
the chambers were housed in individual sound-attenuating boxes 
with smoked perspex viewing windows. Each response on the tray 
door was logged (to the nearest 0.1 sec) by a Cromemco Z2 
microcomputer, which output the time of each response on a visual 
display unit (VDU) , and subsequently produced a listing of 
response times and inter-response times (IRTs), an IRT frequency 
distribution and a log survivor function (see figure lA).
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A: T he f r e q u e n c y  d i s t r i b u t i o n  o f  i n t e r - r e s p o n s e  t i m e s  f o r  a  t y p i c a l  s u b j e c t ,  
an d  t h e  t h e  s u r v i v o r  t r a n s f o r m ,  w h ic h  sh o w s t h e  p r o p o r t i o n  o f  t h e  f r e q u e n c y  
d i s t r i b u t i o n  l y i n g  t o  t h e  r i g h t  o f  e a c h  p o i n t  i n  t h e  f r e q u e n c y  d i s t r i b u t i o n .
N i s  t h e  n u m b e r  o f  r e s p o n s e s  i n  e a c h  I s  IR T b i n  a n d  p ( S )  i s  t h e  p e r c e n t a g e  o f  
s u r v i v o r s .
B: T h re e  t y p i c a l  l o g  s u r v i v o r  f u n c t i o n s .  T he  u p p e r m o s t  c u r v e  i s  ^ h e * lo g  
t r a n s f o r m  o f  t h e  s u r v i v o r  f u n c t i o n  sh ow n  i n  A ; f o r  c l a r i t y ,  t h e  o t h e r  tw o  
e x a m p le s  a r e  d i s p l a c e d  dow n b y  o n e  l o g  u n i t .  T he  b r e a k p o i n t  i n  e a c h  c u r v e  i s
n a r k e d  b y  a n  a r r o w .
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Animals were food deprived for between 17-21 hours, with water 
available ad libertum. Before the start of each experiment, 
animals were trained to press for food reward to asymptotic 
performance. On experimental days, when drug treatments were 
given, the animals were tested for 30—minute sessions in the 
boxes. On days between drug treatments, animals were given ten- 
minute sessions. All testing took place between 10.00 h and 
14.uu h. The animals were fed with standard laboratory diet 
(Dixons, Ware, Herts.) at 14.00 h and deprived at 17.00 h.
3.5.2. ANALYSIS
The IRT frequency distribution, a distribution of the time taken 
between successive responses to take food, can be transformed to 
a survivor function, which shows the number or the proportion of 
IRT’s greater than any given IRT (figure lA). A logarithmic 
transformation of the proportions produces a log survivor
function (figure IB). The log survivor function falls off
steeply over IRT ranges that occur with high frequency, and the
initial fall is in a straight line (indicating an underlying 
Poisson distribution). Usually the slope changes sharply to a 
shallower slope, enabling a breakpoint to be identified fairly 
easily. A small proportion of log survivor curves do not have a 
clean breakpoint which is easily detectable (figure 2A; data
taken from experiment 2). To aid identification of the
breakpoint, grouped log survivor curves are constructed for each 
treatment condition (figure 2B), which define a region in the log 
survivor curve where the breakpoint is likely to occur.
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Animals were food deprived for between 17-21 hours, with water 
available ad libertum. Before the start of each experiment, 
animals were trained to press for food reward to asymptotic 
performance. On experimental days, when drug treatments were 
given, the animals were tested for 30—minute sessions in the 
boxes. On days between drug treatments, animals were given ten- 
minute sessions. All testing took place between 10.00 h and 
14.00 h. The animals were fed with standard laboratory diet 
(Dixons, Ware, Herts.) at 14.00 h and deprived at 17.00 h.
3.5.2. ANALYSIS
The IRT frequency distribution, a distribution of the time taken 
between successive responses to take food, can be transformed to 
a survivor function, which shows the number or the proportion of 
IRT’s greater than any given IRT (figure 1A>. A logarithmic 
transformation of the proportions produces a log survivor 
function (figure IB). The log survivor function falls off
steeply over IRT ranges that occur with high frequency, and the
initial fall is in a straight line (indicating an underlying 
Poisson distribution). Usually the slope changes sharply to a 
shallower slope, enabling a breakpoint to be identified fairly 
easily. A small proportion of log survivor curves do not have a 
clean breakpoint which is easily detectable (figure 2A; data
taken from experiment 2). To aid identification of the
breakpoint, grouped log survivor curves are constructed for each 
treatment condition (figure 2B), which define a region in the log 
survivor curve where the breakpoint is likely to occur.
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The reliability of identifying the breakpoint has been assessed. 
Five independent judges estimated the position of the breakpoint 
for every log survivor function in 21 sets of 12-20 curves. The 
lowest concordance coefficient between the 5 judges was 0.75, 
and the majority of concordances were above 0.85.
Following identification of the breakpoint, the following 
parameters of feeding are calculated: (1) The number of bouts 
(B) , which is equal to the number of gaps (i.e. intervals longer 
than the breakpoint) plus one. (2) Eating time (T), which is 
given by the total of all IRTs smaller than the breakpoint. (3) 
The length of eating bouts, which is given by T/B. (4) Eating 
rate. Since the time taken to eat the final pellet in each bout 
IS neither known nor included in the calculation of eating time, 
the local eating rate is given by (N—B)/T (where N is the total 
number of responses), rather than by N/T. An eating rate of 0.1 
pellets/s is equivalent to 0.27 g/min.
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3.6. EXPERIMENI li VALIDAIION QE MICROSIRUCIURAL ANA^YSIS QF 
EiiQING BEHAVIOUR BY LOG SURVIVOR ANALYSIS
The assumption that IRTs shorter than the breakpoint represent 
eating within a bout, whilst IRTs greater than the breakpoint 
represent eating between bouts, was validated by comparing 
results obtained with log survivor analysis with those obtained 
through direct observation.
:.6.1. METHOD
Subjects
Twelve male Lister hooded rats (weight 330—400 g) were housed in 
pairs and maintained on 21-hour food deprivation, with water 
available ad lib. The animals had had prior experience of 
continuously reinforced lever pressing for food rewards.
Behaviour in the apparatus was recorded on videotape, using a 
video camera adapted for low intensity light. By the use of a 
second camera filming the VDU, and a video-mixer, the 
occurrence and time of each response on the tray door was also 
recorded on the film.
Procedure
Following a pretraining period in which 10-min daily sessions 
were run until all animals achieved asymptotic performance of 
continuous reinforcement, the animals were given a single 30-min 
session, which was recorded and filmed as described. The animals 
were observed to spend long periods eating, directly facing the 
food tray and only moving to take a further food pellet. It was
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possible to identify from the film those inter-reponse intervals 
in which behaviours other than eating (rearing, grooming and 
walking) occurred. Microstructural parameters were calculated 
following identification of the breakpoint, as outlined above.
3.6.2. RESULTS
The rats consumed a mean of 218 pellets <9.8 g) in the 30-minute 
session (range: 148-268). Inspection of the log survivor curve 
for each animal (e.g. figure IB) showed breakpoints varying from 
12 to 25 sec (mean +/- SE = 16.8 +/- 0.9 sec). If the IRT 
frequency distributions are simply summed across animals, without 
regard to the differences in breakpoint, the occurrence of 
behaviours other than eating appears to increase almost linearly 
for IRTs between 10 and 30 sec (figure 3). However, a very 
different picture is shown by the distribution of IRTs around the 
breakpoint (figure 4). The incidence of behaviours other than 
eating now shows a marked discontinuity: other behaviours were 
relatively rare (5.8 +/- 0.8% of inter-response intervals) at 
IRTs shorter than the breakpoint, and highly likely (88.4 +/- 
2.6'/. of intervals) at IRTs longer than the breakpoint. It is 
clear that using the breakpoint for each individual to provide an 
eating criterion (figure 4) affords a far clearer discrimination 
between eating and not eating, than would any arbitrarily chosen 
or aggregate criterion (figure 3).
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Fig.3 •
The f r e q u e n c y  d i s t r i b u t i o n  o f  IR T s  (m e a n  o f  a l l  s u b j e c t s ) ,  t h e  d i s t r i b u t i o n  o f  
th o s e  i n t e r - * r e s p o n s e  i n t e r v a l s  i n  w h ic h  b e h a v i o u r s  o t h e r  t h a n  e a t i n g  w e r e  
o b s e r v e d ,  a n d  t h e  l a t t e r  a s  a  p r o p o r t i o n  o f  t h e  t o t a l .  F o r  c l a r i t y ,  t h e  
p e r c e n t a g e  s c a l e  h a s  b e e n  d i s p l a c e d  u p w a r d s .
Fig. 4
F o r  e a c h  s u b j e c t , -  t h e  b r e a k p o i n t  w a s  i d e n t i f i e d  b y  l o g  s u r v i v o r  a n a l y s i s  ( s e e  
t e x t ) ,  a n d  t h e  f r e q u e n c y  d i s t r i b u t i o n  o f  i n t e r - r e s p o n s e  t i m e s  p l o t t e d  f o r  12 
s e c o n d s  e i t h e r  s i d e  o f  t h e  b r e a k p o i n t .  T h e  f i g u r e  sh o w s t h e  IR T  f r e q u e n c y  - 
(m e an  o f  a l l  a n i m a l s ) , t h e  d i s t r i b u t i o n  o f  t h o s e  i n t e r —r e s p o n s e  
i n t e r v a l s  i n  w h ic h  b e h a v i o u r s  o t h e r  t h a n  e a t i n g  w e r e  o b s e r v e d ,  a n d  t h e  l a t t e r
e s  a  p r o p o r t i o n  o f  t h e  t o t a l .  F o r  c l a r i t y ,  t h e  p e r c e n t a g e  s c a l e  h a s  b e e n  
d i s p l a c e d  u p w a r d s .  • ‘
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TABLE 2
COMPARISON OF MICROSTRUCTURAL PARAMETERS 
DERIVED FROM DIRECT OBSERVATION AND FROM 
LOG SURVIVOR ANALYSIS
E a t i n g  r a t e  
( p e l l e t s / s )
C a l c u l a t e d  .1 6 2 ( 1 .0 0 7 )
E a t i n g  t im e  
( s )
1 2 8 9 (1 7 0 )
T ru e  
E r r o r  %
A d ju s te d  
E r r o r  %
,1 6 4 ( 1 .0 0 7 )
- 1 . 3 ( 1 1 . 0 )
N um ber o f  
b o u t s
1 2 . 3 ( 1 1 .3 )
1 2 0 5 (1 5 5 )  2 3 . 1 ( 1 1 .8 )
6 . 5 ( 1 1 . 7 )  - 4 3 . 7 ( 1 6 . 3 )
1 3 0 8 (1 5 5 )  1 6 . 9 ( 1 1 .3 )
- 2 . 1 ( 1 1 . 4 )  - 2 5 . 0 ( 1 6 . 6 )
B o u t l e n g t h  
( s )
1 2 8 (1 2 1 )
6 2 (1 6 )
4 1 . 0 ( 1 7 .4 )
8 3 (1 7 )
2 2 . 9 ( 1 7 .7 )
M i c r o s t r u c t u r a l  p a r a m e t e r s  w e re  c a l c u l a t e d  u s i n g  t h e  b o u t  c r i t e r i o n  d e r i v e d  
from  lo g  s u r v i v o r  a n a l y s i s  ( s e e  t e x t ) .  " T ru e "  v a l u e s  w e re  o b t a i n e d  by  d i r e c t  
o b s e r v a t i o n .  The " a d j u s t e d "  v a l u e s  a d d  4 .5  s  p e r  b o u t  t o  " t r u e "  e a t i n g  t i m e ,  
and  e x c lu d e  g a p s  o f  l e s s  t h a n  10 s  w hen c o u n t in g  t h e  n um ber o f  b o u t s .  The 
p e r c e n ta g e  e r r o r  te r m s  r e f e r  t o  c a l c u l a t e d  v a l u e s  i n  r e l a t i o n  t o  t r u e / a d j u s t e d  
v a l u e s .  A l l  v a l u e s  a r e  m ean s (1  s t a n d a r d  e r r o r ) .
■t f'l
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Estimates of eating time and local eating rate were calculated 
using the breakpoint as described above. Also, the values of 
these parameters were corrected, by excluding from eating bouts 
the 5.87. of short inter-response intervals which the film showed 
to be false positives, and including the 11.6X of long intervals 
which were false negative^^ Compared with these corrected 
values, the crude values under-estimated eating rate by 1.37. i+/~ 
1.07) and over-estimated eating time by 6.57 (+/- 1.77). Eating 
rate appears to be a very robust measure, which is not 
significantly affected (t = 1.3, p>0.1) by the small proportion 
of errors. Although eating time was less robust, the figure of 
6.57. overestimates and exaggerates the error, since the corrected 
eating time makes no allowance for the final pellet of each bout. 
If it is assumed that these pellets were consumed in the modal 
time of 4.5 sec (figure 3), then a further corrected estimate of 
eating time may be made (table 2). This figure is higher than 
the calculated value by an insignificant 2.17. (+/- 1.47) (t = 
1.5, p>0.1). Thus, as the effects of the two types of error to 
some extent cancel one another out, the original crude values for 
both eating time and eating rate are very close to their true 
values.
ill'Ii, 1
Estimates of the number and length of bouts were less accurate, 
with errors in excess of 407. However, it is likely that a 
proportion of the gaps noted on the film were wrongly 
categorized, since at very short intervals these usually 
consisted of a single rear or turn by the rat, both of which are 
compatible with continued eating} indeed, it was sometimes r'-> KHl
81
M k
1V L' -i »i
i * i
! i’ •>!?«
possible to see that an animal did continue to eat whilst moving 
away -from the -food dispenser. I-f very short gaps (<10 sec) are 
excluded -from the calculation (table 2), then the discrepancy in 
the number and length of bouts, though still marked, is 
considerably reduced <25 and 23'/. respectively).
3.6.3. DISCUSSION
During a microstructural analysis, the emphasis is directed not
to ’what constitutes a meal’, but rather to whether at any moment
an animal is eating or not. In order that there is a high
probability that they will eat during the half hour test session,
animals were deprived for 21 hours. This is necessary for log
survivor analysis, because the method depends on a large number
0of data points. If there were evidence of a meal ending, instead 
of the animals eating in discrete bouts within a meal, then the 
calculated microstructural parameters of feeding could be
misleading. As the intermeal gap length would now have to be 
calculated instead of the interbout gap length, there would be an 
apparent increase in gap length. However, in the experiments 
presented in this thesis gaps of more than 10 minutes (the 
criterion of a meal generally accepted in the literature) are 
almost never seen in control animals.
i|5
In conclusion, the method here described is clearly more 
successful than the use of arbitrary criteria for discriminating 
between eating and not eating. Compared with continuous 
observation, the method produces very accurate estimates of
82 ■r f.rU [. 1
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eating rate and eating time. The method underestimates the 
number and over-estimates the length of eating bouts, but it does 
have the advantage that the bout criterion is unambiguous, rather 
than relying on the often difficult subjective judgement of 
whether an animal is eating or not. Error arises from the fact 
that the frequency of continuously reinforced feeding reponses 
decreases as IRT increases, which means that there are more 
responses at IRT values below the breakpoint than above (figure 
4); the error is therefore relatively constant between subjects. 
As will be shown in the following chapter, results obtained using 
the present method are consistent with those obtained by previous 
authors using conventional observâtional methods.
li i :■
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This microstructural analysis technique has been successfully 
used to analyse feeding behaviour in a number of experiments, 
including those in the next chapter, which assess the relative 
contributions of NA and DA mediated-mechanisms to amphetamine- 
induced suppression of feeding.
Vi
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•findings vary at low doses of the drugs two studies show a 
stimulation of feeding at around 0.1 and 0.25 mg/kg (Blundell and 
Latham 1978, Dobrzanski and Doggett 1976), whilst the more common 
finding is a slight reduction of feeding (Cooper et al 1979). 
Intracranial administration of amphetamine also has variable 
effects on feeding, depending on the site of injection. Low
doses of amphetamine (0.125 mg/kg and 0.25 mg/kg) injected into
the striatum produce a stimulation of feeding (Winn et al 1982); 
the same is true of administration into the PON (Leibowitz 1980) 
and parts of the LH (see experiment 5). However, the more common 
finding following amphetamine injection in the LH is a marked 
reduction in feeding (Leibowitz and Rossakis 1978). Findings at 
higher doses from both peripheral and central studies all concur 
in showing a marked anorexia.
This experiment examined the dose-response relationships of 
amphetamine anorexia using the microstructural analysis of
feeding outlined in the previous chapter. The experiment was 
also used as a further validation study of the log survivor 
analysis of eating, by comparing these results with those
obtained by Blundell and Latham (1980) through direct observation 
(see chapter 3, section 3.2.).
4.2.2. METHOD 
Subjects
Twenty-four male Lister hooded rats (OLAC), weight 280-350g, were 
individually housed and maintained throughout the experiment on a
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21-hour -food deprivation schedule, in which -food was available 
between 14.00h and 17.00h daily, with water available ad lib. 
The animals had been previously trained to press the tray door of 
the operant chamber for food reward.
I
Apparatus
The animals were trained to feed by pressing the door of the 
pellet dispenser in one of six identical operant chambers, as 
described in chapter 3. Ten—minute daily sessions were run until 
all animals reached asymptotic performance.
I
iil
Drugs and Procedure
Six treatment conditions were used: control (distilled water)
and five doses of d-amphetamine sulphate (Smith, Kline and 
French) 0.125, 0.25, 0.40, 0.50 and 1.0 mg/kg. Doses were
calculated as salts and all injections were made i.p. at a volume 
of 1 ml/kg. All animals received each treatment once, over
six experimental days, according to an individually randomized 
design. Animals were injected between the hours of 10.00 and 
13.00, 30 minutes before their test session which lasted for 30
mi ñutes.
l i
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Log survivor curves were constructed for each session for each 
animal; in addition, a set of curves was constructed for each 
treatment condition using the grouped data from all animals. In 
this and all subsequent microstructural analysis experiments 
reported in this thesis, breakpoints were determined for each of 
the individual curves by two independent judges, who were blind
f
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as to the treatments administered. Mhen there was
•lOh;
disagreement, which was seldom, the value was chosen which was 
closer to the centre of the breakpoint region in the grouped 
curves. The grouped curves for the present experiment were 
presented in chapter 3, section 3.5.2. Following identification 
of the breakpoint, the microstructural parameters of feeding were 
calculated, and subjected to analysis of variance, supplemented 
by tests of simple main effects.
4.2.3. RESULTS
Amphetamine caused a small and reliable reduction in total food 
intake at 0.40 (147.) and 0.50 (137.) mg/kg (F (1,115) =9.11 and 
7.88 respectively, p<.01). This reduction was enhanced at 1.0 
mg/kg (377.) and was highly significant <F (1,115) = 64.95, 
p<.00l; see figure 5A). Lower doses of amphetamine either had no 
effect (0.125 mg/kg) or caused a small (57.) but insignificant 
reduction (0.25 mg/kg). The anorexia observed at 0.40, 0.50 and 
1.0 mg/kg is entirely attributable to significant reductions in 
eating time (F (1,115) = 20.09, 38.08, 125.84 respectively, 
p<.001; see figure 50, Amphetamine also caused an increase in 
eating rate, which was significant at 0.50 and 1.0 mg/kg (F 
(1,115) = 8.14 and 8.99 respectively, p<.01, figure 5B).
The reductions in eating time appeared to be brought about 
primarily by reductions in bout length, which - like the effects 
on eating time - were highly significant (F (1,115) = 18.45, 
27.27, 63.45, p<.001) at 0.40, 0.50 and 1.0 mg/kg respectively
■y:
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(figure 5D). At these doses, amphetamine caused significant 
increases in the number of bouts (0.40 mg/kg, F (1,115) » 8.18, 
p<.01, 0.50 and 1.0 mg/kg, F (1,115) * 19.68 and 37.51 
respectively, p<.001, figure 5F). Gap length Mas very slightly 
increased, at 0.25 mg/kg and above, though these changes did not 
reach statistical significance (figure 5E). Amphetamine 
significantly increased the latency to initiate feeding at a dose 
of 1.0 mg/kg (F (1,115) = 8.26, p<.01 figure 5G). Means and 
S.Es. together with overall F-ratios for the microstructural 
parameters are given in table 3.
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TABLE 5
CHiHGES IN MICROSaRDClQRiL PlRiMETmS FOLLOWING TARIODS B08BS( 07 IHFHBIIMINB
Bos« of oqph«tnino (a|/lc|r) 7 BsUo
Nloxostraotaral
Paxaai«t«cr
0 0.125 0¿25 0.40 0.50
Total 213 214 204 184 186
Rat« 0.176 0.184 0.187 0.184 0.202
TIb « 1153.77 1081.21 988.88 903.24 816.4
Bout l«D«r^ 92.9 81.9 67.5 56.1 48.2
Gap lon^ rtii 49.5 47.4 52.0 50.5 50.0
B<mt« 14.6 16.2 17.3 19.9 22.8
Lat«no7 14.59 16.70 14.92 14.53 19.23
Chang« In food 
Intak« %
- 40.5 -5.0 -13.6 -12.7
'll
Bifforone«« b«tv««B oontxol «ad 1,0 «apkotadB« ar« sbovn bf p Tala«««
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4.2.4. DISCUSSION
The most striking result to emerge -from this study is the dose- 
related decrease in eating time, which become apparent at a dose 
as low as 0.25 mg/kg. Reductions in eating time therefore 
appear to be responsible for the anorexia observed following 
amphetamine treatment (Blundell and Latham 1980, Cooper et al 
1979, 1981). Accompanying a reduction in eating time is an
increase in eating rate at the two highest doses of amphetamine 
(0.50 and 1.0 mg/kg). This result is paradoxical in that, 
without a concomitant reduction in time, an increase in eating 
rate would actually increase food intake. This experiment showed 
no increase in food intake following low doses of amphetamine, as 
the small increase in rate and small decrease in time exactly 
cancelled each other out at 0.125 mg/kg. The increase in food 
intake sometimes observed at this dose can pC55cM^  be explained 
by a proportional1y greater increase in eating rate.
a
The dose-related reduction in eating time could be caused by an 
increase in gap length, a decrease in bout length or an increased 
latency, or any combination of these parameters. In fact the 
main component underlying the decrease in eating time is a strong 
dose—related reduction in bout length. Changes in gap length 
were not significant. However, doses of amphetamine that reduced 
food intake did cause non-significant increases in gap length 
compared to control values, whilst a dose of 0.125 mg/kg, which 
did not change food intake, slightly reduced gap length ~ a 
result consistent with stimulation of feeding. An increased
iii
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latency observed at 1.0 mg/kg contributed to the dramatic 
reduction in eating time seen between 0.5 mg/kg and 1.0 mg/kg. 
However, latency measures at other doses showed no significant 
changes, probably due to the high motivational state of the 
animal to eat, imposed by 21 hour food deprivation. In addition 
to these parameters supporting a decrease in eating time, the 
number of bouts taken by the animals increased in a dose-related 
fashion with significance being reached at 0.4 mg/kg (p<.01 ), 0.5 
and 1.0 mg/kg <p<.001).
The results obtained in this study are consistent with those of 
Blundell and Latham (1980), but not of Cooper et al (1979), who 
observed a significant reduction of food intake at 0.25 mg/kg. 
Furthermore, at the higher dose of 1.0 mg/kg. Cooper et al were 
unable to show any increase in rate brought about by amphetamine 
treatment. As discussed in the previous chapter, this result is 
probably an artefact of their methodology.
Estimation of the microstructural parameters of feeding depends 
on the identification of the breakpoint. The mean breakpoint 
values for the 6 amphetamine doses are presented in table 4 
(which also includes comparable data for experiments 3 and 4). 
The breakpoint values differed significantly between the control 
and 1.0 mg/kg treatments (F (1,115) * 4.90, p<.05). If there 
were a problem in the methodology of microstructural analysis, 
the fairly consistent increase in rate following amphetamine 
treatment could be an artefact. For this reason IRT frequency 
curves were constructed to represent the raw data* graphically
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MEAN BBSAEPOINTS FOR E!CP£&IHHra3 2, 3 and 4 
BXPmiHBOT 2
Do0« of antphotuino
(W k ff )
0
0.125
0.25
0.40
0.50
1.00
Moan braakpolnt
16.42
16.16
16.87
16.5
15.0
14.45
h:
m
EXPHUNOrT 3
Zraataant
Control
Propranolol
imphataiilna
Anphatanlni/Propanolol
Moan braakpolnt
ti
EXPmiKBST 4 h I
Traatmant Maan braakpolnt
Control 17Anphataalna 0.5 12
Anphataalna 1.0 13
Plaoalda 0.45 20
Plaoslda 0.45 -i- 17
amphataalna 0.5
Plaoslda 0.45 + 16
asqphatamlna 1.0
Traataant
(■®^)
Control
iaphataaina 0.5 
iBphataaina 1.0 
Biioridaalna 5.0 
BtloxldaBina 5.0 
aaphataaina 0.5 
Ibiorldaslna 5.0 
aiqphataBlna 1.0
Maan braakpolnt
18
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In summary then, the main mechanism by which amphetamine produces 
anorexia is a decrease in eating time, and at the highest dose, 
an increased latency to eat. A concomitant increase in rate is 
also observable. A theory of amphetamine action has been 
proposed by Lyons and Robbins <1975), who explain the behavioural 
effects of amphetamine in terms of increased response rates 
within a decreasing number of response categories. Winn et al 
(1982) present evidence in support of this hypothesis* 
amphetamine injected into the striatum at very low doses was 
found to stimulate feeding and, in the absence of food, other 
behaviours such as locomotion. As the dose of amphetamine was 
increased, feeding was suppressed as well as other complex 
behavioural sequences, until finally simpler acts such as rearing 
and repetitive motor stereotypies were observed. These findings 
suggest that the decreased food intake after amphetamine does not 
represent a true anorexia but simply reflects the facilitation of 
behaviours that are incompatible with feeding. However, 
Dobrzanski and Doggett (1979) and Blundell and Latham (1978) have 
reported that the increased feeding with low doses of amphetamine 
was unaccompanied by evidence of any increase in general 
activity. This raises the possiblity that low doses might be 
selective for brain mechanisms specifically involved in the 
control of food intake, such as the hypothalamic mechanism 
sensitive to NA, which is known to enhance feeding (see chapter 
2, section 2.5.1.).
• >1
vj -l»t I
Studies using DA receptor antagonists to reverse amphetamine
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anoreia have nearly all reached similar conclusions. In most 
studies, pretreatment with a DA-receptor blocking drug can 
reverse a large component of amphetamine anorexia, (e.g. Kruk 
1973). Burridge and Blundell (1979), on the other hand, have 
reported that whilst the DA receptor blocker pimozide (amongst 
other typical neuroleptics) was effective in reversing the 
anorexic effect of higher doses of amphetamine (1.0 mg/kg and 2.0 
mg/kg), thioridazine and clozapine, which are atypical 
neuroleptics, did not attenuate amphetamine anorexia at any dose. 
Typical neuroleptics are known to antagonise DA-mediated 
hyperactivity or amphetamine stereotypy (Costall and Naylor 
1975), whereas atypical neuroleptics are not. On the basis of 
such findings and their own observations, Burridge and Blundell 
(1979) postulated that the anorexia observed following 1.0 and 
2.0 mg/kg of amphetamine treatment is due to the inability of 
animals to eat on account of competing behavioural responses such 
as stereotypy, whilst low dose anorexia is a 'true' anorexia 
mediated in the LH.
H
.■■ ‘.1
Another finding to emerge from thr Burridge and Blundell study 
was evidence of non-DA mediation of the low dose anorexia. All 
neuroleptics, including pimozide, failed to reverse the anorexic 
effect of 0.5 mg/kg amphetamine, and when reversal was apparent 
at the 1.0 and 2.0 mg/kg dose, it was not total, thereby 
implicating the involvement of another mechanisms, most probably 
NA. In addition to the lesion studies of Ahlskog and Leibowitz 
cited in chapter 2, which support this view, is the finding that
i
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low doses o-f amphetamine exert a more potent blockade of the re­
uptake of NA than DA (Samanin et al 1978).
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4.3. EXPERIMENÎ 3i MlÇRQSIRyÇIURAL ANALYSIS OF JHE INVOLyEMENI 
QE BilBrBiCEPIQRS IN AMPHEÎAMINE ANOREXIA 
4.3.1. INTRODUCTION
Studies employing central drug administration also suggest that 
amphetamine anorexia is not mediated solely by DA. Injection of 
beta-adrenergic receptor blocking drugs in the region of the 
perifornical hypothalamus attenuate the anorexic effect of 
centrally or peripherally administered amphetamine; this and 
several other lines of evidence strongly support the concept of a 
beta-adrenergic satiety system in the perifornical hypothalamus 
(see chapter 2, section 2.5.2.2.). On the basis of these
results, it would be expected that amphetamine anorexia should 
also be attenuated by peripherally administered beta-blockers. 
Paradoxical 1 y, however, this does not appear to be the case. 
Preliminary studies in this laboratory failed to demonstrate 
attentuation of amphetamine anorexia by the beta-blocker 
propranolol, and with one exception, (Sanghvi et al 1975), 
previous investigations have had similar results (e.g. Dobrzanski 
and Doggett 1979).
The resolution of this paradox may lie in the observation that 
propranolol impairs the metabolism of amphetamine (Shoeman et al 
1974). This effectively increases the dose of amphetamine 
reaching the brain, which would tend to mask a partial blockade 
of the anorexic effect. In the present experiment, this
100
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possibility Mas investigated using the technique of 
microstructural analysis. It Mas reasoned that if the 
dopaminergic and beta-adrenergic systems control different 
parameters of feeding, then these might be differentially 
affected by propranolol. Specifically, if any amphetamine- 
induced microstructural changes are mediated by beta—receptors, 
then such changes might be blocked by propranolol, Mhilst at the 
same time microstructural changes, Mhich are mediated by DA 
receptors, Mould be enchanced by propranolol because of a higher 
amphetamine dose, arising from impairment of amphetamine 
metaboli sm.
If
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The dose of propranolol used in this experiment Mas chosen on the 
basis of the consideration that the dose should be as high as 
possible, but should not itself produce an anorexic effect, since 
that Mould unduly complicate interpretation of the results. In 
preliminary studies. Me found that a small (20X) but significant 
anorectic effect Mas produced by 10 mg/kg propranolol; a dose of 
5 mg/kg Mas therefore chosen for the present study.
4.3.2. METHOD 
Subjects
TMenty-four male Lister hooded rats (Meight 360-430 g) Mere 
trained to feed by pressing the door of the pellet dispenser in 
one of three identical operant chambers, as described in chapter 
3, experiment 1. Ten-minute daily sessions Mere run until all 
animals attained asymptotic performance.
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Drugs and Procedure
On experimental days, the animals received two intraperitoneal 
injections: propranolol HCl (5 mg/kg) (Sigma) was administered 60 
minutes before the start of the session and d-amphetamine 
sulphate (0.5 mg/kg) (Smith, Kline and French) 30 minutes before. 
Control injections in both cases were distilled water (1 ml/kg). 
Each animal received all four treatment combinations in a 
counterbalanced order, at two-day intervals. On the intervening 
days, a ten-minute session was run, with no drug treatments. 
During experimental sessions, which were 30 minutes long, a 
computer recorded each response on the tray door, as described in 
chapter 3, experiment 1. Analysis of microstructural parameters 
of feeding was carried out as described previously (see chapter 
3, experiment 1). Results were analysed by analysis of variance, 
supplemented by tests of simple main effects. The mean 
breakpoint in the four conditions varied between 16.8 and 18.3 
seconds; the differences were not significant (all F-ratios<l, 
see table 4) .
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4.3.3. RESULTS
Amphetamine caused a small (13/.) but highly significant (F (1,46) 
= 12.83, p<0.001) decrease in food intake (figure 7A), which was
apparently blocked by propranolol pretreatment (interaction: F 
(1,23) = 3.2, 0.05<p<0.1). However, this conclusion would be
seriously misleading. Total food intake may be broken down into 
eating rate and eating time (figures 7B and 70, and propranolol 
actually increased the amphetamine-induced changes in both these
'^3
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parameters: eating rate was only very slightly increased by 
amphetamine alone, but a substantial increase was seen following 
propranolol pretreatment <F (1,46) = 9.22, p<.01); eating time 
was decreased by amphetamine, and this effect was also somewhat 
greater following propranolol pretreatment (F (1,46) = 17.42, 
p<.001). It is the combination of decreased eating time and 
increased eating rate, which results in no significant net change 
in total intake, following propranolol pretreatment.
A description of the distribution of behaviour within the session 
is given by the mean length of feeding bouts, the mean length of 
gaps between bouts, and the initial latency; these three 
parameters determine the total feeding time. As in experiment 2, 
amphetamine reduced eating time and therefore reduced bout length 
and increased gap length. In the present experiment the 
amphetamine-induced increase in gap length was statistically 
significant (F (1,46)= 11.21, p<.01, figure 7E) but the decrease 
in bout length was not (figure 7D). Propranolol treatment 
blocked the effect of amphetamine on gap length (figure 7E). 
There were smaller, but insignificant effects on latency (figure 
7F) .
Propranolol significantly increased bout length (F (1,46) = 5.35, 
P<.01, figure 7D)j this effect led to an increase in eating time 
(F (1,46) = 6.15, p<.01, figure 70, and is reflected in an 
increase in bout size (F (1,46) = 6.44, p<.05, figure 7G), and a 
decrease in the number of bouts (F (1,46) = 5.21, p<.05, figure
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7H). As in the case cj eating rate, propranolol increased the 
effect of amphetamine on bout length (F (1,46) = 7.45, p<.01, 
figure 7D) , bout size (F (1,46 = 7.88, pC.Ol, figure 78) and the 
number of bouts (F (1,46) = 7.22, p<.01, figure 7H)i on each of 
these measures, significant effects of amphetamine were seen 
following propranolol pretreatment, but amphetamine alone 
produced small and insignificant effects.
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E f f e c t  o f  a m p h e ta ia ln e  a n d  p r o p r a n o l o l  o n  m i c r o s t r u c t u r a l  p a r a m e t e r s .
A: T o t a l  f o o d  i n t a k e ;  B ; L o c a l  e a t i n g  r a t e ;  C : E a t i n g  t i m e ;  E : B o u t 
l e n g t h ;  E : G ap l e n g t h ;  F :  L a t e n c y ;  G: B o u t  s i z e ;  H; N um ber o f  b o u t s .  
C i r c l e s  sh o w  t h e  s c o r e s  i n  e a c h  c o n d i t i o n :  L e f t  -  c o n t r o l ,  r i g h t  -  a m p h e ta m in e ;  
w h i te  -  c o n t r o l ,  * b la c k  -  p r o p r a n o l o l .  B a r s  sh o w  t h e  d i f f e r e n c e  b r o u g h t  a b o u t  
b y  a m p h e ta m in e  (m ean  +  s t a n d a r d  e r r o r ) :  w h i t e  -  c o n t r o l ,  b l a c k  -  p r o p r a n o l o l  
p r e t r e a t m e n t .  O ne s t a r  -  p  < 0 . 0 5 ;  tw o  s t a r s  -  p  < 0 . 0 1 ;  t h r e e  s t a r s  -  
P < 0 .0 0 1 .
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In order to explore these interactions further, the correlations 
between effects of amphetamine on the different microstructural 
parameters were examined (table 5). In both pretreatment 
conditions, the effect of amphetamine on eating time was 
significantly correlated with the change in total food intakes 
after propranolol pretreatment, there was also a significant 
negative correlation between the decrease in food intake and the 
increase in eating rate. In both conditions, a significant 
correlation was seen between the increase in eating rate and the 
decrease in bout length (even though in the control condition 
there was no significant net change in either). However, changes 
in these parameters were uncorrelated (in one case, there was a 
significant negative correlation) with increases in gap length. 
In the control condition only, changes in gap length were 
significantly correlated with changes in total food intake.
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TABLE 5
INTERCORRELATIONS BETWEEN AMPHETAMINE-INDUCED 
CHANGES IN MICROSTRUCTURAL PARAMETERS
T o t a l  + R a te  + Tim e +
B o u t
L e n g th  4-
Gap
L e n g th  +
Time 4
B out l e n g t h  4 
Gap l e n g t h  4
The t a b l e  sh ow s c o r r e l a t i o n s  (S p e a rm a n  r a n k - o r d e r  c o r r e l a t i o n  c o e f f i c i e n t s )  
b e tw e e n  t h e  c h a n g e s  I n d u c e d  b y  a m p h e ta m in e  i n  d i f f e r e n t  m i c r o s t r u c t u r a l  
p a r a m e t e r s .  O ne s t a r ,  p  < 0 .0 5 ;  tw o s t a r s ,  p < 0 . 0 1 .  T he u p p e r  p a r t  o f  
th e  t a b l e  show s v a l u e s  o b t a i n e d  i n  c o n t r o l  c o n d i t i o n s ;  t h e  lo w e r  p a r t  show s 
v a lu e s  o b t a i n e d  f o l l o w i n g  p r o p r a n o l o l  p r e t r e a t m e n t .  A rro w s  show  th e  
d i r e c t i o n  o f  c h a n g e ;  u n d e r l i n e d  p a r a m e t e r s  w e re  t h o s e  i n  w h ic h  s i g n i f i c a n t  
n e t  c h a n g e s  w e re  s e e n .
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4.3.4. DISCUSSION
The apparent outcome o-f this experiment v^ as an attenuation of 
amphetamine anorexia by propranolol. However, it is clear from 
the microstructural analysis that this result is largely 
fortuitous, since propranolol, amphetamine and the propranolol- 
amphetamine combination each produced a different pattern of 
behavioural changes.
Propranolol did not affect eating rate, but increased bout 
length, and consequently, bout size and eating time. Whilst 
these effects did not cause a significant increase in food 
intake, it is clear that appropriate testing circumstances might 
reveal hyperphagia, and this has, in fact, been observed 
(Dobrzanski and Doggett 1979). This result is consistent with 
the finding that hyperphagia was caused by lesions to adrenergic 
systems innervating the perifornical hypothalamus (Leibowitz and 
Brown 1980b), and with the concept of a beta—adrenergic satiety
system.
In this experiment amphetamine anorexia was caused by a decrease 
in eating time which led to an increased gap length. In contrast 
to the effect of amphetamine alone, after propranolol 
pretreatment, gap length was the only parameter (other than 
latency) which was not significantly altered by amphetamine. The 
animals showed, on the one hand, a different hypophagic effect 
(decreased bout length), and on the other, a hyperphagic effect 
(increased eating rate). As a result, there was no significant
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(Schmitt 1973). It is important, however, not to lose sight of 
the fact that in the present study, propranolol did block the 
effect underlying amphetamine anorexia, and also blocked the 
correlation between changes in gap length and changes in total 
food intake.
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The starting point for the interpretation of these results is the 
observation that propranolol interferes with the metabolism of 
amphetamine. To what extent may the effects of propranolol be 
understood as simply an increase in the dose of amphetamine? In 
this study, only a single dose of amphetamine, 0.5 mg/kg was 
tested. However, it is well established that amphetamine at 1 
mg/kg significantly increases eating rate and decreases eating 
time, a result supported by experiment 2. It has also been 
reported (or it is possible to calculate from published figures) 
that bout length and bout size were decreased by amphetamine 
(Blundell and Latham 1978, Blundell and Latham 1980*/v experiment 
4). Data on the length of gaps has not previously been reported 
in the literature, but from published figures it is possible to 
calculate that amphetamine caused a substantial increase in gap 
length. Furthermore, the results from experiment 2 (figure 5E)
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show a slight increase in gap length at doses o-f 0.125 mg/kg or 
above, although these increases did not reach statistical 
significance. The effects of propranolol are therefore consistent 
with a functional increase in the dose of amphetamine, with one 
exception: gap length. Propranolol blocked the effect of
amphetamine on gap length, where an increase would be predicted
■from an increase in dose.
Not only was gap length the only parameter which was 
significantly altered by amphetamine alone in this experiment, 
but also, this was the one parameter which was not significantly 
intercorrelated with all the others. The results therefore 
suggest the involvement of two separate mediating systems. At 
low doses, amphetamine induces anorexia by increasing gap length 
(i.e. reducing the tendency to begin eating), and at higher doses 
(assumed to result from propranolol pretreatment), a number of 
other mechanisms come into play. The anorexic effect of the low 
dose appears to be mediated by beta-receptors, since the increase 
in gap length was blocked by propranolol. The other effects 
appear to be dopaminergical 1y mediated, since it has been 
reported that the changes in eating rate, bout length and bout 
size were antagonized by DA receptor blocking drugs (see chapter 
3 ) .  It is of great relevance to the present argument that in the 
study of Blundell and Latham (1980), gap length (calculated from 
published figures) was the one feeding parameter which was 
unaffected by the DA receptor blocker pimozide.
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4.4. EXPERIMENI 4i MICRÜSIRUCIURAL ANALYSIS OF IHE INVOLVEMENI 
QF DOPAMINE RECEPIQRS IN AMPHEIAMINE ANOREXIA
4.4.1. INTRODUCTION
The amphetamine-induced decrease in eating time, increase in 
eating rate and increase in latency to initiate -feeding have been 
shown to be reversed by the DA-receptor antagonist, pimozide 
(Blundell and Latham 1980). In order to confirm an involvement 
of DA in amphetamine anorexia under the present experimental 
conditions, this experiment examined pimozide challenge to two 
doses of amphetamine <0.5 mg/kg and 1.0 mg/kg). The effects of 
the atypical neuroleptic, thioridazine, found to be ineffective 
at reversing amphetamine stereotypy and locomotor activity 
(Dental 1 and Herberg 1980) were also examined.
4.4.2. METHOD 
Subjects
Twelve male Lister hooded rats (weight 280-320g), were 
individually housed and maintained on 21-hour food deprivation, 
with water available ad lib. Animals had had previous experience 
of amphetamine administration (subjects were used in experiment 
2) but had been drug free for approximately one month.
Drugs and Procedure
The animals were reintroduced to the six identical operant 
chambers, in which they had previously been trained to feed by 
pressing the door of the pellet dispenser (experiment 2), and ten
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minute daily sessions were run until all animals returned to 
asymptotic performance. On experimental days, all animals 
received two intraperitoneal injections. As in experiment 3, 
doses of pimozide and thioridazine used in this present 
experiment were chosen on the basis of the consideration that the 
doses should be as high as possible, but should not in themselves 
produces an anorexic effect. The doses chosen, 0.45 mg/kg of 
pimozide and 5.0 mg/kg of thioridazine, were taken from a dose- 
response study of these drugs carried out in this laboratory by 
R. Muscat.
1. -1
Fimozide (N=6, (0.45 mg/kg)), or thioridazine (N=6, (5.00 
mg/kg)), were administered two hours, and d-amphetamine sulphate 
(0.5 mg/kg or 1.0 mg/kg), 30 minutes before the start of the 
session. Control injections in all cases were vehicle, (either 
glacial acetic acid in the case of pimozide, distilled water in 
the case of amphetamine and physiological saline in the case of 
thioridazine), at a volume of 1 ml/kg. Each animal received all 
four treatment combinations in a counterbalanced order, at two 
day intervals; on intervening days a ten minute session was run 
with no drug treatments. During experimental sessions, which 
were thirty minutes long, a computer recorded each response on 
the tray door, as described previously.
Analysis of microstructural parameters of feeding was carried out 
as described in experiment 1. Results were analysed by analysis 
of variance, supplemented by tests of simple main effects.
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4.4.3. RESULTS
4.4.3.1. Pimozide
Amphetamine caused a dose related reduction in -food intake (0.5 
mg/kg, F (1,20) = 11.88, p<.01; 1.0 mg/kg, F (1,20) * 22.63, 
p<.001, figure 8A). As in experiments 2 and 3 amphetamine caused 
anorexia by decreasing eating time (F (1,20) * 24.04 and 36.41, 
p<.001 at 0.5 mg/kg and 1.0 mg/kg respectively, -figure 8 0  ; this 
was caused by slight increases in gap length and latency with 
decreases in bout length, although none o-f these changes reached 
si gni-f i cance owing to the small number o-f subjects (figures 8E, 
8G and 8D respectivly). Amphetamine also increased the rate of 
eating in a dose-related fashion (0.5 mg/kg, F (1,20) = 5.70, 
p<.05; 1.0 mg/kg, F (1,20) = 10.57, p-^ .Ol, figure 80, and also 
increased the number of eating bouts (0.5 mg/kg, F (1,20) = 
13.58, pC.Ol; 1.0 mg/kg, F (1,20) = 17.46, p<.001, figure 8F).
Following pimozide pretreatment, the reduction in food intake 
brought about by amphetamine was greatly attenuated (F (1,15) = 
10.29 and 14.64, p<.01, for 0.5 and 1.0 mg/kg respectively, 
figure 8A). Pimozide pretreatment also blocked the 
amphetamine-induced reduction in eating time (0.5 mg/kg, F (1,15)
= 18.32, p<.001; 1.0 mg/kg, F (1,15) = 11.95, p<.01, figure 80, 
and reversed the slight changes in gap length, latency and 
bout length (figures 8E, 8G and 8D respectively), though none of 
these latter effects reached significance. Pimozide pretreatment 
attenuated the amphetamine-induced increase in rate at 0.5 mg/kg 
<F (1,15) = 6.06, p<.05), but this effect did not reach
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signi-ficance at 1,0 mg/kg (figure SB). The pretreatment also 
attenuated the amphetamine-induced increase in number of bouts 
(0.5 mg/kg and 1.0 mg/kg, F (1,15) = 8.42 and 5.82 respectively, 
p<.05, figure 8F). Pimozide significantly increased bout length 
<F (1,15) = 4.76, p<.05, figure 8D); this effect led to an 
increase in eating time (figure 8 0  and a slight increase in the 
total number of pellets (figure 8A). Changes in these parameters 
were not significant.
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4.4.3.2. Thioridazine
The e-f-fects of amphe'tafnine on food intake were similar to those 
seen in the pimozide experiment. Amphetamine significantly 
reduced food intake (0.5 mg/kg, F (1,20) = 4.95, p<.05| 1.0
mg/kg, F (1,20) = 14.02, p<. .01, figure 9A) . Amphetamine reduced 
eating time (0.5 mg/kg and 1.0 mg/kg, F (1,20) = 17.70 and 29.76 
respectively, p<.001, figure 9 0  and bout length (0.5 mg/kg, F
(1.20) = 3.78, p>.05; 1.0 mg/kg, F (1,20) = 4.70, p<.05, figure 
9D) and increased gap length (figure 9E) and latency (figure 9G), 
although these latter effects did not reach significance. Unlike 
the significant increases in rate seen following amphetamine 
treatment in experiments 2 and 3, the increases in rate observed 
in this experiment did not reach significance (figure 9B). On 
the other hand, a significant increase was observed in the number 
of bouts taken (0.5 mg/kg, F (1,20) = 7.53, p<.01| 1.0 mg/kg, F
(1.20) = 20.78, p<. .001, figure 9F) following amphetamine.
I
Thioridazine pretreatment had minimal effects on the amphetamine- 
induced changes in total food intake, time and rate (figures 9A, 
C and B respectively). Thioridazine pretreatment attenuated the 
increase in the number of bouts shown by amphetamine at 1.0 mg/kg 
(F (l,ltj) = 5,95, p<,05, figure 9F) , but actually enhanced the
increase in latency at this dose (F (1,15) = 7.97, p<.05, figure
9G) , Thioridazine alone had minimal effects on microstructural 
parameters; like pimozide, thioridazine significantly increased 
bout length (figure 9D), but not eating time (figure 9 0  or total
•food intake (figure 9A) ; in fact thioridazine slightly reduced 
total intake.
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4.4.4. DISCUSSION
The anorexic e-ffects of both doses of amphetamine were blocked by 
the typical neuroleptic pimozide, but not by the atypical 
neuroleptic thioridazine. Pimozide blocked amphetamine anorexia 
by attenuating the amphetamine-induced reduction in eating time, 
allowing animals to spend more time eating. The increased rate 
of eating following amphetamine was also reversed, though only at 
the 0.5 mg/kg dose. Blundell and Latham (1980) also showed 
significant reversal of the effects of amphetamine on eating 
time, rate and latency.
However, these effects of pimozide pretreatment are not entirely 
consistent with the literature. The main discrepancy between 
these results and those of Burridge and Blundell (1979) is the 
reversal of low dose amphetamine anorexia. This difference is 
difficult to resolve as the methodologies and baseline 
amphetamine results of the two studies are similar. In both 
studies, 0.5 mg/kg amphetamine produced around a 257. reduction in 
feeding. The dose of pimozide used in the Burridge and Blundell 
study (0.5 mg/kg) was slightly higher than the dose used in the 
present study (0.45 mg/kg). A higher dose could in principle
induce motor incapacitation, which would disrupt eating. 
However, these authors conducted their own dose-response studies 
of pimozide, which showed no impairment of total food intake at 
0.5 mg/kg. This conclusion is supported by other studies carried 
out in this laboratory, that showed no significant change in 
microstructural parameters following 0.5 mg/kg pimozide. Another
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d i iBfsnce beliwBsn the present study and that ot Burridge and 
Blundell (1979) is the time betir,<een neuroleptic drug treatment 
and the amphetamine injection? Burridge and Blundell allowed two 
hours whilst this experiment used one and a halt hours. However, 
a brief survey of the literature shows corresponding time periods 
of between one and a half hours to four hours. It therefore
seems unlikely that this difference in procedure alone could 
explain the different result. Whatever the interpretation of the 
discrepancy, the present experiment has produced clear evidence 
that low-dose amphetamine anorexia does involve a DA component. 
This result is consistent with studies using central drug 
administration which show blockade of amphetamine anorexia with 
DA receptor antagonists (see chapter 2, section 2.7.). More 
specifical 1y, this experiment has suggested that eating rate and 
eating time may be under the control of DA systems which are 
antagonised by neuroleptic drugs.
This experiment also confirmed the inability of the atypical 
neuroleptic, thioridazine, to reverse amphetamine anorexia, even 
at a dose ten fold greater than that used by Burridge and 
Blundell (1979). Bental1 and Herberg (1980) showed that 
thioridazine at doses of 5, 10 and 20 mg/kg were ineffective at 
reversing amphetamine-induced locomotion and stereotypy, whilst a 
ii»uch smaller dose of spiroperidol was effective. The 
implications of these findings seem to be that the established 
antipsychotic action of thioridazine (Creese et al 1976) depends 
on some property of the drug other than its ability to block the
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DA receptors that are stimulated by amphetamine.
-fll
Classical neuroleptics given acutely, such as haloperidol, are 
known to increase DA cell firing . The atypical neuroleptics, 
such as clozapine and thioridazine, have been shown on acute 
treatment to increase DA cell firing in AlO neurones only (Mhite 
and Wong Chiodo and Bunney 19S3) ■ This selective
dissociation of drug action between A9 and AlO neurons is further 
seen following chronic thioridizine treatment, which causes a 
reduction in transmission at AlO neurons only. It may be the 
selectivity of atypical neuroleptics for AlO neurons which gives 
them their antipsychotic properties and perhaps also, for that 
matter, their relatively low incidence of side effects.
However, if thioridazine is specific for AlO systems, it should 
reverse the amphetamine-induced locomotion which is known to 
result from stmulation of this system (see chapter 6, section 
6.1.). As mentioned above, this is not the case. It may be that 
thioridazine exerts its neuroleptic properties largely through
ypre^naptic DA action which is not entirely reflected in 
amphetamine-induced locomotion.
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4.5. GENERAL DISCUSSION
The microstructural analysis of the action of amphetamine on 
feeding behaviour, which was carried out in this chapter, has 
confirmed previous findings of Blundell and Latham (1978, 1980),
that the feeding parameters mediating amphetamine anorexia are a
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reduction in eating time together with an increase in eating 
rate. In addition, experiment 3 showed that a low dose of 
amphetamine also increased gap length, a finding which would 
support the decrease in eating time. A slight increase in gap 
length following amphetamine treatment was also seen in 
experiments 2 and 4 (figures 5E,8E and 9E), but failed to reach 
significance. This may be due to the lability of gap and bout 
length results in this microstructural procedure (see chapter 3, 
experiment 1, discussion).
Given the evidence in experiment 2 of changes in feeding at 
various doses of amphetamine, experiments 3 and 4 set about to 
characterize the neurochemical substrates underlying these 
changes. As pimozide was effective in antagonizing amphetamine- 
induced changes in eating rate, eating time, bout length and the 
number of bouts taken during the feeding session, it is possible 
that DA mechanisms might mediate both low and high dose 
amphetamine anorexia.
Nevertheless, a beta-adrenergic contribution was also evident in 
reversal by propranolol pretreatment of the increase in gap 
length following a low dose of amphetamine. That DA antagonists 
reversed low-dose amphetamine anorexia might suggested an overall 
cotrol of DA systems over beta-adrenergic systems in the 
modulation of feeding behaviour. This is indicated by the 
results of studies using intracranial drug administration which 
show that DA—induced suppression of feeding cannot be reversed 
by beta-blockers, but adrenal in-induced suppression of feeding
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can be reversed by DA receptor antagonists (see chapter 2,
section 2.5.2.),
The amphetamine-induced increase in gap 1 ength/v decrease //\ the 
likelihood ot starting eating, an effect thought to be mediated 
by beta-receptors. This effect of amphetamine could be an effect 
on the normal control of eating. However, the putative DA- 
mediated effect of amphetamine appears less likely to be a 
specific motivational effect. Lyon and Robbin’s (1976) theory, 
that amphetamine increases the intensity of ongoing behaviour 
within a decreasing number of response categories, is supported 
by the correlations (experiment 3) between the amphetamine- 
induced increase in eating rate and shortening of bouts: 
increases in eating rate were significantly correlated with 
decreases in bout length, both in the control condition and also 
following propranolol pretreatment (table 5). Thus, it may be 
that amphetamine has two anorexic effects, one genuine and the 
other an artefact of the (psycho)motor stimulant effect of 
amphetamine not specific to eating. The specific effect, which 
is only apparent at low doses, appears to be mediated by both 
beta-adrenergic and dopaminergic systems, whilst the stimulant 
effect seems to be mediated by dopaminergic systems only.
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CHAPTER FIVE
lidi iEEEQIi QE 0NIÍDEPRESSANT DRUGS QN ^PHEJ^INE ANOREXIA 
5.1- INIBQDyCIiQN
The previous chapter has suggested that amphetamine anorexia can 
be used as a tool to index beta-receptor function. This chapter 
will examine interactions between AD and amphetamine anorexia.
V
The classic action of TADS is to increase adrenergic transmission 
through blockade of re—uptake at NA synapses, which only takes a 
few hours or so (e.g. Carlsson et al 1966). This action of TADs 
was used as evidence to support the CA hypothesis of depression 
(see section 1.4.1.). However, as a result of elevated NA 
transmission (Wolfe et al 1978), subsensitivity of postsynaptic 
beta-receptors develops during chronic treatment as measured by 
the c-AMP technique (Vetulani et al 1976). This chronic effect of 
TADs and virtually all other antidepressant treatments is now 
frequently assumed to reflect the mechanism of clinical action of 
these drugs and has been used as evidence to support the revised 
CA hypothesis of depression, that depression arises from an 
elevation of NA transmission which is decreased by AD (Sulser 
1978). However, subsensitivity of beta-receptors could be nothing 
more than a compensation for the acute adrenergic enhancement 
induced by ADs. In this case the beta-receptor subsensitivity 
following chronic AD treatment would return NA systems to their 
pre-drug state. If, depression did result from an over- 
stimulation of NA systems, then for AD treatments to be
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CHAPTER FIVE
IHE EFFEQIS QF ANIIDEPRESSANI DRUGS ON AMPHEI0MINE ANQRiXIA 
5.1. INIRQDyCIION
The previous chapter has suggested that amphetamine anorexia can 
be used as a tool to index beta-receptor function. This chapter 
will examine interactions between AD and amphetamine anorexia.
The classic action of TADS is to increase adrenergic transmission 
through blockade of re-uptake at NA synapses, which only takes a 
few hours or so (e.g, Carlsson et al 1966). This action of TADs 
was used as evidence to support the CA hypothesis of depression 
(see section 1.4.1.). However, as a result of elevated NA 
transmission (Wolfe et al 1978), subsensitivity of postsynaptic 
beta-receptors develops during chronic treatment as measured by 
the c-AMP technique (Vetulani et al 1976). This chronic effect of 
TADs and virtually all other antidepressant treatments is now 
frequently assumed to reflect the mechanism of clinical action of 
these drugs and has been used as evidence to support the revised 
CA hypothesis of depression, that depression arises from an 
elevation of NA transmission which is decreased by AD (Sulser 
1978). However, subsensitivity of beta-receptors could be nothing 
more than a compensation for the acute adrenergic enhancement 
induced by ADs. In this case the beta-receptor subsensitivity 
following chronic AD treatment would return NA systems to their 
pre-drug state. If, depression did result from an over—  
stimulation of NA systems, then for AD treatments to be
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e-f-fective, they Mould have to functionally reduce NA transmission 
to a level lower than the pre-drug state. Only then would the 
net result be an overall decrease in NA transmission.
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There have been several attempts to address the issue of the net 
effect of ADs on beta-adrenergic function. Biochemical studies 
have typically examined changes in basal cAMP levels as an index 
of beta-adrenergic function. In general, chronic AD treatment 
has not been found to alter basal cAMP levels, suggesting that 
there is no net change in beta—adrenergic function (e.g. Frazer 
and Mendels 1977), As some cortical cAMP is produced at sites 
other than beta-receptors, the value of this approach is limited. 
However, one study examined the cAMP response in the cortex 
following electrical stimulation of the locus coeruleus and found
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Other biochemical models used to assess beta-adrenergic function 
include pineal cAMP and pineal melatonin (see Uiliner 1984 for a 
full discussion). All these biochemical models have largely 
shown that there is little evidence to suggest that beta- 
adrenergic function is significantly altered following chronic AD 
treatment.
Electrophysiological studies reach a similar conclusion. 
Although decreased sensitivity to iontophoretically applied NA 
has been reported following chronic AD treatment in cingulate
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cortex (01pe and Schellenberg 1980; Delina-Stula et al 1982) and 
ir|cerebel lar Purkinje cells (Schultz et al 1981), the baseline 
■firing rate o-f Purkinje cells Mas reduced by approximately 50-70% 
(Schultz et al 1981). As NA is inhibitory on Purkinje cells, the 
reduction in baseline -firing represents an increase in adrenergic 
function and makes it impossible to interpret the reduced effect 
of NA. No baseline data were reported in the cingulate cortex 
studies.
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NA has an inhibitory effect on hippocampal cell function. 
Chronic DMI has been reported to increase the baseline firing 
rate of hippocampal cells (Huang 1979), thereby indicating a 
decrease in beta-adrenergic function. In contrast, four other 
studies have found that the response of hippocampal cells to 
iontophoretical1y applied NA was unchanged by chronic DMI and a 
variety of other AD treatments including ECT (De Montigny 1980; 
De Montigny and Aghajanian 1978, De Montigny et al 1981, Gallager 
and Bunney 1979). However, it was shown that changes in firing 
rate of hippocampal cells following DMI treatment were an exact 
reflection of changes in the firing of locus coeruleus cells 
(Huang et al 1980). Therefore, the proportional reduction of 
firing in response to stimulation of the locus coeruleus was 
unaltered by chronic DMI treatment, despite changes in basal 
firing rate (Huang 1979).
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■n i 5.2. BEHAVIOURAL ASSAYS OF BEIAzADRENERGIC FUNCIION DURINB 
CHRONIC DMI IREAIMENI
Attempts to assess beta-adrenergic function via behavioural 
methods have been hampered because there are no models which 
which are thought to unequivocally reflect beta—adrenergic 
receptor stimulation. An approach to assess beta-adrenergic 
receptor function has recently been developed by Mason and Angel 
(1983). This model is based on the duration of thiopentone 
anaesthesia in the rat and is assumed to be sensitive to the net 
functional activity of the locus coeruleus NA system. Drug 
manipulations, which increase activity in the locus coeruleus, 
have been shown to shorten thiopentone anaethesia (Mason and 
Angel 1983). Chronic DMI treatment (10 mg/kg) once daily for 10 
or 20 days was found to increase the duraton of thiopentone 
anaesthesia, suggesting a net decrease in beta-adrenergic 
function. The problem with this study is that testing was 
carried out 48h into withdrawal and therefore does not assess the 
net effect of chronic DMI treatment at beta-adrenergic synapses.
A second approach to assess beta-receptor function utilized the 
DBEE (dorsal bundle extinction effect), which is thought to 
reflect a decrease in beta-adrenergic function during resistance 
to extinction. During chronic DMI treatment, no increase in 
resistance to extinction was seen in three different behavioural 
paradigms, except when the animals were tested during withdrawal 
(Montgomery and Wiliner 1980; Wiliner et al 1981b). These results 
would suggest that beta-receptor subsensitivity is unmasked by
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withdrawing DMI, and simply compensates for the acute NA 
enhancing effects of the drug. However, there is some 
uncertainty as to whether the resistance to extinction induced 
by DMI is in fact mediated by the DNAB (Wiliner and Towel1 1982b; 
see chapter 1, section 1.11).
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A third behavioural approach to index beta-receptor function uses 
the anorexic effects of small doses of amphetamine on food 
intake; as discussed in the previous chapter this effect appears 
to have a beta-adrenergic component. Acute pretreatment with DMI 
or iprindole potentiated the anorexic effect of low doses of 
amphetamine (Wiliner and Montgomery 1980; Wiliner, Towel1 and 
Montgomery 1984). However, after two weeks’* treatment, 
amphetamine anorexia in drugged animals did not differ 
significantly from that in controls. The anorexic response to 
amphetamine remained tolerant, showing neither enhancement nor 
attenuation, after more than two months' treatment (Wiliner and 
Montgomery 1981a). This tolerance to the acute potentiating 
effect of ADs is probably mediated by change in NA function, 
since tolerance was not seen to the enhancement of amphetamine- 
induced stereotyped behaviour (Wiliner and Montgomery 1981a; 
Winner, Towel 1 and Montgomery 1984) - a presumed DA mediated 
effect (Kelly 1977).
In these studies amphetamine anorexia was attenuated during 
withdrawal from DMI or iprindole. Again, an underlying NA 
fnediation is implicated, since amphetamine-induced locomotor
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activity and stereotyped behaviour were not attenuated - in fact 
both behaviours were slightly enhanced (Wiliner and Montgomery 
1980a, 1981, Wiliner, Towel 1 and Montgomery 1984). These results 
suggest that during withdrawal from DMI or iprindole, NA 
transmission is decreased. However, during drug treatment, this 
effect is exactly offset by the acute, potentiating effects of 
the drugs, resulting in no net increase or decrease in NA 
transmission.
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This conclusion relies on the assumption that the initial 
potentiation of amphetamine anorexia is not dependent on changes 
on amphetamine metabolism. However, it is known that DMI and 
iprindole impair amphetamine metabolism effectively making more 
amphetamine available to produce an enhancement of its effects 
(Consolo et al 1967, Lewander 1968, Lemberger et al 1970). If the 
potentiation of amphetamine anorexia following acute AD treatment 
is artefactual, then the tolerance which develops during chronic 
treatment does not give a true representation of beta-adrenergic 
function. If the potentiation of amphetamine anorexa by DMI is an 
artefact of metabolism then the changes seen in amphetamine 
anorexia during chronic treatment may actually reflect a 
reduction in beta-adrenergic function. It is clearly necessary 
therefore to assess the contribution of the metabolic artefact to 
the potentiation of ampheamine anorexia by ADs.
j'
.if Two recent observations suggest that the enhancement of 
amphetamine anorexia by acute AD pretreatment may in fact be an 
artefact of impaired amphetamine metabolism. First, as noted
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5.3.2. METHOD 
Subjects
A group of 12 Lister hooded rats (Olac, Bicester, Oxon), weighing 
approximately 300g at the time of surgery, were housed 
individually under conditions of controlled temperature and 
humidity, on a 12-hour light-dark cycle (09.00h to 21.00h light). 
Animals were maintained on 21-hour food deprivation, and fed with 
standard laboratory diet (Dixon, Ware, Herts) from 14.00h to 
17.00h daily. Water was freely available at all times.
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Procedure
At 14.00h each day, a weighed amount of food was placed in each 
animal's cage. Uneaten food was removed briefly at 14.30h, 
weighed, and then returned to the cage. Food uneaten at 17.00h 
was removed and weighed; all results reported refer to the first 
30 minutes of the feeding session. Food intake scores were 
subjected to one-way analysis of variance, supplemented by 
Scheffe contrasts.
:!(U
Following stabilization of food intake, cannulae aimed at the PFH 
were implanted bilaterally under pentobarbital anaesthesia, as 
described below. The coordinates, chosen according to the atlas 
of Pellegrino and Cushman (1967), were anterior 5«6mm, medial 
1.6mm and ventral 2.4mm; at the end of the experiment, cannulae 
placements were verified histologically. The cannulae were of 
26-gauge stainless steel (Arnold and Horwell, London); 
injections through them were made using a microsyringe with a 33-
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gauge needle (V.A. Howe, London). Details of the micro-cannula 
system and surgery are given below.
Following their last injection, animals were perfused with 
buffered formalin under sodium pentobarbital (100 mg/kg i.p.) and 
their brains were rapidly removed and stored in lOX formalin for 
approximately 10 weeks. Frozen lOOum sections were stained with 
fast cresyl violet and cannula placement was verified 
histological 1 y. Placements were identified as being ventral or 
lateral to the fornix, at the level of, or slightly posterior to, 
the ventromedial hypothalamus (see figure 10).
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Micro-cannula System (see figures llA and HB)
The dimensions of the cannulae used in these experiments were 
determined by the smallest possible needle size currently 
available (33 gauges outer diameter = 0.2mm inner diameter * 
0.1mm). Therefore 26 gauge (outer diameter « 0.46-0.47mm; inner 
diameter = 0.24-0.28mm) stainless steel cannulae (Arnold and 
Horwel1, London) were cut to 20mm lengths using a grinding 
machine. Where necessary, the ends of the cannulae were de-burred 
by inserting a small length of injection needle into one end of 
the cannula and gently rubbing this needle up and down the length 
of the cannula.
Outer sleeves were constructed from 2.5mm diameter screws. These 
served two purposes: first, they strengthened the cannulae and 
prevented the rat from damaging the implant by scraping its head 
against the metal bars at the top of the cage; and, secondly, the 
sleeves served as guides to facilitate the entry of the needle 
into the cannula.
r<!;
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Using a size 0.5mm drill, a hole was drilled centrally along the 
length of the screw, using the centre of the posidrive head as a 
guide. The head was removed by a grinding machine leaving a 
0.5cm length of threaded screw. The remaining length was mounted 
in a vice machined side up and a contersunk drill was lowered to 
enlarge the existing aperture. The sleeve was cleared of 
shavings by inserting a piece of 26 gauge tubing through it.
V 1
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Injections were made through the guide cannula with Hamilton 33 
gauge stainless steel needles (V.A.Howe, London) reduced to a 
2<-)mm length. The needle was -filled and attached to a -filled 
Hamilton lOul syringe. A visual check was made that no bubbles 
were present in either. The syringe was centred in a Hamilton 
repeating dispenser which enabled the delivery of 0.22ul of 
solution or multiples of that amount.
Surgery
Animals were anaesthetized under sodium pentobarbital <40-50mg/kg 
i.p.). Cannulae were implanted bilaterally using a student
stereotaxic machine (David Kopf Instruments). As the machine did 
not permit implantation from both right and left sides, it was 
necessary to devise a system which would enable bilateral
implantation during a single operation. On the central arm (or 
electrode carrier) of the machine, the cannula was inserted in a 
pre-machined groove and adjusted such that 13mm of cannula 
portruded from the base plate (see figure IIB). Following normal 
calibration of the machine co-ordinates, and insertion of the 
first cannula, it was possible to insert the second cannula by 
placing it in the groove in exactly the same way as before. This 
procedure ensured a reasonable degree of accuracy in placement.
Five small holes were made in the skull using a 10 BA self­
tapping drill operated by a Radio Spares 12-volt hand drill. Two
of the holes were used for cannula insertion, whilst the other
three were used as anchorage points to secure the implant. Into
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the three anchorage holes were inserted cheese head 10 BA 
stainless steel screws (Clerkenwell Screws, London) which were 
tightened by approximately -four complete revolutions. After 
cannulae were inserted in place, dental cement was liberally 
applied to the implant area such that all three screws and the 
base of the cannulae were covered. When the cement had dried, the 
sleeves were carefully positioned onto the cannulae, bevel side 
up. Care was taken to ensure that the top of the cannula sat at 
the bottom of the bevel (see figure llA). More dental cement was 
applied to the implant to ensure that the sleeves were securely 
placed. Animals were removed to their home cages and a minimum of 
one week was allowed before their first injection. During this 
time animals were handled and mock—injected every other day.
Drugs and Procedure
Drug trials began 14 days after surgery, when food intakes were 
stable. All drugs were dissolved in distilled water and made up 
to volume with phosphate buffer, pH 7.0, which was also used for 
control injections. All intraperitoneal (i.p.) injections were 
made at a volume of 1 ml/kg. Intracranial (i.c.) injections were 
made in a volume of 0.44ul. A minimum of two drug-free days were 
allowed between successive treatments.
DMI (Geigy, 7.5 mg/kg) was administered i.p. at 17.00h on the day 
before feeding tests. D-Amphetamine sulphate (Smith, Kline and 
French) was administered either at 0.5 mg/kg i.p. 30 min. before 
feeding, or at 200 nM i.c. 5 mins before feeding. Phentolamine
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hydrochloride (Ciba) was administered at 50nM i.c., 10 mins 
be-fore -Feeding. Doses were calculated as salts. The treatment 
combinations and the sequence of treatments are shown in table 6.
5.3.3. RESULTS
Phentolamine and DMI, alone or in combination, did not 
signi-ficant 1 y change food intake from that seen after a control 
injection (1 vs 4, 8, 9: maximum F(l,81) = 0.90, p>0.1). 
Intracranial administrati on of amphetamine significantly 
increased feeding <1 vs 2: F(l,81) = 9.88, p<0.01), but a 
significant reduction of feeding was apparent when i.c. 
amphetamine was preceded by phentolamine (1 vs 3: F(l,81) = 
24.45, p<.0.001). In fact, the anorexic effect of i.c. 
amphetamine, with phentolamine pretreatment, did not differ 
significantly from that seen after i.p. administrati on of 
amphetamine, at approximately 5 times the dose <3 vs 6: F(l,81) = 
1.80, p.'O.l). Phentolamine did not interact significantly with 
amphetamine administered i.p. (6 vs 10: F<1,81) = 2.47, p>0.1).
i i
The effects of DMI pretreatment on amphetamine anorexia are shown 
in figure 12. DMI greatly enhanced the anorexic effect of i.p. 
amphetamine (5 vs 6: difference = 2.51g; F(l,81) * 67.57, 
P 0.001), but only slightly enhanced the anorexic effect of i.c. 
amphetamine (3 vs 7: difference * 0.65g; F(l,81) * 4.53, p<0.05). 
The potentiation of peripherally induced anorexia by DMI was 
approximately 4 times the size of the potentiation of centrally 
induced anorexia (5 vs 7: F(l,81) = 22.55, p<0.001).
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OSE EFFECT OF 71BIOÜS I2BTJG TfiEASfQHTS OH FOOD INTAKE
PRETREATMENT TIME 
2 1 h  3 0  m in 10 m in  5 m in
FOOD
M ean
INTAKE ( g ) *
1  S t a n d a r d  E r r o r
SAL i . c 5 . 6 6 ±  0 .3 0  a
AMP i . c . 6 .6 2 ± 0 .A 8  b
PHEN i . c .  AMP i . c . A. 15 ± 0 .2 7  c
DMI i . p . SAL i . p . 5 . 9 2 ± 0 .3 2  a
DMI i . p . AMP i . p . 2 .0 5 ± 0 .2 9  d
AMP i . p . - A .5 6 ± 0 .3 5  c
DMI i . p . PHEN i . c .  AMP i . c . 3 .5 0 ± 0 . 3 1 e
DMI i . p . PHEN i . c . 5 . 8 7 ± 0 .2 9  a
PHEN i . c . 5 .9 5 ±  0 . 2 6  a
AMP i . p . PHEN i . c . A .0 8 ±  0 .3 6  c
SAL: S a l i n e ;  DM I; d e s m e t h y l i m i p r a m i n e ;  PHEN: p h e n t o l a m i n e ;
AMP: a m p h e ta m in e  -\
t r e a t m e n t s  w i t h  t h e  sam e  s u f f i x  d o  n o t  d i f f e r  s i g n i f i c a n t l y ;  
d i f f e r e n c e s  b e t w e e n  t r e a t m e n t s  w i t h  d i f f e r e n t  s u f f i x e s  a r e  h i g h l y  
s i g n i f i c a n t  ( p < 0 .0 1  o r  b e t t e r ) ,  w i t h  t h e  e x c e p t i o n  o f  c v s  e ,  f o r  
w h ic h  p < 0 .0 5 .
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s5.3.4. DISCUSSION
The sequence o-f treatments was not randomized in this study, 
owing to practical constraints. However, it seems unlikely that 
this factor compromised the results: control procedures were 
administered at various points throughout the series (1,4,8,9), 
with no change in baseline food intake. Furthermore, there was 
no discernible tendency towards either sensitization or tolerance 
to amphetamine as a function of repeated administration. It is 
also noted that phentolamine was not administered in combination 
wih DMI and peripheral amphetamine. Again, however, it is 
unlikely that this is a significant omission, as phentolamine did 
not interact with either DMI or peripheral amphetamine 
administered separately.
With this reservation, the results are straightforward. Blockade 
of alpha-receptors by phentolamine unmasked an anorexic effect of 
i.c. amphetamine, as has been previously reported (see 
introduction) . This anorexic effect was slightly enhanced by 
DMI; beta-adrenergic synapses in the PFH are the most likely site 
for this interaction. DMI also enhanced the anorexic effect of 
peripherally administered amphetamine, but much more 
substantially. The discrepancy between the sizes of the two 
enhancements suggests that under these conditions approximately 
three quarters of the potentiation by DMI of peripherally induced 
anorexia is mediated peripheral1 y. This potentiation is 
artefactual in origin: DMI inhibits the inactivation of 
amphetamine by the liver, resulting in higher circulating levels
145
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In conclusion, acute DMI pretreatment has been shown to 
signi-ficantly potentiate amphetamine anorexia via a peripheral 
mechanism. A direct consequence of this finding is to unmask an 
attenuation of anorexia during chronic treatment. However, the 
implications of this finding with regard to beta and alpha- 
adrenergic mechanisms are unclear.
5-4. EXPERIMENI 6i IHE EFFECIS OF CHRONIC MIANSERIN IREAIMENI 
□N AMPHEJAMINE ANOREXIA 
5.4.1. INTRODUCTION
Although the attenuation of amphetamine anorexia following 
chronic AD treatment has been used as evidence of beta-receptor 
subsensitivity, the results are open to more than one
interpretation. When amphetamine is used to elevate NA 
transmission, both the alpha-adrenergic feeding system and the 
beta-receptor satiety system could theoretical 1y be stimulated. 
In fact the results of the previous experiment showed evidence of 
alpha-adrenergic stimulation by amphetamine, which caused an 
increase in food intake. Consequently, an attenuation in 
amphetamine anorexia following chronic DMI treatment, which has 
been taken to reflect a decrease in beta-receptor activity, could 
reflect an increase in alpha-receptor activity» chronic AD 
treatment has been shown to have both effects.
It is difficult to address this issue experimentally, because of 
the peripheral interaction between DMI and amphetamine which was 
demonstrated in the previous experiment. Mianserin, however, does
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not appear to impair aphetamine metabolism. Acute pretreatment 
with mianserin had no significant effects on amphetamine 
anorexia, or on other effects of amphetamine, such as stereotyped 
behaviour (Wiliner. Towel1 and Montgomery 1984). Mianserin does, 
however, attenuate amphetamine anorexia with chronic 
administration.
One way of assessing the contribution of alpha-adrenergic 
mechanisms to this attenuation of amphetamine anorexia by 
mianserin is to administer the alpha-adrenergic blocker 
phentolamine concurrent1y. If attenuation of anorexia by chronic 
mianserin is still seen, then this would suggest a beta- 
adrenergic involvement. However, if mianserin-induced 
attenuation of amphetamine anorexia is blocked by phentolamine, 
then this would suggest an alpha-adrenergic involvement.
A problem in drug interaction studies of this kind is that 
changes in amphetamine anorexia following phentolamine 
pretreatment could mask any concomittant change in beta-receptor 
function. This problem was highlighted in chapter 4, experiment 
3, in which a microstructural analysis of feeding behaviour was 
used to unmask propranolol-amphetamine interactions. It is for 
these reasons that the microstructural technique was used in this 
experiment to examine mianserin-amphetamine-phentolamine 
i nter acti ons.
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5.4.2. METHOD 
Subj ects
Twenty-four male Lister hooded rats (weight 330-365g), were 
individually housed and maintained on 21-hour food deprivation 
with water available ad lib.
Drugs and Procedure
The animals were trained to feed by pressing the door of the 
pellet dispenser in one of six identical operant chambers, as 
described in experiment 1, chapter 3. Daily ten-minute sessions 
were run until all animals reached asymptotic performance. 
Animals were divided into two groups of 12. Mianserin 
hydrochloride (10 mg/kg, Beecham, Epsom, England) was 
administered at approximately 17.00h daily, for a period of 21 
days to one group whilst the other group received the same number 
of control injections (distilled water). Amphetamine (0.5 mg/kg, 
Smith, Kline and French) was administered 30 minutes prior to 
feeding (i.e. 19-20 hours following mianserin pretreatment),
whilst phentolamine (Ciba, 1.0 mg/kg) was administered 10 minutes 
prior to feeding. All injections were made at a volume of 1 
ml/kg and the drugs were administered i.p. Doses were calculated 
as salts. Control injections consisted of the vehicle (distilled 
water).
Treatments (amphetamine, phentolamine and a combination of 
amphetamine and phentolamine) were administered in a 
counterbalanced order between days 14 and 21 of mianserin
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treatment. An amphetamine-phentolamine challange was also 
carried out two days into withdrawal (see table 7). At least one 
day intervened between successive amphetamine-phentolamine 
treatments, on which control injections were given.
Anorexia was measured as suppression scores. Suppression was 
calculated as the mean food intake (total number of pellets taken 
during the half hour session) of the day directly before and the 
day directly after the amphetamine test day, minus food intake on 
the amphetamine test day. Microstructural parameters of feeding 
were calculated as suppression scores in the same manner. 
Suppression scores for each microstructural parameter were 
subjected to an analysis of variance, and where appropriate were 
supplemented by tests of simple main effects. An additional 
analysis was carried out on control data taken at the beginning 
of the experiment (day 14) and at the end of mianserin treatment 
(day 20; see table 7). The purpose of this analysis was to 
establish if chronic mianserin treatment changed baseline scores, 
as such an effect would complicate interpretation of the main 
analysis. Only data on the total food intake, eating rate and 
eating time are presented, as consideration of the other 
microstructural parameters adds no further information.
5.4.3. RESULTS
Mianserin did not significantly change total food intake, eating 
time or eating rate during the course of chronic treatment (F 
(1,22) = 3.10, 0.21 and 2.62, respectively, p>.05). As observed
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in previous experiments (2, 3 and 4) amphetamine caused a 
reduction in food intake (figure 13A) which was characterized by 
a decrease in eating time (figure 130 and an increase in eating 
rate (figure 13B).
Mianserin pretreatment attenuated both amphetamine anorexia and 
the amphetamine-induced decrease in eating time and enhanced the 
amphetamine-induced increase in eating rate, although none of 
these effects reached statistical significance (figures 13A-C)-
The effect of phentolamine treatment on the amphetamine-mianserin 
interaction was to slightly block the mianserin-induced 
attenuation of amphetamine anorexia, and also to slightly block 
the mianserin-induced attenuation of the amphetamine change in 
eating time. The mianserin-induced enhancement of the 
amphetamine-induced increase in eating rate was totally blocked 
following phentolamine treatment. A more descriptive analysis of 
the effect of phentolamine on the mianserin-amphetamine 
interaction is given in table 7. The suppressant effect of 
amphetamine on total food intake and eating time was attenuated 
by 317. and 187 respectively following mianserin pretreatment. 
When phentolamine was conurrently administered, the mianserin- 
induced attenuation of amphetamine’s suppressant effects on 
totals and time were slightly blocked (157 and 107 respectively). 
However, the mianserin-induced enhancement of the amphetamine- 
induced increase in eating rate was totally abolished by 
phentolami ne.
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TABLE 7
EFFECTS OF CHRONIC MLABSiHIN IfiBAmEST ON AMFHBIAMHiB ABQRSZIA
Seqaeno« of ±eag troatmanti in four groop« of (m^)«
See tort for dotallB« ; I
Bro^ pretroatBont
Gp 1 Control 
Gp 2 Miattsorln
Gp 3 Control 
Gp 4 Hiansexln
Bays of dro^ troataont ^ Vitfadrawal
14 15 16 17 18 19 20 21 22 23
c a /p c p c a c c
A
Mean anppreaslon of food intake following amphataaiine or phen-feftT««**"*
Mianserin pretreataent Control pretreatMnt
Pellets
P A V p V p P A V p53 70 124 91 56 102 146
Hae 295 558 782 702 237 680 870Hate -.005 -.025 -.015 -.024 -.001 -.014 -.015
Sappreeeant offoot of 
anphetaaine (in abeolnte 
and %) following alanserln
pretreataent and
Pellets 32 (J19Ì) 22Time 122 b m 88Hate .011 (79«) 0
Snppreesant effect of 
aaphetaalne (in absolute 
and %) following phentolealne
15?é)
W )
A s aaphetaalne 
P B phentolaalne 
C M control
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5.4.4, DISCUSSION
Phentolamine pretreatment enhanced the suppression of total food 
intake and eating time in control and mianserin treated animals. 
Chronic mianserin treatment attenuated amphetamine anorexia, an 
effect that has recently been reported (Wiliner, Towel 1 and 
Montgomery 1984), although this effect was not statistically 
significant in this experiment. This lack of significance in the 
mianserin-induced attenuation of amphetamine anorexia precludes a 
proper analysis of the effects of phentolamine on the mianserin- 
amphetamine interaction. In fact, phentolamine pretreatment 
decreased the magnitude of the mianserin-induced attenuation of 
amphetamine anorexia, although this effect was not significant. 
The decrease of the mianserin-induced attenuation of amphetamine 
anorexia and the reduction in eating time following phentolamine 
pretreatment could be evidence for an enhancement of alpha- 
adrenergic function during chronic mianserin treatment. However, 
the mianserin-induced enhancement of the amphetamine-induced 
increase in eating rate was totally blocked by phentolamine. This 
might suggest that some component of eating rate is also mediated 
by alpha-adrenergic mechanisms. This conclusion is examined in 
the next chapter.
5-5. general discussion
Wi liner and Montgomery (1980) proposed that the effects of DMI on 
amphetamine anorexia could be understood as compensatory adaptive 
changes, which occur during chronic treatment (a presumed beta- 
adrenergic subsensitivity effect), and which carry through into
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withdrawal. However, if the acute enhancement of amphetamine 
anorexia is an artefact of the metabolic effect* outlined in 
experiment 5, then the model would be incorrect. Instead of 
there being no effect on amphetamine anorexia during chronic 
treatment, there would be an attenuation of amphetamine 
anorexia. This revised model would postulate a more plausible 
explanation of the clinical action of AD than the earlier model, 
which concluded that there was no net change in the output of NA 
systems.
If attenuation of amphetamine anorexia following mianserin 
pretreatment does indeed have an alpha-receptor component, it is 
likely that the other and larger component of the mianserin- 
induced attenuation of amphetamine anorexia is beta-adrenergic. 
The most likely mechanism for attenuation of amphetamine anorexia 
is a beta-receptor subsensitivity which becomes apparent during 
chronic mianserin treatment. This interpretation is consistent 
with that of the previous experiment, in its conclusion that 
chronic DMI, iprindole and mianserin treatment reduce NA 
transmission through the mechanism of beta-receptor 
subsensitivity. It must be noted, however, that even if ADs do 
lower NA transmission by inducing beta-receptor subsensitivity 
which over-compensates for the NA stimulatory effect of AD*; it 
does not necessarily follow that beta-receptor subsensitivity is 
responsible for the clinical effects of ADs. In fact, recent 
evidence suggests that it is not (see chapter 8, section 8.3.).
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CHAPTER SIX
assaying PRESYNAPIIC dopamine RECEPIQRSi VALIDAIION SIUDIES
6.1. INIRQDyCIIQN
The preceding chapter considered the contribution o-f beta- 
receptor subsensitivity as a possible mediator of AD treatment. 
It is also evident that AD treatments interact with DA systems. 
This evidence has been presented in chapter one, section 1.8., 
and can be briefly summarised by the hypothesis that chronic AD 
treatment increases DA transmission. In addition to clear 
effects on postsynaptic measures of DA transmission, it is also 
possible that chronic AD treatment induces subsensitivity of 
presynaptic DA receptors. This chapter examines a behavioural 
assay for presynaptic DA receptor activation.
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The dose response curve for the effects of apomorphine on 
locomotor activity is biphasic ; low doses cause sedation whilst 
higher doses cause stimulation of behavioural activity (Costall 
et al 1980, 1981; Carlsson 1975). This biphasic profile of 
apomorphine is explained by the proposal that low doses of the 
drug act as an agonist specifically at presynaptic DA 
autoreceptors, whilst higher doses are agonistic to both pre and 
postsynaptic sites (Skirboll et al 1979). Autoreceptor 
stimulation results in inhibition of DA release, producing 
sedation, whilst postsynaptic stimulation enhances DA 
transmission to increase behavioural activity (DiChiara et al 
1978; Carlsson 1975). The anatomical substrates for the
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postsynaptic effects of apomorphine have been identified from 
experiments in which DA was injected directly into the terminal 
areas. Enhancement of locomotor activity has been attributed to 
the stimulation of the mesolimbic DA system (Makanjuola et al 
1980), whilst the mesocortical DA pathway has been implicated in 
attenuation of locomotor activity (Tassin et al 1978); the 
nigrostriatal DA pathway mediates the stereotyped behaviour seen 
at very high doses of apomorphine (Fog et al 1971).
In addition to the nigrostriatal and mesolimbic systems being 
regulated by autoreceptors the nigrostriatal system is also 
regulated by a striato-nigra feedback circuit (Bunney and 
Aghajanian 1976). The nigrostriatal system is therfore capable of 
buffering receptor changes to a greater extent than the 
mesolimbic system and in consequence will show less change to 
treatments which selectively interact with autoreceptors. In 
contrast, the mesocortical system, an extension of the mesolimbic 
system, appears to be devoid of autoregulation (Chiodo and Bunney 
1983).
This simplistic account of the anatomical localisation of 
apomorphines behavioural effects is complicated by evidence 
implicating a multiplicity of DA receptor sites. Up until the 
late 1970s DA receptors were classified by their ability to 
stimulate cAMP formation (Creese 1982). DAI (Dl) receptors 
stimulated cAMP formation whilst D2 receptors did not (Kebabian 
and Caine 1979). Recently, a classification of DA receptors has 
emerged based on the relative affinities for various DA agonists
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and antagonists to bind with specific receptor types. D3 
receptors are thought to be located on DA terminals and might 
correspond to autoreceptors whilst D4 receptors are thought to be 
associated with endings of cortico-striatal neurons (Sokoloff et 
al 1980).
As outlined in chapter one, the behavioural effects of low doses 
of apomorphine have been used to index presynaptic DA activity 
during AD treatment and some studies have reported autoreceptor 
subsensitivity following chronic AD treatment (e.g. Serra et al 
1979). These studies typically examined changes in locomotor 
activity, a behaviour that is quantified either by complex and 
often unreliable rating scales or by the use of photocell 
matrixes. Interprétâtion of these data are often complicated by 
the limitations of these procedures. It is for these reasons, 
together with the practical consideration that a microstructural 
feeding technique had already been set up in the laboratory, that 
we decided to examine the possibility that autoreceptor activity 
could be assayed by the effects of apomorphine on food intake.
The results of a microstructural study of feeding under various 
doses of apomorphine carried out in this laboratory (Wiliner and 
Jackson unpt^ished) are shown in figure 14. Apomorphine at all 
doses tested reduced total food intake (p<.001), eating rate 
(p<.001) and eating time (0.08 mg/kg, p<.05; 0.16 mg/kg, p<.001). 
Doses of apomorphine specific for presynaptic receptors (0.04, 
0.08 mg/kg) reduced bout length (0.08 mg/kg, p<.01), but did not 
affect latency or gap length. Postsynaptic doses 00.16 mg/kg)
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■further reduced bout length (pC.OOl) and also increased latency 
(p<.001) and gap length (p<.05). This dissociation between pre- 
and postsynaptic doses of apomorphine on latency and gap length, 
together with the dose-related effect on total, time, rate and 
bout length indicate that apomorphine anorexia appears to be a 
sensitive tool for studying presynaptic DA receptor stimulation. 
This conclusion is examined in this chapter, by attempting to 
reverse apomorphine anorexia with treatments known to be DA 
antagonists, at doses selective for presynaptic blockade.
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6.2. EXPERIMENI Zi JHE EFFECIS OF HALOPERIDOL PREIREAIMENI ON 
APQMQRPHINE ANORgXIA
6.2.1. INTRODUCTION
Although biochemical evidence suggests that presynaptic * DA 
receptors do mediate apomorphine-induced behavioural sedation 
(Sokolof-f et al 1980; Hjorth et al 1982), the behavioural 
evidence for this hypothesis is controversi al. It has been 
reported that apomorphine-induced hypomotility together with the 
concurrent decrease in DOPAC concentrations was reversed by 
pimozide (0.3 mg/kg), haloperidol (0.05 mg/kg), sulpiride (10.0 
mg/kg) and a variety of other neuroleptics at doses which in 
themselves did not influence motor activity or brain DOPAC 
concentrations (Dichiara et al 1976). However, another study in 
the same species (mice) confirmed reversal by pimozide <0.3mg/kg) 
and sulpiride (20 mg/kg) but failed to replicate reversal of 
apomorphine-hypomoti1ity by haloperidol (0.05 and 0.1 mg/kg). 
This study also demonstrated reversal with two alpha blockers, 
yohimbine and prazosin (Summners et al 1981).
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A third study, by Costali et al (1980), failed to antagonize 
apomorphine inhibition of locomotor activity in mice with a large 
range of neuroleptics, including those mentioned so far.
However, no precise details of the doses of apomorphine were 
given by Costali et al (1980), apart from the fact that doses 
were in the ug/kg range! These authors attributed problems in 
replication to the strain of mice used and differences in 
methodologies encountered in other studies. More recently, using 
rats as subjects, Montanaro et al (1982) showed reversal of
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apomorphine-induced hypomotility using low doses of -sulpiride 
but not +sulpiride, and also showed reversal of both apomorphine 
hypomotility and apomorphine hypermotility with the same doses of 
haloperidol (.03, .05 and 1.0 mg/kg). However, no data were 
presented on haloperidol induced changes in motility, making the 
results of this study difficult to evaluate.
Protais et al 1983, have further examined the dose-response 
relationship of apomorphine on locomotor activity in mice and 
found it to be not byphasic but polyphasic. In this model, 
attenuation of locomotor activity occured at 0.025mg/kg and 
0.015mg/kg; restoration of this hypokinesia occured at 0.075mg/kg 
and 0.0375mg/kg respectively. The hypokinesia produced at 
0.025mg/kg was effectively antagonised by haloperidol only 
(u.u2(J and 0.040 mg/kg); otheftypical and atypical neuroleptics 
were without effect. Antagonism of the hypokinesia produced at 
0.015mg/kg of apomorphine was apparent across a range of 
neuroleptics at relativey small doses (e.g. 0.050mg/kg 
haloperidol). From the relative potency of neuroleptics to 
antagonise hypokinesia and its respective restoration. Protais et 
al chracterize their 0.025mg/kg and 0.0150mg/kg hypokinesia as 
being mediated by D3 and D4 receptors respectively. However, to 
the authors knowledge this is the first demonstration of a 
polyphasic dose-response curve for apomorphine and the shift in 
phase occurs within a very narrow dose range. The result 
therefore requires confirmation before the conclusions can be 
taken seriously.
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On the basis of these different results, sometimes using animals 
from the same species, it is uncertain whether apomorphine dose- 
response studies on mice, and their subsequent pharmacological 
characterizaton can be meaningfully extrapolated to apomorphine 
dose-response studies using rats or other species. This problem 
will at least be partially resolved when attempts at replication 
are carried out using similar procedures to those used in 
previous studies.
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Given the lack of consistent replicabi1ity of neuroleptic 
reversal of apomorphine-induced hypomoti1ity, it is important 
for the present purpose to establish whether the anorexia induced 
by a low dose of apomorphine in rats could be antagonised by a 
non-sedative doses of neuroleptic drugs.
6.2.2. METHOD 
Subj ects
12 male Lister hooded rats (weight 330-41Og), were individually 
housed and maintained on 21 hour food deprivation with water 
available ad libitum. Animals had had prior experience of 
continous reinforcement lever pressing and acute neuroleptic 
treatment, but had been drug free for a period of approximately 2 
months.
!ii
Drugs and Procedure
Animals were trained to feed by pressing the door of the pellet 
dispenser in one of six identical operant chambers, as described
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in chapter 3, experiment 1. Ten-minute daily sessions were run 
until all animals attained asymptotic per-f ormance. On 
experimental days, the animals received two injections: 
apomorphine hydrochloride <0.05mg/kg; Sigma) was administered 
s.c. in the scru-f-f of the neck 10 mins. before the start of the 
session and haloperidol (0.02mg/kg; Jansen) was administered i.p. 
30 minutes before the start of the session. Apomorphine was 
dissolved in 0.02V. ascobate solution, whilst haloperidol was 
dissolved in distilled water. Drug solutions were prepared fresh 
daily. Control injections consisted of vehicle solutions, 
administered s.c for ascorbate and i.p for distilled water. All 
injections were at a volume of 1 ml/kg. Each animal received all 
four treatment combinations in a counterbalanced order, at two 
day intervals. On the intervening days, a ten minute session was 
run, with no drug treatments. Microstructural analysis of feeding 
was carried out as described in chapter 3, experiment 1. Results 
were analysed by analysis of variance, supplemented by tests of 
simple main effects.
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6.2.3. RESULTS
Apomorphine caused a significant (46%) reduction in food intake 
(p<.001, figure 15A) which was blocked by haloperidol 
pretreatment (interaction: F (1,11)=12.56, p<.01). Microstructural 
analysis showed that the reduction of food intake by apomorphine 
was produced by reductions in both eating rate and eating time. 
Haloperidol pretreatment blocked the effect on eating time. 
However, haloperidol did not block the effect on eating rate 
(figures ISB and C). It is therefore the increase in eating time
i
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■following haloperidol pretreat/nent that is responsible -for the 
restoration o-f eating -following apomorphine.
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Examination o-f other mi crostructural parameters adds little 
further information. Apomorphine increased gap length and reduced 
bout length; both effects were reversed by haloperidol 
pretreatment (figures 15D and 15E). No significant changes were 
seen in the number of bouts taken during the session or the 
latency to start eating (figures 15F and 15G). Haloperidol alone 
slightly increased the total number of pellets eaten, eating 
time, bout time and the number of bouts taken during the session, 
and decreased gap time and latency- none of these effects were 
si gni f i cant.
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These effects were further investigated by examining 
intercorrelations between the various microstructural effects of 
apomorphine, with and without haloperidol pretreatment. The 
apomorphine-induced decreases in eating time and bout length, 
were significant1y correlated with each other and with the 
concomitant reduction in total food intake (table 8). After 
haloperidol pretreatment, the apomorphine-induced reduction in 
eating rate was slightly enhanced and the reduction in eating 
time was reversed to control values; these two parameters were 
now both significantly correlated with the reduction in food 
intake. No other significant correlations between apomorphine- 
induced changes in parameters were seen. It is noteworthy that 
the reduction in eating rate was not correlated with the 
reduction in total food intake following apomorphine alone, but 
was correlated with the reduction in total food intake following 
haloperidol pretreatment.
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As no reversal was seen in the apomorphine-induced decrease in 
rate following haloperidol pretreatment a closer, descriptive 
analysis was carried out on these data (figure 16). The purpose 
of this analysis was to unmask any potential artefactual 
distortions arising from the microstructural analysis method. 
Freguency distributions of IRTs were constructed for the four 
treatment conditions, control, haloperidol, apomorphine and 
haloperidol-apomorphine. Any decreases in eating rate will be 
readily visualised by a shift in the peak of small IRTs to the 
right of the distribution. When the four treatment 
distributions are superimposed they appear as two pairs! One pair 
represents haloperidol and control treatments whilst the other, 
shifted to the right, represents apomorphine and haloperidol- 
apomorphine treatments. These observations are consistent with 
the conclusion derived from the microstructural analysis that 
haloperidol did not reverse the effect of apomorphine on eating 
rate.
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6.2.4. DISCUSSION
Haloperidol pretreatment antagonised the reduction in -food intake 
brought about by low doses of apomorphine. This antagonism is 
presumed to be mediated by presynaptic DA receptors, as no 
sedative effects were seen following haloperidol treatment. 
Microstructural analysis revealed that the antagonistic effect of 
haloperidol on apomorphine anorexia was consequent on an increase 
in eating time and bout length together with a decrease in gap 
length. It is the reduction in gap length and increase in bout 
length that results in the animals spending more time eating and 
therefore increasing their total food intake.
The apomorphine-induced reduction in rate was not reversed, 
suggesting that this effect of apomorphine is not in fact 
mediated by classical presynaptic DA receptors. This conclusion 
is supported by the findings of experiment 10, which show that 
apomorphine injected directly into nucleus A9 and AlO, reduces 
eating time, but has no significant effect on eating rate. The 
intercorrelations presented in table 8 also support this 
conclusion, in that in haloperidol pretreated animals there was a 
significant correlation between changes in total food intake and 
changes in eating rate.
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In conclusion, it appears that apomorphine-induced decreases in 
eating time can be reversed by haloperidol pretreatment at such 
a dose as to implicate a presynaptic DA involvement. The next 
experiment examines this conclusion, using the atypical
f
173
> o
1 !_
1 ;
rfTi t ••q-
neuroleptic thioridazine to reverse apomorphine anorexia.
6.3. EXPERIMENI ii IHE EFFEQIS OF IHIQRIDAZINE PREIREAIMENI ON 
APQMQRPHINE ANOREXIA
6.3.1. INTRODUCTION
The DA hypothesis of depression (see chapter 1 section 1.4.2.), 
which states that certain types of depression are due to a 
lowering of DA transmission in the brain, has received support 
from studies which show that treatments that functionally 
increase brain DA transmission are effective as AD in certain 
sub-populations of patients (Robertson and Trimble 1982, Jenner 
and Marsden 1982). Paradoxically, amongst these DA enhancing 
treatments are the atypical neuroleptic drugs that are known to 
decrease DA transmission and be without serious side effects in 
the treatment of schizophrenia. However these drugs (in
paticular thioridazine and sulpiride) have been shown to possess 
AD properties; and some studies have shown thioridazine and 
sulpiride to be of similar potency or indeed more potent than 
amitriptyline in the treatment of depression (Smith et al 1973; 
Aylward et al 1980). It is possible that thioridazine exerts its 
AD effects through antagonism of pre-synaptic DA receptors, dis- 
inhibiting DA release and increasing DA transmission. Typically, 
it is claimed that patients show response to thioridazine or 
sulpiride therapy after 4 or 5 days treatment or so, as compared 
with two weeks or so for TAD therapy. It was therfore of 
interest to investigate the effect of acute thioridizine 
pretreatment on apomorphine anorexia, which is mediated in part 
by presynaptic DA receptors (see experiment 7).
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The effect of subchronic thioridazine treatment was also studied 
in this experiment. If, as hypothesized, thioridazine exerts its 
clinical antidepressant effects by disinhibiting DA neurons and 
increasing DA transmission, apomorphine anorexia should be 
antagonised in thioridizine treated animals by an enhancement of 
DA transmission, an effect which should persist and might become 
more apparent over treatment.
; I
6.3.2. METHOD 
Subjects
Twenty-four male hooded rats (390-450g) (Olac, Bicester) were 
individually housed and maintained on 21 hour food deprivation, 
with water available ad libitum. The animals had had prior 
experience of continously reinforced lever pressing for food 
rewards and had received acute neuroleptic drug treatment four 
months prior to the experiment.
V i
Drugs and Procedure
Animals were trained to feed by pressing the door of the pellet 
dispener in one of six identical operant chambers. Ten-minute 
daily sessions were run until all animals attained asymptotic 
performance. Animals were assigned to one of two groups (n = 12) 
which were matched for prior lever pressing performance. Animals 
were tested daily in the operant chambers for half-hour sessions 
between the of 10.00 and 14.00 hours.
On each of eight consecutive days, animals received two
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injections two hours before a test session. One group received 
thioridazine (6 mg/kg5 Sandoz), whilst the other received 
physiological saline. Ten minutes before the commencement of the 
session, all animals received either apomorphine s.c. (0.05 
mg/kgj Sigma) or its vehicle s.c. (0.057. ascorbate) on alternate 
days. Thioridazine was dissolved in physiological saline whilst 
apomorphine was dissolved in 0.057. ascorbate to prevent rapid 
oxidisation of the drug. All injections were made at a volume of 
1 ml/kg. Apomorphine or its vehicle were administered s.c. in the 
scruff of the neck whilst thioridazine was administered i.p. 
Analysis of microstructural parameters of feeding were carried 
out as described in chapter 3, experiment 1. Results were 
analysed by analysis of variance, supplemented by tests of simple
main effects.
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6.3.3. RESULTS
In both the control and thioridazine treated groups, food intake 
rose steadily through the course of the experiment. This 
increase in food intake can probably be accounted for by the fact 
that animals had not attained asymptotic performance during half- 
hour experimental sessions, as they were only trained on 10 
minutes sessions (due to financial constraints).
□n the first control da^, thioridazine pretreatment decreased
food intake; however on subsequent control days thioridazine had
(noino significant effect on food intake^ ^
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Apomorphine caused a significant reduction in food intake over 
each of the four days when it was administered(F(3,66)=3. 39, 
p<;.05). This effect was blocked by thioridazine pretreatment on
day 1 a'TDut on subsequent tests, thioridazine pretreatment had no 
effect on apomorphine anorexia ( ACt sKci-^ A ),
Results of the microstructural analysis are only presented in 
detail for the first apomorphine trial. Apomorphine
significantly reduced eating rate (F(1,88)=12.06, p<.001, figure
17B) and increased latency (F(1,88)=32.18, pi.OOl, results not 
shown). Eating time was slightly decreased by apomorphine 
(F (1,88) =1. 18, p>.05, figure 170. Thioridazine alone
significantly decreased eating time (F (1,88) =lO. 87, p<.. ul, f i gure
170. However, thioridazine pretreatment reversed the reduction 
of food intake by apomorphine (F(1,88)=5.56, p<.01, figure 17A),
b y  reversing the effects of apomorphine on latency (F(1,88)=1.79, 
p>.05, results not shown) and eating time (F(1,88)=7.76, p<.01, 
figure 170. The apomorphine-induced reduction in eating rate 
was unaffected by thioridazine pretreatment (F<1,88)=.07, p>.05,
f i gure 17B).
On trials 2,3 and 4 apomorphine reduced eating rate in both 
control and thioridazine pretreated groups (F(1,132)=7.48, 
pC.OOl, results not shown), but otherwise analysis of the 
mi crostructural parameters on trials 2,3 and 4 was generally 
unremarkablei No significant differences were apparent with the 
single exception of a significant difference in gap length on the 
third control day (F(1,88)=5.25, p<.05, results not shown).
i
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6.3.4. DISCUSSION
On the first test day, thioridazine pretreatment reversed the 
reduction in food intake brought about by apomorphine (figure 
17A) by reversing eating time (figure 170 and latency . However, 
eating rate was not reversed by thioridazine, suggesting again 
that this parameter is not mediated by DA (figure 17B). The 
reversal of total food intake and eating time was masked by 
differences in baseline scores between thioridazine and control 
treatments. This difference in baseline scores cannot argue 
against the reversal of apomorphine-induced efects on total food 
intake and eating time, as the mean value of both these 
parameters was actually increased above that of apomorphine 
following thioridQiine pretreatment. The reversal of the 
apomorphine—induced reduction in latency by thioridazine is 
consistent with a restoration of normal food intake. These 
results agree with the findings of the previous experiment, 
where haloperidol was shown to reverse the number of pellets 
eaten and the time spent eating but not the rate of eating.
It is likeTy that the (157.) increase in food intake following 
haloperidol could have been caused by specific presynaptic 
blockade, thereby increasing DA transmission and facilitating 
feeding. The reduction in feeding following thioridazine (127.), 
on the other hand, could have been caused by both presynaptic and 
postsynaptic DA receptor blockade, the consequence of which was 
to functionally reduce DA transmission, and cause a reduction in 
feeding.
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Thioridazine pretreatment is thought to have non-speci-fic effects 
on DA transmission at relatively low doses. Thioridazine (5, 10 
and 15 mg/kg) has been shown to be without effect at blocking 
amphetamine induced locomotor activity and stereotypy, unlike 
typical neuroleptics which produce a dose related blockade 
(Bentall and Herberg 1980). Iversen and Koob (1977) showed 
blockade of amphetamine induced locomotion with 4.0 mg/kg 
thioridazine, but were subsequently unable to replicate this 
result. Thioridazine is also known to be a potent blocker of 
central Ach receptors (Herberg et al 1980), and also of alpha- 
receptors (Jenner and Marsden 1982) at relatively low doses. 
This failure of thioridazine to reverse amphetamine-induced 
behaviours may well be accounted for by its interaction with 
preynaptic DA receptors.
Factors that were likely to contribute to the general lack of 
signficant effects of thioridazine on microstructural parameters 
on trials 2,3 and 4 are the general increase in feeding over the 
four test days, the lack of selectivity of thioridazine at pre- 
and post—synaptic sites, together with concurrent adaptive 
changes in receptor sensitivity that might take place in response 
to these factors. In conclusion, taking these factors into 
account, it is possible that thioridazine exerts its potential AD 
activity by facilitating DA transmission through presynaptic DA 
receptor blockade. However, as thioridazine only blocked 
apomorphine anorexia on day 1, it appears that the animals 
rapidly became tolerant to repeated thioridazine treatment. It 
is unlikely then that the therapeutic potential of thioridazine
rv- -i
180
; I
as an AD is mediated via presynaptic DA blockade.
6.4. GENERAL DISCUSSION
Microstructural characterization of apomorphine anorexia showed 
that it was caused primarily by reductions in both eating rate 
and eating time. In experiment 7, a non-sedative dose of 
haloperidol reversed apomorphine anorexia, by reversing the 
apomorphine-induced reduction in eating time but not eating rate. 
In experiment 8, the atypical neuroleptic thioridazine also 
reversed the effect of apomorphine on eating time, but again had 
no effect on eating rate. These results suggest that the 
reduction in eating rate following apomorphine is not mediated by 
DA receptors.
Some results from experiment 10, described more fully in the 
following chapter will be mentioned briefly here in support of 
this conclusion. Aministrati on of apomorphine into either of the 
dopamine cell body areas, nuclei A9 and AlO, reduced total food 
intake (figure 18). The reduction in food intake was more 
apparent in AlO (F(1,144)=11.31, pC.Ol) than in A9 animals 
(F(1,144)=6.41, p<.05) but in both cases the effect was brought 
about by reductions in eating time which were significant in A9 
animals (F(1,144)=8.40, p<.01, figure 180 but not in AlO 
animals. However, in contrast to the previous experiments where 
systemic apomorphine decreased eating rate, eating rate was 
sligthly increased with central administration and reached 
significance in A9 animals <F(1,144)=5.83, p<.05, figure 18B). 
The differences between the effects of central and peripheral
Mi41
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apomorphine administration are shown clearly in -figure 19. Eating 
rate is slightly increased with central administration in marked 
contrast to systemic administration (-figure 19B) . Both eating 
time and total food intake show similar effects, independent of 
the route of apomorphi^e admini stration (figures 19C and A 
respectively).
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As alpha blockers have been shown to reverse apomorphine-induced 
hypomoti1ity in mice, it would be of interest to see if the 
reduction in rate, or indeed any other microstructural parameters 
could be reversed by alpha-receptor blockade. In fact, in a 
recent study carried out in this laboratory, yohimbine was found 
to be similar to haloperidol, in reversing anorexia by reversing 
eating time but not eating rate. We are currently attempting to 
establish the neurochemical basis of the reduction of eating rate 
by apomorphine so far without success.
In conclusion, the apomorphine-induced reduction in eating time 
appears to be a robust and usable assay for pre-synaptic DA 
receptors. The next chapter presents the results of two 
experiments in which low doses of apomorphine were used to index 
presynaptic DA receptor function during chronic DMI treatment.
i I •
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CHAPTER SEVEN
ASSAYING PRESYNAPIIQ DOPAMINE RECEPIQRS DURING CHRONIC DMI
IREAIMENI
7.1. INTRODUCTION
In support of a DA hypothesis of depression, that depression 
arises from a lowering of DA transmission at certain functionally 
important synapses in the brain, are the findings that chronic 
TAD treatments increase DA transmission (e.g. Modigh 1975). A 
mechanism by which ADs could increase DA transmission is by 
inducing autoreceptor subsensitivity, to disinhibit DA neurons. 
The evidence in support of this hypothesis is controversial (see 
chapter 1, section 1.8.2.).
Serra et al (1979) first reported evidence for autoreceptor 
subsensitivity in that chronic treatment with imipramine, 
amitriptyline and mianserin counteracted or reversed the effect 
of small doses of apomorphine on motor activity and potentiated 
the central stimulant response to larger doses of apomorphine. 
Changes in apomorphine responses were seen after 10 but not 2 
days of imipramine treatment and persisted up to 4 days of 
imipramine withdrawal. This effect was subsequently confirmed 
using other AD treatments, including MAOIs and ECS (Serra et al 
1982) and also lithium (Harison-Read 1980).
Spyraki and Fibiger (1981), however, failed to confirm 
autoreceptor subsensitivity following chronic DMI treatment— a 
conclusion which is supported by at least three unpublished 
studies (Winner 1983c). It is noteworthy that Spyraki and
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Fibiger report that -following chronic DMI treatment there was a 
tendency towards a reduced effectiveness of low doses of 
apomorphine in producing hypmotility, although this did not reach 
statistical significance in their study. It may be that although 
autoreceptor subsensitivity was apparent it was not of sufficient 
magnitude to be detected by their apparatus using apomorphine- 
induced hypomotility as an assay.
The previous chapter proposed apomorphine aorexia as an assay for 
presynaptic DA receptors. More specifically it was shown that the 
aomorphine reduction in eating time was mediated by presynaptic 
DA receptors. The present experiments investigated the effects of 
chronic DMI treatment on apomorphine anorexia.
7. EXPERIMENI ?1 ASSAYING PRESYNAPIIC DOPAMINE RECEPIQRS 
DURING CHRONIC DMI IREAIMENI USING SYSIEMIC APOMORPHINE
This experiment attempted to assay the sensitivity of presynaptic 
DA receptors by means of the anorexic response to a low dose of 
apomorphine (0.06 mg/kg).
‘ .Si
7.2.1. METHOD 
Subj ects
Twenty—four male hooded rats <350—420g)(OleCp Bicester) were 
individually housed and maintained on 21 hour food deprivation, 
with water available ad libitum.
n\
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Drugs and Procedure
Animals were trained to -feed by pressing the door o-f the pellet 
dispenser in one o-f six identical operant chambers as outlined in 
chapter 3, experiment 1. Ten-minute daily sessions were run 
until all animals attained asymptotic performance. Animals were 
then assigned to one of two matched groups (n—12), either 
receiving DMI (7.5 mg/kg i.p.) or saline treatment for 32 
consecwLtive days. Testing was carried out between 10.00 and 
14.00 h. The animals had free access to food from 14.00 to 17.00 
h and DMI was administered between 17.00 and 18.00 h.
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On each test day, all animals received apomorphine s.c. (0.05 
mg/kg; Sigma) ten minutes before the commencement of the test 
session. Vehicle injections (0.057. ascorbate) were given on the 
day before and the day after each apomorphine treatment. Thus the 
experiment consisted of successive groups of 3 test days. On the 
intervening days, animals were run in the apparatus for ten 
minutes. Animals were tested with apomorphine at six day
intervals during drug treatment and at 3 day intervals during 10 
days of withdrawal. Apomorphine was dissolved in 0.057. ascorbate 
to prevent rapid oxidisation of the drug, and DMI was dissolved 
in distilled water. All injections were made at a volume of 1 
ml/kg. Analysis of microstructural parameters of feeding were 
carried out as described in chapter 3, experiment 1.
An initial analysis of variance was carried out on all data 
derived from vehicle injections on days before and after the I '
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apomorphine probe days. These analyses showed that there was no 
significant difference between DMI and control pretreatment 
either on total food intake (F (1,22) = 0.20, p>.05) or on any
other microstructural parameter. Having established there was no 
differential effect of DMI on control treatments data were 
transformed into suppression scores according to the formula:
day before + day after__________ - apomorphine day
2
These suppression scores were then subjected to analysis of 
variance, supplemented by tests of simple main effects.
I r
7.2.2. RESULTS
As observed in previous experiments (e.g. experiment 7), 
apomorphine anorexia (figure 20A) was characterized by a decrease 
in both eating rate (figure 20B) and eating time (figure 200. 
DMI pretreatment had no significant effects on the apomorphine- 
induced decreases in eating rate (figure 20B). However the change 
in eating time was significantly enhanced (F (1,198) = 8.09,
pC.Ol) by acute (2 days) DMI pretreatment (figure 200, causing 
an enhanced anorexic effect (F (1,198) = 9.26, p<.01, figure
20A). Subsequently, during chronic DMI treatment, the effect was 
reversed: significant attenuation of the decrease in eating time
was observed on days 8 and 26 of DMI and day 7 of withdrawal (F 
(1,198) = 4.58, 5.55 and 5.94 respectively, p<.05, figure 200,
though not on the other test days.
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7.2.2. DISCUSSION
Acute pretreatment with DMI significantly enhanced apomorphine 
anorexia, probably by stimulating presynaptic DA receptors to 
reduce DA transmission. This initial increase in stimulation of 
autoreceptors was associated with an enhancement of the
apomorphine-induced decrease in eating time. It is the reversal 
of this acute effect of DMI on eating time, which becomes 
apparent during chronic treatment, that provides evidence for 
autoreceptor desensitization. This result extends previous
accounts of autoreceptor desensitization (Serra et al 1979, 
Chiodo and Antelman 1980), in that the effect was demonstrated 
during maintained DMI treatment, not simply during withdrawal, 
and furthermore that the desensitization may be related to an 
initial increase in stimulation of presynaptic DA receptors.
It is difficult to explain why the attenuation of the decrease xn 
eating time was observed only on days 8 and 26 of DMI and on day 
7 of withdrawal. On the remaining test days, (with the exception 
of day 2 which showed an enhancement of the effects of 
apomorphine on eating time), there were no significant results. 
However, there were some differences between control and DMI 
pretreated animals both within and between apomorphine probe 
days. The configuration of results between apomorphine probe days 
conformed approximately to a sinusoidal function. This 
configuration of results is consistent with control theory 
(Bayliss 1966). Control theory would account for these results in
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terms o-f homeostatic compensatory deviations. Such deviations are 
claimed to allow a system to obtain an optimal state or set 
point, by allowing the system to search around the set point. In 
other words, DA systems might be searching through extremes of 
synaptic function to obtain autoreceptor subsensitivity. It 
should be noted, however, that these fluctuations in results 
between apomorphine probe days were not apparent when apomorphine 
was administered intracranial 1 y (see figure 220.
In summary, this experiment has produced results which provide 
some evidence for the hypothesis that chronic DMI treatment 
induces autoreceptor subsensitivity at DA synapses, and by so 
doing, enhances dopaminergic transmission.
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It is possible that there could be clearer results with central 
administration of apomorphine as each DA system can be 
manipulated independently from the other. The next experiment 
examined the relative contributions of the nigrostriatal and 
mesolimbic pathways to DMI-induced autoreceptor subsensitivity.
* T3
I 1
,i3)
194
-■ oy
A
w
7.3. EXPERIMENI lOi ASSAYING PRESYNAPIIC DOPAMINE RECEPIQRS
DURING CHRONIC DMI IREAIMENI USING CENTRAL APOMORPHINE 
ADMINIilRAIION
7.3.1. INIRQDyCIION
The dose-dependent pattern o-f behavioural e-f-fects produced by DA 
agonists such as apomorphine is well documented: moderate doses
produce locomotor hyperactivity, whilst higher doses produce 
stereoyped behaviour (e.g. Kelly et al 1975). It is now
generally accepted that the locomotor stimulant e-f-fect o-F 
moderate doses is mediated by the mesolimbic DA system, whilst
the stereotyped behaviour seen at higher doses is mediated by the
nigrostriatal system (e.g. Makanjuola et al 1982). Changes seen 
in locomotor activity and stereotypy following AD treatment have
therefore been used to index DA transmission in the mesolimbic
and nigrostriatal pathways.
Following chronic, but not acute AD treatment, behaviours 
elicited by moderate doses of DA receptor agonists are enhanced, 
indicating increased responsiveness in the mesolimbic system 
(e.g. Spyraki and Fibiger 1981; Willner 19830. These results are 
also open to the interpretation that increases in postsynaptic 
responsiveness reflect the absence of the sedative component of 
stimulant drug action, as a result of AD-induced autoreceptor 
subsensitivity, rather than an increase in postsynaptic 
responsiveness. This possibility has been ruled out in the case 
of ECS , in that enhancement by repeated ECS of the stimulant
effect of DA was seen when DA was injected directly into the
195
1nucleus accumbens (Heal et al 1978). In addition, when reserpine 
IS given at a dose to selectively abolish presynaptic DA 
activity, the locomotor stimulant e-ftect of apomorphine was still 
enhanced by repeated ECS treatment (Modigh 1979). However, it is 
still possible that ADs might increase DA -function primarily by 
the mechanism of autoreceptor subsensitivity.
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The effects of repeated AD treatments on the nigrostriatal system 
are less clear. Some studies have shown increases in apomorphine 
and amphetamine-induced stereotyped behaviour following chronic 
treatment with a variety of AD (e.g. Wiliner. Towel 1 and 
Montgomery 1984), but others have failed to show this effect 
(e.g. Delina-Stula et al 1979). However, difference in 
methodologies employed by these studies, such as different rating 
scales and drug doses, may account for some of these 
discrepancies (see Willner 1983b for a fuller discussion). There 
is at least some evidence which points to an increase in 
nigrostriatal responsiveness similar to that observed in the 
mesolimbic system following chronic AD treatment.
The purpose of this experiment was to evaluate the contribution 
of autoreceptor subsensitivity to changes in the responsiveness 
of nigrostriatal and mesolimbic DA systems during chronic DMI 
treatment.
o
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7.3.2. METHOD
Subj ects
A group of 28 Lister hooded rats (Olac, Bicester, Oxon), weighing
196
.fv-. approximately 300g at the time o-f surgery, were housed 
inividually under conditions of controlled temperature and 
humidity, on a 12 hour light-dark cycle (09.00h to 21.00h light). 
Animals were maintained on 17-21 h food deprivation, and fed with 
standard laboratory diet (Dixon, Ware, Herts) from 14.00h to 
17.00h daily. Water was freely available at all times.
Drugs and Procedure
The animals were trained to feed by pressing the door of the 
pellet dispenser in one of six identical operant chambers, as 
described in experiment 1. Ten minute daily sessions were run 
until all animals reached asymptotic performance. Animals were 
divided in to 2 matched groups. Cannulae aimed at either nucleus 
A9 or AlO were implanted bilaterally under pentobarbital 
anaesthesia. The coordinates, chosen according to the atlas of 
Pellegrino and Cushman (1967), were anterior +2.7mm, depth -3.3mm 
and lateral + or -2.5 for nucleus A9, and anterior +2.9mm, depth 
-3.4mm and lateral + or -1.2mm for nucleus AlO. At the end of the 
experiment, animals were perfused with buffered formalin under 
sodium pentobarbital (100 mg/kg i.p.) and their brains were 
rapidly removed and stored in 107. formalin for approximately 10 
weeks. Frozen lOOum sections were stained with fast cresyl violet 
and cannula placement was verified histologically. Cannulae were 
confirmed to be in the vicinity of either nucleus A9 or AlO (see 
figure 21).The cannulae were of 26-gauge stainless steel (Arnold 
and Horwell, London); injections through them were made using a 
microsyringe with a 33-gauge needle (O.A. Howe, London). Details
197
0+ the micro-cannula system and surgery are given in chapter u, 
experiment 5. Following surgery, animals returned to training 
sessions in the operant chambers until asymptotic performance was 
once again reached. The A9 and AlO groups were further 
subdivided into 2 matched groups .
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DMI (7.5 mg/kg i.p., Geigy) was administered at 17.00h each day 
for 21 consequetive days to one of the A9 groups, whilst its 
vehicle (distilled water) was administered to the other. The 
same treatments were administered to the AlO animals. On test 
days, animals received apomorphine hydochloride (7.24nM i.c., 
Sigma) or its vehicle (0.05‘/. ascorbate) directly before the start 
of the session. Apomorphine was dissolved in 0.057. ascobate 
solution and made up to volume with phosphate buffer, whilst DMI 
was dissolved in distilled water. Drug solutions were prepared 
fresh daily. Control injections consisted of vehicle solutions, 
administered i.c. for ascorbate and i.p. for distilled water. 
All i.p. injections were at a volume of 1 ml/kg, whilst i.c. 
injections were at a volume of 0.44 ul.
Apomorphine was administered on days 4, 7, 13 and 20 of DMI 
treatment, and on days 3 and 6 after withdrawal; control 
injections were given on the day before and the day after 
apomorphine probes. On test days, sessions lasted 30 minutes, 
□n the intervening days (see table 9), a ten minute session was 
run, with no central drug treatments. Microstructural analysis 
of feeding was carried out as described in chapter 3. Results 
were analysed by a 4-way analysis of variance, supplemented by
198
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7.3.3. RESULTS
Like systemic apomorphine, administration o-F central apomorphine 
significantly reduced food intake. On the first apomorphine probe 
day (day 4) apomorphine anorexia was more apparent in AlO than A9 
animals (F(1,144)=11.31 and 6.41, p<.01, p<.05 respectively,
figure 22A). As noted in section 6.4., these effects of 
apomorphine were brought about by reductions in eating time, but 
not in eating rate. The apomorphine-induced reduction in eating 
time, was significant in A9 animals <F(1,144)=8.40, p<.01,
figure 220, but failed to reach significance in AlO animals. In 
contrast to the results with systemic administration of
apomorphine, eating rate was actually increased by the
administration of apomorphine into nucleus A9 (F(1,144)=5.83, 
p<.05, figure 22B) and unchanged in nucleus AlO (F(1,144)=0.59,
p>.05, figue 220.
Taking the results over all six test days, apomorphine anorexia 
was greater with AlO infusions (F (1,24) = 9.96, p^.Ol, figure 
22A) and again was characterized by decreases in eating time 
(F(l, 124)=36.93, p< . 001, f i gure 220.
DMI pretreatment enhanced apomorphine anorexia on day 4 (the 
first probe day) in both A9 and AlO animals (F(1 ,144)*7.52 and 
10.09 respectively, p<.01, figure 22A). This effect was 
maintained until day 7 in AlO animals (F(l,144) 6.66, p<.05,
figure 22A). Sub-acute DMI pretreatment in AlO animals, 
enhanced the apomorphine-induced reduction in eating time
i. ^
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( F ( l ,  144)=B.40, p<-01, figure 220. No other significant changes
in microstructural parameters were seen following sub-acute DMI 
pretreatment. The effects of chronic DMI treatment were minimal! 
a reduction in eating time was seen on day 20 of treatment in A9 
animals (F (1, 144) =7.49, p<.01, figure 220. In AlO animals
however, an enhancement in the apomorphine increase in gap length 
was seen on day 7 of DMI treatment (F(1,144)=17.06, p<.001,
results not shown), an effect which was reversed on day 20 of DMI 
treatment ( F (1,144)=4.42, pC.OS, results not shown).
During withdrawal from DMI in AlO animals only, apomorphine 
anorexia, and the apomorphine-induced suppression of eating time 
were attenuated in contrast to the (non-significant) enhancement 
of these parameters during the course of chronic DMI treatment 
(figures 22A and 22C respectively). A separate analysis of 
variance was carried out comparing the last apomorphine probe day 
during DMI treatment with the first probe of withdrawal from DMI 
in AlO animals. The apomorphine-induced reduction in food intake 
was now shown to be significantly attenuated following withdrawal 
from DMI (F(1,24)=7.80, p<.05, figure22A); this effect did not
quite r^ ach statistical significance in eating time (F(1,24)=4.Oj , 
p>.05, figure22C). In addition, in the second withdrawal probe, 
the apomorphine-induced suppression of eating time was almost 
totally abolished. This effect did not reach statistical 
significance in the main analysis of variance but was clearly 
significant on a Mann—Whitney U—test (n—7, U=4, p<.01).
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7.3.4. DISCUSSION
Like the previous experiment, acute pretreatment with DMI 
significantly enhanced apomorphine anorexia, in both A9 and AlO 
animals, probably by stimulating presynaptic DA receptors. In the 
case of AlO animals, this initial increase in stimulation of 
autoreceptors was associated with an enhancement of the 
apomorphine-induced decrease in eating time. The apomorphine- 
induced decrease in eating time has been shown to be reversed by 
DA antagonists (see chapter 6) and can therefore be used as an 
index of presynaptic DA receptor function. The initial increase 
in stimulation in A9 animals is more difficult to characterize as 
no significant effects were seen on day 4 of treatment in any of 
the microstructural parameters.
As no reversal of the acute enhancing effects of DMI were seen 
over chronic treatment, it would appear that there is no evidence 
for autorecetor desensitization. However, a closer examination 
of the results from AlO animals showed that during withdrawal 
from DMI there was an attenuation of apomorphine anorexia and the 
aomorphine-induced decrease in eating time. These effects during 
withdrawal from DMI did not reach significance in the main 
analysis but were confirmed statistically, in a more selective 
analysis of the chronic component of the experiment.
The result that AlO animals seem to be preferential1y affected by 
apomorphine in comparison to A9 animals, can possibly 
explained by the function of the striato-nigral feedback loop 
which provides an inhibitory homeostatic influence on A9 neurons.
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It IS quite possible that the behavioural consequence o-f 
autoreceptor stimulation could be masked in the nigrostriatal 
system, but not in the mesolimbic system.
In summary, no clear evidence tor autoreceptor subsensitivity 
during DMI treatment was found in either the A9 or AlO DA 
systems. However, during withdrawal from DMI, apomorphine 
anorexia and the apomorphine-induced decrease in eating time were 
both attenuated in AlO animals. This provides some indication for 
autoreceptor subsensitivity in the mesolimbic system during 
withdrawal from DMI.
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7.4. GENERAL DISCUSSION
As in the previous experiments o+ chapter 6, confirmation of a 
non-dopaminergic mediation of the effects of apomorphine on 
eating rate was given by both the peripheral and central 
experiments. In the case of the peripheral experiment, the
apomorphine-induced reduction in eating rate was unaffected by 
DMI. In the case of the central experiment, not only did Dtll
fail to interact with apomorphine on this measure, but
apomorphine failed to lower eating rate. This result is strong 
evidence for a non-dopaminergic mediation of the apomorphine- 
induced reduction in eating rate.
Apomorphine administered both peripherally and centrally caused 
an anorexia that was enhanced by acute DMI pretreatment. As 
apomorphine anorexia has been sliown to be mediated by 
autoreceptors, the mechanism underlying this initial enhancement
i.
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o-F apomorphine anorexia was probably a stimulation o-f DA 
autoreceptors. In both experiments, the microstructural
parameter which primarily mediated autoreceptor subsensitivity 
appeared to be eating time, and was shown by the attenuation of 
the apomorphine-induced decrease in this measure. Evidence that 
chronic DMI treatment caused a subsensitivity of DA autoreceptors 
was sometimes seen in the peripheral experiment, and seen even 
less in the central experiment.
A passible explanation o-f the inconsistent results in. the 
peripheral experiment is the development of postsynaptic 
supersensitivity, as 0.06 mg/kg apomorphine might have a
postsynaptic action in addition to its presynaptic action. As, in 
this model, pre and postsynaptic ef-fects work in the same 
direction, (i.e. they decrease -feeding), a postsynaptic
supersensitivity could mask presynaptic subsensitivity. To 
investigate this possibility, a replication of the peripheral 
experiment was carried out using a lower dose of apomorphine 
(0.03 mg/kg). The results of this experiment are not presented in 
full, as they were essentially the same as the experiment using 
0.06 mg/kg apomorphine- there was an enhancement of the effects 
of apomorphine on food intake and eating time by acute DMI, 
however, there were no clear interactions thereafter. These 
results suggest that 0.06mg/kg apomorphine has a primarily 
presynaptic action. The conclusions of the peripheral experiment 
using 0.06mg/kg apomorphine therefore appear to be valid.
i
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The central experiment did not produce results consistent with 
the hypothesis of DMI induced autoreceptor subsensitivity. 
However, on withdrawal from DMI, there was a tendency for DMI to 
attenuate the apomorphine-induced reductions of both totals and 
time in AlO animals only. The experiments presented in this 
chapter extend all previous accounts of autoreceptor 
subsensitivity following chronic AD treatment in that testing 
was carried out throughout drug treatment and not just during 
withdrawal from DMI. In fact, according to Antelman et al (1982/, 
the development of autoreceptor subsensitivity depends simply on 
the passage of time (approximately 10 days) following acute TAD 
treatment. In light of the Antelman et al result it is therefore 
possible that autoreceptor subsensitivity could appear during 
maintained FAD treatment.
It is of interest to these experiments that Antelman and Chiodo 
(1984) have reported that immobilization stress can induce the 
same time dependent subsensitivity of A9 autoreceptors that they 
had previously reported following ECS (Chiodo and Antelman 1980, 
see section 1.8.). Given that both s.c. apomorphine injections 
and i.c. injections both involve immobilisation to some extent 
and can both be stressful to the animal, these injection 
procedures could theoretically contribute to autoreceptor
subsensitivity.
These two experiments have therefore shown that the phenomenon of 
AD-tnduced autoreceptor subsensitivity, as indexed behaviourally, 
is not a robust effect. This conclusion is consistent with both
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the biochemical, electrophysiological and behavioural literature: 
where some studies support AD-induced autoreceptor subsensitivity 
(e.g. Serra et al 1979), whilst others do not (Wi liner 1983c). I-f 
AD-induced autoreceptor subsensitivity is to be seriously 
considered as a possible mechanism o-f clinical action, it is 
clear that the exact conditions and extent to which autoreceptor 
subsensitivity occurs should be more -fully elucidated.
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CHAPTER EIGHT 
CONCLUDING DISCUSSION
8.1. SUMMARY CONCLUSIONS
The major conclusions of the present investigation may be 
summarised as follows:
(1) At low doses (0.5 mg/kg) amphetamine anorexia appears to have 
both a beta-adrenergic and dopaminergic component, whilst at 
higher doses <1.0 mg/kg) amphetamine anorexia appears only to 
have a DA mediation.
(2) The enhancement of amphetamine anorexia following acute DMI
treatment is an artefact of impaired amphetamine metabolism. In 
consequence, chronic DMI treatment does not just merely 
compensate for acute beta-receptor stimulation, but will actually 
over-compensates to reduce beta-receptor function. The
implication of this result is that central beta-receptors could 
be over-stimulated in depression.
(3) The decrease in eating time following a low dose of 
apomorphine can be used to index presynaptic DA receptor
function.
(4) There is some evidence that chronic DMI treatment induces a 
subsensitivity of preynaptic DA receptors although this effect 
was not consistently seen during treatment or withdrawal.
The implications and detailed basis of these conclusions are now
discussed.
8.2. AMPHEIAMINE ANOREXIA
A catecholaminergic mediation of amphetamine anorexia was shown 
by the results of the experiments in chapter 4. Microstructural
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analysis of amphetamine anorexia showed that suppression of food 
intake could be accounted for by a dose-dependent decrease in 
eating time (figure 50. Reductions in eating time were brought 
about by dose-dependent decreases in bout length (figure 5D) and 
an increase in gap length (figure 50. Amphetamine anorexia was 
also characterized by an increased eating rate - which could 
potentially increase food intake.
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The amphetamine-induced reductions in total food intake, eating 
time and bout length and the increase in eating rate were 
reversed by pimozide pretreatment (figures 8A, C, D and B 
respectivly). However, the amphetamine-induced increase in gap 
length, which was seen at a dose of 0.5 mg/kg, was reversed by 
propranolol pretreatment (figure 7E). These results suggest that 
both beta-adrenergic and DA mechanisms mediate amphetamine 
anorexia at low doses (0.5 mg/kg), whilst amphetamine anorexia 
at high doses (1.0 mg/kg) is mediated primarily by DA .
The above evidence, for a dose-dependent CA mediation of 
amphetamine anorexia, is consistent with some of the literature 
which shows that lesions of the VNAB attenuated amphetamine 
anorexia at low doses but not at higher doses of the drug. 
Studies employing central drug administration also confirm that 
amphetamine anotrexia is not mediated solely by DA. Injection of 
beta-adrenergic receptor blocking drugs in the region of the PFH 
attenuate the anorexic effect of peripherally and centrally 
administered amphetamine ( see chapter2, section 2.5.2.).
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These dose-dependent results o-f amphetamine are also consistent 
with Lyon and Robbings theory o-f stimulant action, which accounts 
ior amphetamine anorexia in terms of an increased intensity of 
ongoing behaviour (increased eating rate), within a decreasing 
number of response cateories (shortening of eating bouts).
8.3. NA AND DEPRESSIDN
From the evidence cited in chapter 2 and the results of 
experiment 3, it is likely that low dose (0.5 mg/kg) amphetamine 
anorexia can be used to index central beta-adrenergic receptor 
function. When low dose amphetamine anorexia was used as a 
behavioural assay to study the effects of chronic TAD treatment, 
attenuation of amphetamine anorexia was observed during 
withdrawal from DMI or iprindole, but not during the course of 
chronic treatment (Wiliner and Montgomery 1980, Wiliner, Towel 1 
and Montgomery 1984, see section 5.2.). These results suggested 
that the effects of chronic TAD treatment merely compensate for 
the acute NA-enhancing effects of the drug by inducing a beta- 
receptor subsensitivity, and by implication, does not cause a 
functional decrease in beta-receptor function. However, the 
results obtained using central administration of amphetamine 
suggest that the enhancement of amphetamine anorexia by acute 
pretreatment with DMI (and possibly with iprindole) results from 
inhibition of the peripheral metabolism of amphetamine.. If, as 
experiment 5 suggests, approximately 75V. of the enhancement of 
amphetamine anorexia following acute DMI treatment is an 
artefact of impaired amphetamine metabolism, then it follows that
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chronic DMI treatment would attenuate amphetamine anorexia during 
the course o-f chronic treatment, as well as during withdrawal. An 
attenuation oi amphetamine anorexia following chronic DMI 
treatment is supported from the finding that mianserin, which 
does not inhibit amphetamine metabolism, did attenuate 
amphetamine anorexia during the course of chronic treatment 
(Winner, Towel 1 and Montgomery 1984).
As amphetamine anorexia has been used and validated as an assay 
of beta-adrenergic receptor function, the attenuation of anorexia 
seen following chronic AD treatment is evidence of a reduction in 
beta-receptor function. However, since an alpha-adrenergic 
system stimulates feeding, and chronic AD treatment enhances 
alpha-adrenergic function, changes in amphetamine anorexia could 
represent an increase in alpha adrenergic function. The results 
of experiment 6 indeed showed indications of alpha-adrenergic 
augmentation: the attenuation in amphetamine anorexia following 
chronic mianserin treatment was partly blocked by the alpha- 
antagonist phentolamine. It is therefore possible that chronic AD 
treatment produces changes in both beta- and alpha-adrenergic 
function, a conclusion consistent with the literature (see
section 1.7.).
The evidence cited so far suggests that chronic AD drug 
treatment reduces central beta-adrenergic function. The inference 
has been made that central beta-receptors are over-stimulated in 
depression (e.g. Segal et al 1974). It might therefore be 
expected that AD which most reduce the sensitivity of beta-
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receptors would be the most potent AD clinically. However, this 
is not the case “ there is a highly significant negative 
correlation between clinical potency and beta-receptor binding 
(Winner 1984a), i.e. the more potently a drug desensitizes beta- 
receptors, the less potent it is clinically.
Some hormonal effects on beta-receptors also support the 
conclusion that beta-receptors desensitization is not responsible 
for the clinical effects of ADs (Willner 1984a). NA-stimulated 
c-AMP generation is known to be decreased by cortisol (Mobley and 
Sulser 1980) and by adrenocorticotrophic hormone (Kendall et al 
1982). If antidepressants work by normalizing supersensitive 
beta-receptors, then depression should be associated with reduced 
circulating levels of these steriod hormones. However,
depressive episodes are accompanied by abnormally elevated 
pituitary-adrenal activity (Carroll 1982) and cortisol levels 
(Carroll et al 1976), and there is a high incidence of depression 
in Cushing's disease, which is known to result from elevated 
cortisol (Kelly et al 1980). Similarly, beta-receptor 
responsiveness is lower in females than in males (Sulser and 
Mishra 1982) and is decreased by estradiol (Biegon et al 1982). 
However, depression is two to three times more frequent in women 
than in men (Weissman and Paykel 1974), and symptoms of 
depression are claimed to have been experienced by approximately 
50’/. of women taking oral contraceptives (Parry and Rush 1979).
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In summary, it is suggested that although the desensitization o-f 
cortical beta-receptors by AD supports the revised NA hypothesis 
oi depression, this phenomenon is probably not responsible -for 
the therapeutic effects of these drugs.
8.4. APOMORPHINEzANOREXIA
Low doses of apomorphine thought to be selective for presynaptic 
dopamine receptors produce a dose-dependent anorexia (see section
6 .1 .). Microstructural characterization of apomorphine anorexia 
showed that it was caused by reductions in both eating rate and 
eating time (figure 4B and C respectively). Non-sedative doses 
of haloperidol and thioridazine reversed apomorphine anorexia by 
reversing the apomorphine-induced reductions in eating time 
(figures 15C and 17C respectively). However, eating rate was
unaffected by haloperidol or thioridazine (figure 15B and 17B 
respectively). These results suggest that the reduction in 
eating rate following apomorphine is not mediated by dopamine 
receptors. This conclusion is supported by the results of 
experiment 10 in which administration of apomorphine into 
dopamine cell body areas did not reduce eating rate but did
reduce eating time.
As the changes in eating time brought about by apomorphine were 
reversed by DA-receptor antagonists at doses which did not appear 
to interact with postsynaptic receptor sites» it is conclu 
that these changes may be mediated by presynaptic dopamine 
receptors. However, the changes in eating rate brought about by
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apomorphine are not reversed by DA-receptor antagonists, and 
therefore remain to be characterized pharmacologial1y. Recent
work in our laboratory (Towel 1, Wiliner and Muscat, unpublished) 
has shown that the alpha- 2  receptor blocker yohimbine mimicked 
haloperidol in reversing eating time but not eating rate, whilst 
the serotonin blocker methergoline and the opiate antagonist 
maloxone did not interact with apomorphine on either measure.
The intercorrelations of the microstructural parameters observed 
in experiment 7 showed that the apomorphine-induced reduction in 
eating time was correlated with the reduction in total food 
intake, whereas the apomorphine-induced reduction in rate was 
not. Therefore, apomorphine anorexia and, more specifically, the 
apomorphine-induced reduction in eating time can be used to index 
presynaptic DA receptor function.
8.5. CHRONIC DMI TREAIMENI AND PRESYNAPIIC DOPAMINE RECEPIQRS 
Apomorphine anorexia was used as an assay oi presynaptic DA 
receptor function during chronic DMI treatment. Enhancement of 
apomorphine anorexia is likely to represent a stimulation of 
autoreceptors, whilst an attenuation of apomorphine anorexia is 
likely to represent a reduction in autoreceptor stimulation, 
probably through the desensitization of presynaptic DA receptors. 
With systemic administration of apomorphine acute DMI treatment 
enhanced apomorphine anorexia and the apomorphine-induced 
decrease in eating time. It is assumed that these changes in 
apomorphine anorexia result from the stimulation of 
autoreceptors, the consequence of which is a lowering DA
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transmission (see section 8.4.). Some evidence was seen of pre- 
synaptic DA receptor subsensitivity following chronic DMI 
treatment. Autoreceptor subsensitivity was shown by an
attenuation of the apomorphine-induced reduction in eating time. 
However, autoreceptor subsensitivity was not seen consistently 
throughout chronic treatment and withdrawal, but was seen only on 
days 8 and 26 of DMI treatment and on day 6 of withdrawal. No 
effects were seen on the apomorphine-induced reduction in eating 
rate throughout DMI treatment, a result consistent with this 
measure not having a presynaptic DA mediation (see section 8.4.).
When apomorphine was applied centrally to DA cell body areas, it 
produced a similar anorexia to that seen with systemic
administration. Acute pretreatment with DMI significantly
enhanced apomorphine anorexia. In the case of AlO animals, DMI- 
induced stimulation of autoreceptors was associated with an 
enhancement of the apomorphine-induced reduction in eating time. 
In A9 animals, however, no significant changes were seen in any 
of the microstructural parameters, making it difficult to 
account for the enhancement of apomorphine anorexia following 
acute DMI treatment. Following chronic DMI treatment, there was 
no significant reversal of the acute enhancing effects of DMI in 
either A9 or AlO animals. However, there appeared to be some 
tolerance towards repeated DMI treatment, and in AlO animals 
there was a tendency towards an attenuation of the apomorphine 
induced reduction in totals and eating time following withdrawal
from DMI.
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In summary, using systemic apomorphine to index presynaptic DA 
function, there is some evidence for autoreceptor subsensitivity 
following chronic DMI treatment. This result extends previous 
accounts which report autoreceptor subsensitivity during 
withdrawal only. Central administration of apomorphine yielded 
no clear evidence of autoreceptor subsensitivity during chronic 
DMI treatment. It would appear therefore that TAD-induced 
autoreceptor subsensitivity, as indexed behavioural1 y by 
apomorphine, is not a robust effect. Therefore, before 
autoreceptor subsensitivity can be considered as a potential 
mediator of AD therapy, the exact conditions under which 
autoreceptor subsensitivity occurs will have to be established.
8.6 . IHE USE OF BEHAVIOyR IQ SJUDY BRAIN SYSIEMS
Using biochemical techniques to assess the integrated functioning 
of synaptic systems is problematic as only a static component of 
the system is being measured, more often than not in vitro. 
Biochemical studies do not therefore, represent the functional 
state of a system. In contrast, electrophysiological recording 
techniques can be used to measure the functional state of a 
system. Typically, the method involves recording from an
anatomical location within a particular system. These are,
however, limitations in the use of electrophysiological recording 
techniques such as sampling biases and recording artefact. These 
limitations can be overcome to an extent, by observing changes in 
behaviour known to be mediated by receptors that input a 
particular system. It should then be possible to assess the
219
integrated and dynamic -functioning o-f the system using behaviour.
w i
The experiments in this thesis have made use o-f behaviour 
elicited by CA agonist probes to study neural mechanisms o-f 
action of antidepressant drugs. For this approach to be 
effective, it is essential to select agonist-induced behaviours 
that represent specifically and solely the synaptic mechanisms 
under investigation. For example, it is a problem if the 
behaviour under investigation is consequent on post-synaptic 
receptor stimulation (as amphetamine-induced suppression of food 
intake seems to be), because any changes in behaviour resulting 
from presynaptic receptor stimulation are liable to be masked. 
Therefore, amphetamine-induced-suppression of food intake cannot 
be used to index presynaptic receptor activity. Similarly, 
apomorphine-induced suppression of food intake at higher doses of 
the drug is a resultant of two opposing effects- an inhibitory 
presynaptic effect and an excitatory postsynaptic effect. 
Therefore, apomorphine-induced suppression of food intake at 
these higher doses cannot be used to index presynaptic function 
as, again, any presynaptic effects will be masked by postsynaptic 
effects. However, the behaviour resulting from low doses of 
apomorphine, can be used to index presynaptic activity at doses 
which are specific for presynaptic receptors and do not interact 
with postsynaptic receptors sites.
Often, however, drugs act at a multiplicity of receptor types. 
This can and does make interpretation of behavioural experiments
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Evidence suggesting that DMI-induced resistance to extinction is not 
mediated by the dorsal noradrenergic bundle
PAUL WILLNER and ANTHONY TOWELL
Psychology Department, City of London Polytechnic, Old Castle St., London El 7 NT (U.K.) 
(Accepted December 24th, 1981)
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Rats were trained to press a lever for food rewards, then given a 5 week break, followed by a single extinction ^ lon. Animals which received 14 daily desmethylimipramine (DMI) injections, ending 4 days before the extinction session, showed resistance to extinction; no effect was seen in animals which received DMI during acquisition. The opposite pattern of results would be predicted if the effect were mediated by changes in the efficacy of the dorsal noradrenergic bundle.
We have recently reported that subchronic treatment with the tricyclic antide­
pressant desmethylimipramine (D M I) induces resistance to the extinction o f learned 
behaviours. This effect has been observed in rats lever pressing or running for food 
rewards^i, and in rabbits performing a classically conditioned eyeblink response’. The 
effect was only seen during withdrawal from the drug, although other antidepressants 
may also cause resistance to extinction during maintained drug treatment^.
Resistance to  extinction is also induced by lesions to the dorsal noradrenaline 
(NA) bundles.6. Subchronic treatment with tricyclic antidepressants reduces a number 
of parameters o f noradrenergic function, notably NA synthesis« and /5-adrenergic 
receptor sensitivityL». Whilst there is some doubt as to the significance of these 
changes during continued drug treatment«, it appears likely that during withdrawal 
from tricyclics, noradrenergic transmission is functionally depressed^®. We have 
therefore suggested that DMI-induced resistance to extinction might be mediated by a 
decrease in the functional efficacy o f the dorsal bundle^^.
A test o f this hypothesis is afforded by the observation“* that the dorsal bundle 
extinction effect depends upon changes induced during acquisition: it was reported 
that the effect was only seen in animals lesioned prior to  acquisition, but not in 
animals lesioned following acquisition and before extinction. Hence, if DMI-induced 
resistance to extinction is mediated by the dorsal bundle, then the effect should be seen 
in animals treated with DM I during acquisition, but not in animals receiving DM I 
between acquisition and extinction.
0006-8993/82/0000-0000/$02.75 © Elsevier Biomedical Press
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Fig. 1. White bars, controls; hatched bars, DMI treatment during acquisition; black bars, DM1 treatment between acquisition and extinction. Values are means (+ standard error); n = 12. A: leverpresses in the reacquisition session. B: presses to criterion in extinction. C: time to criterion in extinction.
Thirty-six male Lister hooded rats (weight 250-300 g), housed in pairs and main­
tained on 2I-h food deprivation, were trained to lever press for food reward in an 
operant chamber (Campden Instruments Ltd., London). Following the attainment of 
asymptotic performance, they were maintained on continuous reinforcement (CRF) 
for 14 daily 10-min sessions. During this time, one group of animals (n =  12) received 
injections of DMI each evening (7.5 mg/kg i.p.; Geigy Pharmaceuticals Ltd., 
Macclesfield, U.K.). Following an interval of 19 days without training or injection, a 
second group (n =  12) received 14 daily DMI injections. Control injections in both 
cases were distilled water (1 ml/kg). On the third day after the final injection, all 
animals received a single 10-min CRF reacquisition session. The following day they
were allowed to make 10 reinforced presses, then extinguished to a criterion of 2 min 
with no lever presses.
The 3 groups did not differ significantly in their performance on the reacquisi- 
tion session (Fig. lA . F(2,33) =  0.2, P  >  0.25). In extinction, the group which 
receive I during acquisition were indistinguishable from controls. However, 
resistance to extinction was shown by the group treated with DM I several weeks after 
acquisition (and extinguished during withdrawal): they made more presses and took a 
onger time to reach the extinction criterion than the other groups (Fig. IB : F(l,33) =
5.5, P <  0.025 and Fig. 1C: F(l,33) =  4.4, P <  0.05).
I^ as claimed , the dorsal bundle extinction effect is only seen in animals 
esione prior to acquisition, then, contrary to our earlier hypothesis, the present 
results are not consistent with dorsal bundle mediation o f DMI-induced resistance to 
 ^possibility of a dopaminergic involvement is currently under investiga-
recep^'subsensiUvhv’hv Chanda, S. K., Development of beta-adrenergic
oifood motiva^t^ amitryptiline and mianserine (Org. GB94)concentration in the limh'  ^ trained in a runway: possible correlation with biogenic amine concentration in the limbic system, Psychopharmacohgy, 61 (1979) 143-147.
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Micro Structural Analysis o f the 
Involvem ent o f Beta-Receptors in 
Amphetamine Anorexia
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WILLNER, P. AND A. TOWELL. Microstructural analysis of the involvement of beta-receptors in amphetamine 
anorexia. PHARMAC, BIOCHEM. BEHAV. 17(2) 255-262, 1982.—Rats were trained to take food by pushing the door of the pellet dispenser in an operant chamber. Log survivor analysis of the inter-response time frequency distribution was used to determine whether or not an animal was eating, at any time during a thirty minute session. This information was used to compute eating time, eating rate, and the mean length of bouts of eating and gaps between eating bouts. Video­recordings confírmed that the method discriminated eating from not eating with an accuracy of approximately ninety percent. Amphetamine (0.5 mg/kg) significantly reduced total food intake and eating time, and increased gap length; propranolol (5 mg/kg) signifícantly increased eating time and bout length. Following propranolol pretreatment, am­phetamine significantly reduced eating time and bout length but also significantly increased eating rate; as a result there was no significant decrease in total food intake. The possible mediation of these effects by beta-adrenergic and dopaminergic systems is discussed.
Feeding Microstructural analysis Catecholamines Rats Log survivor analysis Amphetamine Propranolol
AMPHETAMINE has for many years been treated as a 
reference drug in pharmacological studies of anorexia. How­
ever, uncertainty still exists as to the mechanisms which 
mediate amphetamine anorexia. In common with many other 
actions of amphetamine the anorexic effect is attenuated by 
neuroleptic drugs, which are known to be dopamine (DA) 
receptor blocking agents [1,6, 13, 15, 16, 19, 20, 33] and by 
lesions to dopaminergic pathways in the brain [9,14,21, 26]. 
However, it was recently reported that neuroleptics were 
ineffective in blocking the anorexic effect of a low dose of 
amphetamine (0.5 mg/kg) [6], suggesting that transmitters other than DA might be involved, particularly at low doses.
Studies employing central drug administration confirm 
that amphetamine anorexia is not mediated solely by DA. 
Injection of beta-adrenergic receptor blocking drugs in the 
region of the perifomical hypothalamus also attenuated the 
anorexic effect of centrally or peripherally administered am­
phetamine [18, 19, 20, 22]; this and several other lines of 
evidence strongly support the concept of a beta-adreneiigic 
satiety system in the perifomical hypothalamus [2,8,18, 19, 
20, 22, 23, 24, 26], On the basis of these results, it would be 
expected that amphetamine anorexia should also be at­
tenuated by peripherally administered beta-blockers. 
Paradoxically, however, this does not appear to be the case. 
Preliminary studies in this laboratory failed to demonstrate 
attenuation of amphetamine anorexia by the beta-blocker 
propranolol, and with one exception [27] previous investiga­
tions have had similar results [13, 15, 17, 28],
The resolution of this paradox may lie in the observation 
that propranolol impairs the metabolism of amphetamine 
[29]. This effectively increases the dose of amphetamine, 
which would tend to mask a partial blockade of the anorexic 
effect. In the present study, this possibility was investigated 
using the technique of microstmctural analysis [31]. Previ­
ous workers have demonstrated that anorexic drugs do not 
simply reduce total food intake, but also produce charac­
teristic changes in the fine structure of behaviour—for 
example, amphetamine reduces food inintake primarily by 
reducing eating time, whilst fenfluramine acts primarily by 
slowing down the rate of eating [4,5,10,11]. It was reasoned 
that if the dopaminergic and beta-adrenergic systems control 
different parameters of feeding, then these might be differ­
entially affected by propranolol. Specifically, if any 
amphetamine-induced microstructural changes are mediated 
by beta-receptors, then such changes might be blocked by 
propranolol whilst at the same time, owing to the increase in 
amphetamine dose, microstructural changes which are 
mediated by DA receptors would be enhanced by proprano­
lol.
The sine qua non of microstructural analysis of feeding is 
knowing at any time whether a subject is eating or not. This 
is usually achieved by direct observation [4, 5, 10, 11, 12]. 
However, direct observation is extremely time consuming 
and labour intensive. We were therefore interested in devel­
oping an automated method. Such a method is available in 
the technique of log survivor analysis [30]: by inspection of
Copyright ® 1982 A N K H O  International Inc.—0091-3057/82/080255-08$03.00/0
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the frequency distribution of inter-response times, it is 
possible to establish a bout criterion for each subject; this 
criterion is then applied to decide whether a particular inter­
response interval is within or between eating bouts. This 
method has only previously been used to analyse twenty- 
four hour feeding patterns, involving thousands of responses 
[7,30]. Experiment 1 was carried out to determine whether 
log survivor analysis could also be used to analyse brief 
(thirty minute) feeding sessions. Experiment 2 describes the 
application of the technique to the interaction between pro­
pranolol and amphetamine.
EXPERIMENT 1 
METHOD
Subjects
Twelve male Lister hooded rats (weight 330-400 g) were 
housed in pairs and maintained on 21-hour food deprivation, 
with water available ad lib. The animals had had prior expe­
rience of continuously reinforced lever pressing for food re­wards.
Apparatus
An operant chamber (Campden Instruments Ltd., Lon­
don), from which the levers had been removed, was pro­
grammed to deliver a 45 mg food pellet whenever the 
perspex food tray door was pressed, subject to the constraint 
that presses spaced less than one second apart were ineffec­
tive. The house light and tray light were illuminated con­
tinuously, and the chamber was housed in a sound attenuat­
ing box with a smoked perspex viewing window. Each re­
sponse on the tray door was logged (to the nearest 0.1 sec) by 
a Cromemco Z2 microcomputer, which displayed the time 
on a visual display unit (VDU), and subsequently produced a 
listing of response times and inter-response times (IRTs), an 
IRT frequency distribution and a log survivor function (see 
below). Behaviour in the apparatus was also recorded on 
videotape, using a video camera adapted for low intensity 
li^ t. By the use of a second camera filming the VDU, and a 
video-mixer, the occurrence and time of each response on the tray door was also recorded on the film.
Procedure
Following a pretraining period in which 10-min daily ses­
sions were run until all animals achieved asymptotic per­
formance, the animals were given a single 30-min session, 
which was recorded and filmed as described. The animals 
were observed to spend long periods eating, directly facing 
the food tray and only moving to take a further food pellet. 
From the film, it was possible to identify those inter­
response intervals in which behaviours other than eating (rearing, grooming and walking) occured.
Microstructure Analysis
The IRT finequency distribution can be transformed to a survivor function, which shows the number, or the propor­
tion, of IRTs greater than any given IRT (Fig. lA). A further 
log transform produces a log survivor function (Fig. IB). The 
log survivor function typically falls off steeply, usually in a 
straight line (indicating an underlying normal distribution), 
which at the breakpoint changes sharply to a much shallower
slope. The assumption underlying log survivor analysis, and 
tested in the present experiment, is that IRTs shorter than 
the breakpoint represent responses within a continuous bout 
of feeding, whilst IRTs longer than the breakpoint represent 
gaps between feeding bouts.
Following identification of the breakpoint the following 
parameters of feeding may be calculated: (1) The number of 
bouts (B) is equal to the number of gaps (i.e. intervals longer 
than the breakpoint) plus one. (2) Eating time (T) is given by 
the total of all IRTs smaller than the breakpoint. (3) The 
length of eating bouts is given by T/B. (4) Since the time 
taken to eat the final pellet in each bout is neither known nor 
included in the calculation of eating time, the local eating 
rate is given by (N-B)7T (where N is the total number of 
responses), rather than by N/T. An eating rate of 0.1 pellets/s is equivalent to 0.27 g/min.
RESULTS AND DISCUSSION
Subjects consumed a mean of 218 pellets (9.8 g) in the 
30-minute session (range: 148-268). Inspection of the log 
survivor curve for each animal (Fig. IB) showed breakpoints 
varying from 12 to 25 sec (mean±standard error=16.8±0.9 
sec). If the IRT frequency distributions are simply summed 
across animals, without regard to the differences in break­
point, the occurrence of behaviours other than eating ap­
pears to increase almost linearly for IRTs between 10 and 30 
sec (Fig. 2). However, a very different picture is shown by 
the distribution of IRTs around the breakpoint (Fig. 3). The 
incidence of behaviours other than eating now shows a 
marked discontinuity: other behaviours were relatively rare 
(5.8±0.8% of inter-response intervals) at IRTs shorter than 
the breakpoint, and highly likely (88.4±2.6% of intervals) at IRTs longer than the breakpoint. It is clear that using the 
breakpoint to provide an eating criterion for each individual 
(Fig. 3) affords a far clearer discrimination between eating 
and not eating than would any arbitrarily chosen criterion (Fig. 2).
Estimates of eating time and local eating rate were calcu­
lated by use of the breakpoint, as described above (Table 1). 
The true values of these parameters were also calculated, by 
excluding from eating bouts the 5.8% of short inter-response 
intervals which the film showed to be false positives, and 
including the 11.6% of long intervals which were false nega­
tives. Compared with these true values, the calculated val­
ues under-estimated eating rate by 1.3 (±1.0)%, and over­
estimated eating time by 6.5 (±1.7)%. Eating rate appears to 
be a very robust measure, which is not significantly affected 
(r = 1.3, p>0.1) by the small proportion of errors. Although 
eating time is accurate to 6.5%, this figure is actually an 
over-estimate of the error, since the true eating time makes 
no allowance for the final pellet of each bout. If it is assumed 
that these pellets were consumed in the modal time of 4.5 sec 
(Fig. 2), then a further estimate of true eating time may be 
made (Table 1). This figure is higher than the calculated 
value by an insignificant 2.1 (±1.4)% (/=1.5, p>0.1). Thus 
as the effects of the two types of error to some extent cancel 
one another out, the values calculated for both eating time 
and eating rate are very close to their true values.
Estimates of the number and length of bouts were less 
accurate, with errors in excess of 40%. However, it is likely 
that a proportmn of the gaps noted on the film were wrongly 
categorized, since at very short intervals these usually con­sisted of a single rear or turn, both of which are compatible
FIG. 1. A: The frequency distribution of inter-response times for a typical subject, and the survivor transform, which shows the proportion of the frequency distribution lying to the right of each point in the frequency distribution. N is the number of responses in each Is IRT bin and p(S) is the percentage of survivors. B: Three typical log survivor functions. The uppermost curve is the log transform of the survivor function shown in A; for clarity, the other two examples are displaced down by half a log unit. The breakpoint in each curve is marked by an arrow.
with continuous eating; indeed, it was sometimes possible to 
see that an animal did continue to eat whilst moving away 
from the food dispenser. If very short gaps (<10 sec) are 
excluded from the calculation (Table 1), then the discrep­
ancy in the number and length of bouts, though still marked, 
is considerably reduced (25 and 23% respectively).
In conclusion, the method here described is clearly more 
successful than the use of arbitrary criteria, for discriminat­
ing between eating and not eating. Compared with continu­
ous observation, the method produces very accurate esti­
mates of eating rate and eating time. The method under­
estimates the number and over-estimates the length of eating 
bouts, but it does have the advantage that the bout criterion 
is unambiguous, rather than relying on the often difficult 
subjective judgement of whether an animal is eating or not. 
The error arises from the fact that the frequency of responses
decreases as IRT increases, which means that there are more 
responses to the left of the breakpoint than to the right (Fig. 
3); the error is therefore relatively constant between sub­
jects. As will be shown below, results obtained using the 
present method were consistent with those obtained by pre­
vious authors using conventional observational methods (Note 1 and Refs. [4, 5, 10, 11, 12]).
EXPERIMENT 2
The doses of amphetamine and propranolol used in the 
present experiment were chosen on the basis of the following 
considerations:
(1) We have found that whilst log survivor analysis produces reliable estimates of microstructural parameters
a
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FIG. 2. The frequency distribution of IRTs (mean of all subjects), the distribution of those inter-response intervals in which be­haviours other than eating were observed, and the latter as a pro­portion of the total. For clarity, the percentage scale has been dis­placed upwards.
vivor analysis (see text), and the frequency distribution of inter­response times plotted for 12 seconds either side of the breakpoint. The figure shows the IRT frequency distribution (mean of all animals), the distribution of those inter-response intervals in which behaviours other than eating were observed, and the latter as a proportion of the total. For clarity, the percentage scale has been displaced upwards.
TABLE 1
COMPARISON OF MICROSTRUCTURAL PARAMETERS DERIVED FROM DIRECT OBSERVATION AND FROMLOG SURVIVOR ANALYSIS
Eating Rate (pellets/sec) Eating Time (sec) Number of Bouts Bout Length (sec)
Calculated 0.162 (±0.007) 1289 (±70) 12.3 (±1.3) 128 (±21)
True Error % 0.164 (±0.007) -1.3 (±1.0) 1205 (±55) 6.5 (±1.7) 23.1 (±1.8) -43.7 (±6.3) 62 (±6) 41.0 (±7.4)
Adjusted Error % 1308 (±55) -2.1 (±1.4) 16.9 (±1.3) -25.0 (±6.6) 83 (±7) 22.9 (±7.7)
»..vivsuuviuia. poioiiicicis were cHicuiaieo usmg me Dout criterion denved from log survivor analysis (see text). True values were obtained by direct observation. The adjusted values add 4.5 sec per bout to true eating tuM, and exclude gaps of less than 10 sec when counting the number of bouts. The percental error terms refer to calculated values in relation to true/adjusted values. All values are means (±SE)
when animals are making hundreds of responses, it becomes 
difficult to identify the breakpoint when the number of re­
sponses is small. It is therefore necessary to use a low dose 
of amphetamine which produces a relatively small anorectic 
effect; we chose a dose of 0.5 mg/kg, which in a previous study [32] produced an anorectic effect of roughly 30%.
(2) The dose of propranolol should be as high as possible, 
but should not itself produce an anorectic effect, since that 
woidd unduly complicate interpretation of the results. In 
preliminary studies, we found that a small (20%) but signifi­
cant anorectic effect was produced by 10 mg/kg propranolol; 
a dose of 5 mg/kg was therefore chosen for the present study.
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METHOD
Twenty-four male Lister hooded rats (weight 360-430 g) 
were trained to feed by pressing the door of the pellet dis­
penser in one of three identical operant chambers, as de­
scribed above. Ten-minute daily sessions were run until all 
animals attained asymptotic performance. On experimental 
days, the animals received two intraperitoneal ejections: 
propranolol HCl (5 mg/kg) (Sigma) was administered 60 min 
before the start of the session and d-amphetamine sulphate 
(0.5 mg/kg) (Smith, Kline and French) 30 min before. Control 
injections in both cases were distilled water (1 ml/kg). During 
experimental sessions, which were 30 min long, a computer 
recorded each response on the tray door, as described 
above. Each animal received all four treatment combinations 
in a counterbalanced order, at two-day intervals. On the in­
tervening days, a 10-min session was run, with no drug 
treatments. Analysis of microstructural parameters of feed­
ing was carried out as described above. Results were 
analysed by analysis of variance, supplemented by tests of 
simple main effects. The mean breakpoint in the four condi­
tions varied between 16.8 and 18.3 sec; the differences were 
not significant (all F-ratios <1).
RESULTS
Amphetamine caused a small (13%) but highly significant 
(p<0.001) decrease in food intake (Fig. 4A), which was ap­
parently blocked by propranolol pretreatment (interaction: 
F(l,23)=3.2, 0.05<p<0.1). However, this conclusion would 
be seriously misleading. Total food intake may be broken 
down into eating rate and eating time (Figs. 4B and C), and 
propranolol actually increased the amphetamine-induced 
changes in both these parameters: eating rate was only very 
slightly increased by amphetamine alone, but a substantial 
increase was seen following propranolol pretreatment; eating 
time was decreased by amphietamine, and this effect was also 
somewhat greater foUowing propranolol pretreatment. It is 
the combination of decreased eating time and increased eat­
ing rate, following propranolol pretreatment, which results in no signfficant net change in total intake.
A description of the distribution of behaviour within the 
session is given by the mean length of feeding bouts, the 
mean length of gaps between bouts, and the initial latency; 
these three parameters determine the total feeding time. 
Amphetamine did not significantly decrease bout length (Fig. 4D), but did significantly increase the length of gaps (Fig. 
4E). Propranolol treatment blocked this effect (Fig. 4E). 
There were smaUer, but insignificant effects on latency (Fig. 
4F) (see Note 1).
Ftopranolol significantly increased bout length (Fig. 4D); 
this effect led to an increase in eating time (Fig. 4C), and is 
reflected in an increase in bout size (Fig. 4G), and a decrease 
in tlte number of bouts (Fig. 4H). As was the case for eating 
rate, propranolol increased the effect of amphetamine on 
bout length (Fig. 4D), bout size (Fig. 4G) and the number of 
bouts (Fig. 4H): on each of these measures, significant ef­
fects of amphetamine were seen following propranolol pre­
treatment, but amphetamine alone produced small and in­
significant effects.In both pretreatment conditions, the effect of am­
phetamine on eating time was significantly correlated with 
the change in total food intake; after propranolol pretreat- 
ment, there was also a significant negative correlation be­
tween the decrease in food intake and the increase in eating 
rate (Table 2). In both conditions, a significant correlation
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FIG. 4. Effect of amphetamine and propranolol on microstructural parameters. A: Total food intake; B: Local eating rate; C: Eating time; D: Bout length; E: Gap length; F: Latency; G: Bout size; H: Number of bouts. Circles show the scores in each condition: Left— control, right—amphetamine; white—control, black—propranolol. Bars show the difference brou^ t about by amphetamine (mean + standard error): white—control, black—propranolol pretreatment. One star—p<0.05; two stars—p<0.01; three stars—p<0.001.
was seen between the increase in eating rate and the de­crease in bout l e n ^  (even though in the control condition 
there was no significant net change in either). However, 
changes in these parameters were uncorrelated (in one case, 
there was a significant negative correlation) with increases in 
gap length. In the control condition only, changes in gap 
length were significantly correlated with changes in total food intake.
GENERAL DISCUSSION
The apparent outcome of Experiment 2 was an attenua­
tion of amphetamine anorexia by propranolol. However, it is clear from the microstructural analysis that this result is 
laigely fortuitous, since propranolol, amphetamine and the 
propranolol-amphetamine combination each produced a dif­
ferent pattern of behavioural changes. The results reveal the 
wealth of information which is lost by restricting studies of 
feeding to measures of total food intidie. The generality of 
the following discussion must obviously be qualified by the 
fact that only a single dose of each drug was tested. How­
ever, in view of the complexity of the behavioural data, it
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TABLE 2
INTERCORRELATIONS BETWEEN AMPHETAMINE-INDUCED CHANGES IN MICROSTRUCTURAL PARAMETERS
Total i Rate t Time i
Bout Length i GapLength t
Total i -.28 .46* .24 .47*
Rale t -.45* .63t .45* -.08
Time 1 .50+ .46* .80+ .12
Bout length i .35* .40* .81+Gap length | .09 -.18 -.12 -.44*
The table shows correlations (Spearman rank-order correlation coefficients) between the changes induced by amphetamine in different microstructural pa­rameters. *p<0 05; tp<0.01. The upper part of the table shows values obtained in control conditions; and the lower part shows values obtained following proprano­lol pretreatment. Arrows show the direction of change; italicized parameters were those in which significant net changes were seen.
might be noted in passing that a similar criticism could be 
levelled at the more standard design, in which a range of drug 
doses are tested against the single dependent variable, total 
food intake.
Propranolol did not affect eating rate, but increased bout 
length, and consequently, bout size and eating time. Whilst 
these effects did not cause a significant increase in food in­
take, it is clear that appropriate testing circumstances might reveal hyperphagia, and this has, in fact, been observed (see 
Note 2). This result is consistent with the finding that hyper­
phagia was caused by lesions to adrenergic systems innervat­ing the perifomical hypothalamus [2, 20, 21], and with the 
concept of a beta-adrenergic satiety system.
It has been previously reported that the anorexic effect of 
a low dose of amphetamine (0.25 mg/kg) was caused by a 
selective effect on eating time with no change in eating rate 
[II]. The present study confirmed this observation; it was 
also found that the decrease in eating time was brought about 
primarily by an increase in the length of gaps, with no signifi­
cant change in the length of eating bouts.
In contrast to the effect of amphetamine alone, after pro­
pranolol pretreatment, ^ p  length was the only parameter 
(other than latency) which was not significantly altered by 
amphetamine. The animals showed, on the one hand, a dif­
ferent hypophagic effect (decreased bout length), and on the 
other, a hyperphagic effect (increased eating rate). As a re­
sult, there was no significant net change in food intake. Since 
the interaction of propranolol with amphetamine produces 
such contradictory effects, it is clear that, depending on the 
dose and specific experimental conditions, the outcome 
might be a decrease in the efficacy of amphetamine (the 
present study and ref. [27]), no change [13,15,17], or even an 
increase [13, 15, 28]. It is important, however, not to lose 
sight of the fact that in the present study, propranolol did 
block the effect underlying amphetamine anorexia, and also 
blocked the correlation between changes in gap length and changes in total food intake.
The starting point for the interpretation of these results is the observation that propranolol interferes with the metabo­
lism of amphetamine [29]. To what extent may the effects of 
proprarralol be understood as simply an increase in the dose
of amphetamine? In this study, only a single dose of am­
phetamine, 0.5 mg/kg was tested. However, it is well estab­
lished that amphetamine at 1 mg/kg significantly increases 
eating rate and decreases eating time [3, 4, 5, II, 12]. It has 
also been reported (or it is possible to calculate from pub­
lished figures) that bout length and bout size were decreased 
by amphetamine [4,5]. Data on the length of gaps have not 
previously been reported, but from published figures it is 
possible to calculate that amphetamine caused a substantial 
increase in gap length (see Note 3). The effects of proprano­
lol are therefore consistent with a functional increase in the 
dose of amphetamine, with one exception: gap length. Pro­
pranolol blocked the effect of amphetamine on gap length, 
where an increase would be predicted from an increase in 
dose.
Not only was gap length the only parameter which was 
significantly altered by amphetamine alone, but also, this 
was the one parameter which was not significantly intercor- 
related with all the others. The results therefore suggest the 
involvement of two separate mediating systems. At low 
doses, amphetamine induces anorexia by increasing gap 
length (i.e. reducing the tendency to begin eating), and at 
higher doses (assumed to result from propranolol pretreat­
ment), a number of other mechanisms come into play. The 
anorexic effect of the low dose appears to be mediated by 
beta-receptors, since the increase in gap length was blocked 
by propranolol. The other effects appear to be dopa- 
minergically mediated, since it has been reported that the 
changes in eating rate, bout length and bout size are antago­
nized by DA receptor blocking drugs [5,11]. It is of great 
relevance to the present argument that gap length was the 
one feeding parameter which was unaffected by the DA re­
ceptor blocker pimozide (see Note 3).
The relationship of the observed effects to the physiolog­
ical control mechanisms for food intake is uncertain. The 
putative beta-receptor mediated effects of amphetamine and 
propranolol (decreases in the likelihood of starting and 
stopping eating, respectively), may represent direct effects 
on hunger and satiety mechanisms; the present methods are 
appropriate for further investigation of this problem. How­
ever, the putative DA-mediated effect appears less likely to
BETA-RECEPTORS IN AMPHETAMINE ANOREXIA
be a direct satiety effect. A general theory of stimulant drug 
action has proposed that the effects of amphetamine may be 
described as an increase in the intensity of ongoing be­
haviour combined with an increased tendency to change be­
haviour [25]. This model is strongly suggested by the corre­
lations observed in the present study between the 
amphetamine-induced increase in eating rate and shortening 
of bouts: increases in eating rate were significantly corre­
lated with decreases in bout length, both in the control con­
dition and also following propranolol pretreatment (Table 2). 
Thus, it may be that amphetamine has two anorexic effects, 
one genuine and the other an artefact of the stimulant effect, 
mediated respectively by beta-adrenergic and dopaminergic systems.
NOTES
Note /
In general, the microstructural parameters reported in 
this study are comparable to those of other workers. The 
exception is eating latency; values reported here are some 
10-25% of those in previous reports [4, 5, 10, 11, 12]. This 
difference might reflect the salience of the food dispenser in 
the present study, and also the subjects' long experience of 
the testing procedure. The short initial latency suggests a 
high degree of stimulus control by the food dispenser, which 
would tend to reduce disruptive drug effects.
Note 2
In most studies, propranolol reduces food intake at higher 
doses, probably by a non-specific sedative effect. In one 
study [13], however, a significant increase in food intake was 
observed at a dose of 4 mg/kg (r(l I)=3.2, p<0.01, calculated from published figures).
Note 3
From values of latency, eating time and number of bouts, 
published by Blundell and Latham [5], it is possible to calcu­
late the following figures for mean gap length: saline—76 sec; 
amphetamine—142 sec; pimozide—49 sec; pimozide -i- 
amphetamine—144 sec. In the present discussion, it is as­
sumed that bout length and gap length are the primary vari­
ables, the values of which determine the number of bouts: 
the animal decides when to start eating and when to stop, but 
cannot control the number of bouts, even if it wanted to, 
since it does not know how long the session will last.
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Amphetamine-induced anorexia and stereotjped behaviour were studied in rats, following pretreatment with the 
antidepressants DMI, inprindole and mianserin. A complex drug-dependent and dose-dependent pattern of results was 
obtained. Acute pretreatment with DMI and iprindole enhanced amphetamine anorexia and stereotypy; at high doses 
only, the enhancement of anorexia disappeared during chronic treatment. Mianserin had no effects acutely, but 
chronic treatment with high doses attenuated anorexia and enhanced stereotypy. High doses of all three drugs 
attenuated anorexia ai.d enhanced stereotypy during withdrawal. The most parsimonious account of these results is 
that the acute affects of DMI and iprindole are artefactual, and that chronic administration of all three antidepressants 
increased dopaminergic function and decreased /3-adrenergic function.
Catecholamine hypothesis of depression
Stereotyped behaviour
Dopamine
1. Introdiiction
Amphetamine
Iprindole
As originally formulated, the catecholamine hy­
pothesis of depression proposed that depression 
resulted from a deficiency of noradrenaline (NA) 
at certain functionally important synapses in the 
central nervous system, and that the action of 
antidepressant treatments was to increase nor­
adrenergic activity (Schildkraut, 1965). This view 
was based in part on the well-established observa­
tion that tricyclic antidepressant drugs enhance 
NA function, by, blocking reuptake of NA from 
the synapse. The development of two new non-tri­
cyclic antidepressant drugs challenged this con­
cept: mianserin was found to have only slight
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Desmethylimipramine
Mianserin
Noradrenaline
Anorexia
effects on NA uptake, whilst iprindole appeared to 
be almost totally ineffective (Zis and Goodwin,
1979). Subsequently, however, it was established 
that these drugs are antagonists at presynaptic 
« 2-receptors. TTiey also, therefore, enhance NA 
activity, by disinhibiting NA neurons and thereby 
increasing NA release (Baumann and Maitre, 1976; 
Hendley, 1978).
A different challenge to the catecholamine hy­
pothesis came from studies of chronic antide­
pressant treatment. It is now well-established that 
a number of parameters of NA function are re­
duced, rather than increased, by chronic antide­
pressant treatments, most notably, the sensitivity 
of postsynaptic /8-receptors (Sulser, 1978). These 
findings have led to a reformulation of the 
catecholamine hypothesis, in terms diametrically 
opposed to the original: in this view, depression is 
seen to result from hyperactivity at NA synapses, 
which is ‘downregulated’ by a n tid e p re s^ ts  (Segal 
et al., 1974; Sulser, 1978).
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When attempting to adjudicate between these 
two approaches, it is essential to know the net 
effect of antidepressants at )8-adrenergic synapses: 
since antidepressants have two opposed effects at 
NA synapses, the outcome might be an increase, a 
decrease or no change in the efficacy of the syn­
apse, depending upon which effects predonunate. 
A hypothesis concerning the mechanism of clinical 
action of antidepressants must incorporate the 
solution to this problem. However, it is clear that 
the problem cannot be solved by methods which 
assess single parameters of synaptic activity (such 
as receptor assays), but only by methods which 
assess the integrated activity of the synapse (Maas, 
1981). We have previously suggested that one ap­
proach might be to use behaviour mediated by NA 
pathways for this purpose (Willner and Mont­
gomery, 1980a, 1981; Willner et al., 1981).
Amphetamine-induced anorexia is a behaviour 
which appears to have a central noradrenergic 
component, since this effect of amphetamine is 
partially attenuated by lesions to fibres of the 
ventral NA bundle (Ahlskog, 1974; Leibowitz and 
Brown, 1980; Samanin et al., 1978). In previous 
studies, amphetamine anorexia was found to be 
enhanced by acute pretreatment with the tricylic 
antidepressant desmethylimipramine (DMI), and 
attenuated during withdrawal from chronic treat­
ment. However, during the course of chronic treat­
ment, neither enhancement nor attenuation were 
seen (Willner and Montgomery, 1980b, 1981). 
These findings suggested that during chronic DMI 
treatment, the NA-enhancing and NA-reducing 
effects of DM I exactly cancelled out. In the pre­
sent paper, this conclusion is reassessed, using a 
wider range of drugs and doses than those used 
previously.
The use of amphetamine-induced behaviours to 
test for effects of antidepressants is problematic, 
owing to the fact that a large number of antide­
pressants, including DMI and iprindole (but ex­
cluding mianserin), which were used in the present 
study, impair the metabolism of amphetamine (e.g. 
Lemberger et al., 1970). This problem does not 
arise when tests are carried out during drug 
withdrawal following a wash-out period, but makes 
interpretation of results o b ta in ^  during chronic
drug treatment extremely difficult. Nonetheless, it 
seemed important to make the attempt, in view of 
the uncertainty over the net effects of antide­
pressants at NA synapses, the clinical significance 
of this controversy, and the absence of any other 
well-established behavioural test for )8-receptor 
activation (Davis, 1982). The strategy employed 
has been to use effects observed during withdrawal 
to guide the interpretation of results obtained dur­
ing drug treatment.
We have previously suggested (Willner and 
Montgomery 1980a, 1981) that the enhancement 
of amphetamine anorexia by acute antidepressants 
does not, in fact, result significantly from a meta­
bolic interaction between the two drugs, as a result 
of the observation that DM I appeared to potenti­
ate the maximal anorexic effect of amphetamine, 
but not to prolong the effect. This conclusion 
arose from an experiment in which no anorexia 
was seen in the final 2.5 h of a 3 h feeding session 
(Willner and Montgomery, 1981, experiment 4). In 
the light of results obtained in the present study, 
this issue was also re-examined.
After the experiments reported here were com­
pleted, a paper appeared which suggested that 
amphetamine anorexia at low doses might, in fact, 
be a peripheral phenomenon, possibly mediated 
by hepatic glycogenolysis, since the effect was 
blocked by interruption of the sympathetic nervous 
innervation of the viscera (Tordoff et al., 1982). 
However, this study used undeprived animals. It is 
unlikely that a hepatic effect would contribute 
markedly to amphetamine anorexia in deprived 
animals, since liver glycogen stores run down 
within the first few hours of fasting (Tordoff, pers. 
comm.) Moreover, it is well established that the 
anorexic effect of peripherally administered 
amphetamine may be abolished by hypothalamic 
lesions, (e.g. Russek et al., 1973), by lesions of the 
ventral NA bundle (see above), or by administra­
tion of the /8-blocker propranolol to the lateral 
hypothalamus (Leibowitz, 1975). Since there is no 
evidence that peripheral effects do, in fact contrib­
ute to amphetamine anorexia in food-deprived 
animals, the observations of Tordoff et al. (1982) 
do not preclude the use of amphetamine anorexia 
as an index of central /8-receptor activation.
2. Materials and methods
2.1. Subjects
Adult, male. Lister hooded rats (Olac, Bicester, 
England), weighing 300-400 g, singly housed in 
plastic cages, and maintained on a 12-h light/dark 
cycle (light period 09:00-21:00), were used in all 
experiments. They were allowed access to a 
weighed amount of lab chow (Fisons) from 13:00 
to 16:00 daily; food was removed briefly for 
weighing at 13:30. Water was freely available at all 
times. Spillage of food appeared to be minimal; 
any spilled food which was noticed was also re­
moved and weighed.
2.2. Drugs
The following drugs were used; desmethyli­
mipramine hydrochloride (Geigy, Macclesfield, 
England); iprindole hydrochloride (Wyeth, Tap- 
low, England); mianserin hydrochloride (Beecham, 
Epsom, England); d-amphetamine sulphate (Smith, 
Kline and French, Welwyn Garden City, England). 
Drugs were dissolved in distilled water, which was 
also used for control injections; doses were calcu­
lated as the salts. All injections were 
traperitoneal, in a volume of 1 m l/kg.
in-
2.3. Procedure
Antidepressants were administered at approxi­
mately 17.00 h. In feeding studies, with the excep­
tion of experiment 8, amphetamine (0.5 m g/kg) 
was administered 30 min prior to feeding (i.e. 
19-20 h following antidepressant pretreatment). 
All food intake results refer to the first 30 min of 
the 3-h feeding session. In acute studies, animals 
received either a single antidepressant pretreat­
ment followed by amphetamine, or the antide­
pressant followed by a control injection; both 
procedures were administered, in a counter-bal­
anced order, with at least two drug-free days inter­
vening. In chronic studies, antidepressants were 
administered daily, and the anorexic effect of 
amphetamine was assessed in relation to food in­
take on the preceding day. Anorexia was measured 
as food intake (g) on the control day minus food
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intake (g) on the test day. In some experiments, 
amphetamine stereotypy was also tested: ampheta­
mine (3 m g/kg) was administered at approxi­
mately 09:30 h, and seven blind, half-hourly rat­
ings of stereotypy were made, using the 7-point 
scale of Creese and Iversen (1973), beginning 30 
min after the injection.
Amphetamine doses and experimental proce­
dures were based on those used previously (Wil­
lner and Montgomery, 1980b, 1981). Under these 
experimental conditions, 0.5 m g/kg amphetamine 
produces an anorexic effect of approximately 
30-40%, and 3 m g/kg  produces a moderate stere- 
otypy (3-4  on the Creese and Iversen scale) lasting 
1.5-2.5 h. In each case, both increases and de­
creases in the response may be readily observed.
A total of seven experiments were carried out 
using these procedures (one DMI, four iprindole, 
two mianserin). Where both acute and chronic 
studies were carried out in the same animals, the 
acute tests were run first, and at least three drug- 
free days were allowed before beginning the 
chronic study. At least two amphetamine-free days 
intervened between a stereotypy test and a subse­
quent anorexia test. Chronic treatment lasted be­
tween two and three weeks, and tests were also 
carried out for up to two weeks following 
withdrawal. Full details of numbers, doses and the 
sequence of tests are shown in table 1.
In the final experiment (table 1, Expt. 8) the 
effects of varying the time of amphetamine admin­
istration were studied. Following pretreatment 
(19.5-20.5 h) with DMI or distilled water, 
amphetamine (0.5 m g/kg) or distilled water was 
administered to three groups of animals, either 30, 
60 or 90 min before food presentation. All four 
drug combinations were presented, in a counter­
balanced order, at three-day intervals.
Anorexia scores (see above), food intake on 
anorexia control days, and the means of the series 
of seven stereotypy ratings, were subjected to two- 
way analysis of variance (with drug doses as a 
between-groups factor and amphetamine tests as a 
within-groups factor), followed, where ap­
propriate, by post-hoc t-tests; two-tailed tests were 
used throughout. We have consistently observed 
that taking the mean of a series of stereotypy 
ratings produces data which are approximately
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TABLE 1
Experimental details.
Experiment Drug n Doses(mg/kg) Days of chronic treatment
Anorexia test days ® Stereo­typy test days “
(1) DMI 10 0, 2.5, 7.5 17 A 7. 12, 17 4W, 9W, 12W A 14 6W(2) IPR 10 0, 15 - A(3) IPR 8 0, 7.5 14 7, 11, 14 4W, 7W(4) IPR 12 0, 7.5, 20 14 7, 14 4W, 6W, 8W, low(5) IPR 16 0, 15 20 14, 18 5W, 7W, IIW 20 8W(6) MIAN 12 0, 3, 10 17 A 7, 12, 17 4W, 9W, 12W A 14 6W(7) MIAN 12 0, 15 21 A 7, 12, 14, 21 5W, low, 13W A 6W(8) DMI 12 0, 7.5 _ A**
• A, acute test; W, withdrawal.Variable amphetamine pretreatment time.
normally distributed, and therefore suitable for 
parametric statistics. Four animals receiving the 
highest dose of iprindole stopped eating during 
chronic treatment, lost weight, and died; all data 
obtained from these animals were discarded. The 
results of this experiment were analyzed in two 
ways: in one analysis, data were estimated for the 
missing ammals, while in the second, four animals 
were randomly discarded from each of the other 
groups; the two methods of analysis gave similar 
results.
amine days, food intake did not change signifi­
cantly during the course of the experiments, and 
did not differ significantly between antide­
pressant-treated and untreated animals.
During the period of drug treatment, both drugs 
caused a large enhancement of amphetamine-in­
duced stereotypy; at the higher doses, this effect, 
though substantially reduced, was also seen during 
withdrawal (table 2). Additionally, at the higher
3. Results
DMI and iprindole showed similar patterns of 
results. Amphetamine anorexia was enhanced by 
acute pretreatment with both drugs. At lower do­
ses (2.5 m g/kg DMI and 7.5 m g/kg iprindole), 
the enhancement was maintained throughout 
chronic treatment, but absent during withdrawal. 
However, at higher doses (7.5 m g/kg  DMI and 
15-20 m g/kg iprindole), the enhancement of 
anorexia disappeared during chronic treatment, 
and significant attenuation of anorexia was seen 
during withdrawal (figs. 1 and 2: the results are 
expressed a little differently in the two figures 
owing to the need to combine the results of four 
separate experiments in fig. 2). Except on amphet-
Fig. 1. Effects of DMI on amphetamine anorexia (n -= 10). The period of DMI administration is shown by the bar above the figure. Stars refer to significant differences between DMI- treated and control animals.
Iprindele admlnUlration
• 7.5mg/kg 
- w -  15mg/kg 
— 20mg/kg
★  P <  0.05  ^ P<0.01
-2 i
Days 30
Fig. 2. Effects of iprindole on amphetamine anorexia. Four separate experiments were carried out; the acute (one-day) experiment (n = 10), and three chronic experiments denoted by the solid (n = 12), dashed-circles (n = 8) and dashed-triangles (n = 16) lines. In order to combine the four sets of results without loss of clarity, the results have been expressed as the difference between the anorexic effects shown by drug-pre- treated and control animals (i.e. the corresponding control mean has been subtracted from every iprindole mean). Stars refer to significant differences between iprindole-treated and control animals (i.e. significant deviations from zero). The period of iprindole administration is shown by the bar at the top of the figure. In one experiment (dashed line-triangles) there were an extra 6 days of drug treatment (not shown) prior to the first amphetamine test.
TABLE 2
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dose of DMI, chronic pretreatment caused signifi­
cantly more stereotypy than acute pretreatment; 
this comparison could not be made for iprindole, 
as no acute test was run. As previously observed 
(Willner and Montgomery, 1981), examination of 
the frequency distribution of each of the half- 
hourly stereotypy ratings did not reveal any quali­
tative differences between untreated and antide- 
pressant-pretreated animals.
A different pattern of results was seen with 
mianserin. Acute mianserin pretreatment had no 
significant effects on amphetamine anorexia, but 
at the higher doses (10 and 15 mg/kg), a signifi­
cant attenuation of anorexia developed during 
chronic treatment, and carried over into with­
drawal (fig. 3). As these results differ from those 
previously described, the results of the two experi­
ments are presented in full, rather than combining 
them into a single figure, and expressed both as 
absolute scores and difference scores, to facilitate 
comparison with fig. 1 (fig. 3, solid hnes) and fig. 2 
(fig. 3, dashed lines). Again, there were no signifi­
cant changes in food intake on control days. 
Amphetamine stereotypy did not differ signifi­
cantly between untreated and mianserin-pre- 
treated animals. However, the higher doses did
Effect of antidepressant pretreatment on amphetamine-induced stereotypy
Values are the means of 7 half-hourly stereotypy ratings. The figures above each panel refer to: length of treatment (days); day of chronic test; day of withdrawal test; number of subjects.
DMI Iprindole
See caption 17;14;6;10 20;20;8;16
Dose (mg/kg) 0 2.5 7.5 0 15
Acute 1.87 3.09" 3.83' _ _Chronic 1.8v,‘ 3.37' 4.21 2.23 3.62“Withdrawal 1.93 2.43 2.64' 1.88 3.13'
Mianserin
See caption 17;14;6;12 21;-;6;12
Dose (mg/kg) 0 3 10 0 15
Acute 1.70 1.75 1.59 2.08 1.99Chronic 1.81 1.89 1.87'’ - -Withdrawal 1.83 1.83 1.93*’ 2.29 2.56'
* Increased at P < 0.01, relative to control. ^ Increased at P < O.OS, relative to acute test. ‘ Increased at P < 0.01, relative to acute test.
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4 sRuU increase in sensitixitx to 4mf<het-
amine with repeated testing (fig. 3, upper panel). 
In general, however, no consistent changes were 
observed in untreated animals (fig. 1; fig. 3, lower 
panel; iprindole experiments not shown). Simi­
larly, no significant or consistent change was shown 
by untreated animals in their stereotypy response 
to the higher dose of amphetamine, on repeated 
testing (table 2, all four panels).
Except at the lowest dose of each antide­
pressant, chronically treated animals receiving 
DMI or iprindole lost weight relative to controls, 
and by the end of drug treatment were 10-15% 
lighter. No weight changes were seen in mianserin- 
treated animals.
When the time of amphetamine administration 
was varied (expt. 8), acute DMI pretreatment was 
found to enhance the anorexic effect significantly 
at all amphetamine pretreatment intervals. At the 
longest interxal (90 min), DMI pretreated animals 
showed a substantial anorexic effect (mean 2.1 g. 
cf. figs. 1 and 3). compared with a very slight 
anorexia (0.6 g) in untreated animals (difference: 
P<0.01).
4. Discussion
Results obtained with the higher dose of DMI 
confirm our prexious finding of attenuated am­
phetamine anorexia during DMI withdrawal 
(Willner and Montgomery. 1980b. 1981); this ob- 
ser\ativ>n is now extended to iprindole and 
mianserin. As drugs were administered on a mg kg 
basis, it is conceivable that the difference in weight 
between drug-treated and cc»nirol animals might 
accvxmt in part for the observed attenuation of 
amphetamine anorexia. We have addressed this 
question in a previous study, and shown that 
anorexia wiis attenuated during DMI withdrawal 
even after an exp^im ental manipulatioa which 
eliminated the weight differential (Willner and 
Montgomery. l')$0b. expt. 3). In the present study, 
attenuauon of anvvexia was als<' seen in mian- 
senn-ueated animals, in the absence of any signifi­
cant weight loss. Morecwer. since the attenuation 
of amphetamine anorexia is accvvropanied by an 
increased stimuLauon of kvom otce activity. (Will- 
ner and Montgomery. expt. 2) it is unlikely
that this effect results from a reduction in compet­
ing behaviours. Increased stereotypy, observed 
during withdrawal from all three drugs, has been 
previously reported by a number of authors, fol­
lowing chronic antidepressant drugs or ECT, 
though this effect has not been universally ob­
served (see Willner, 1983 for review).
The major new observations to emerge from the 
present study are the differences between low and 
high doses of DMI and iprindole, in their effects 
on amphetamine anorexia, and the attenuation of 
amphetamine anorexia which developed during the 
course of chronic mianserin administration.
A framework for interpreting the results of 
these experiments is given by the models shown in 
fig. 4. The models have two components: the acute 
components (enhancement of anorexia and stereo­
typy) are present during the period of drug admin­
istration; the chronic components (attenuation of 
anorexia and enhancement of stereotypy) develop 
slowly during chronic treatment, and persist fol­
lowing withdrawal; the combination of these two 
components results in there being no significant 
net change in anorexia and a further increase in 
stereotypy during chronic treatment. Within this
DRUG ,1------ '
Acute 
Chronic 
Net effect
Stereotypy
Fig. 4. Two-component models of the effects of antidepressants on amphetamine-induced anorexia and stereotypy. The acute components are present during the period of drug administra­tion; the chronic components develop slowly, and persist fol­lowing withdrawal.
’7 '-t
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framework, the results may be summarised as fol­
lows: high doses of DMI and iprindole show both 
components, low doses of DMI and iprindole show 
the acute components only, and high doses of 
mianserin show the chronic components only.
In the case of amphetamine stereotypy, identi­
fication of the two components is relatively 
straightforward. A number of effects of amphet­
amine are known to be enhanced by acute pre­
treatment with DMI and iprindole, but not 
mianserin (e.g. Van Riezen, 1972), and it has been 
demonstrated many times that the mechanism of 
these effects is the impairment of amphetamine 
metabolism by the liver, which effectively in­
creases the dose of amphetamine reaching the 
brain. In other words, the acute component is 
artefactual. This artefact cannot, however, explain 
the chronic component, which is shared by DMI 
and mianserin. Amphetamine stereotypy is known 
to be mediated by the dopaminergic (DA) aigro- 
striatal pathway (Kelly et al., 1975); the chronic 
component probably represents a change in DA 
function. In addition to increases in stereotyped 
behaviour, a number of other behavioural and 
physiological changes suggesting that chronic anti­
depressant treatments increase DA function have 
also been reported recently (see Willner (1983) for 
review). The present results are consistent with 
these findings, and extend them by the observation 
that in addition to the effects during withdrawal, 
increased stereotypy was also present during the 
course of chronic treatment. It is not yet clear 
whether putative antidepressant-induced increases 
in DA function represent direct effects on DA 
neurons or indirect effects, mediated perhaps by 
concomittant changes in NA (Antelman and Cag- 
giula, 1977; Green and E)eakin, 1980). There is 
considerable evidence from binding studies that 
antidepressants do not increase the sensitivity or 
number of DA receptors (Chamey et al., 1981).
In view of the fact that DA function appears to 
be increased by chronic antidepressant administra­
tion, whereas amphetamine anorexia has been 
shown to be attenuated by treatments which 
specifically reduce DA function (e.g. Burridge and 
Blundell, 1979; Leibowitz, 1975; Leibowitz and 
Rossakis, 1978; Samanin et al., 1977), it seems 
most unlikely that the chronic component of the
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anorexia model is mediated by DA. Since it is well 
established that chronic treatment with many anti­
depressants, including DMI, iprindole and mian­
serin, induces subsensitivity of central ;8-receptors 
(Sulser, 1978; Wolfe et al., 1978), it seems more 
likely that this component represents a /8- 
receptor-mediated decrease in the functional ef­
ficacy of the ventral NA bundle, although the 
possibility of a peripheral effect cannot be ex­
cluded (Tordoff et al., 1982). Amphetamine 
anorexia has been shown to be attenuated by 
lesions to the ventral NA bundle (Ahlskog, 1974; 
Garattini et al., 1978; Hoebel, 1979; Leibowitz 
and Brown, 1980; Samanin et al., 1978), and by 
peripheral (Sanghvi et al., 1978; Willner and 
Towell, 1982) and central (Leibowitz, 1975, 1978; 
Leibowitz and Rossakis, 1978) administration of 
^-blockers. An alternative hypothesis, which would 
also be compatible with the present results is that 
antidepressant-induced changes in amphetamine 
anorexia might reflect an increase in postsynaptic 
a-adrenergic function (Chamey et al., 1981; Davis, 
1982).
The acute component of the anorexia model has 
previously been taken to represent the enhance­
ment of )8-adrenergic transmission by acute anti­
depressant treatment (Willner and Montgomery, 
1981). However, two aspects of the present results 
suggest that this may not be the case. Firstly, since 
the ‘down-regulation’ of /8-receptors by antide­
pressants has been shown to be an indirect effect, 
mediated by an increase in NA levels (e.g. Wolfe 
et al., 1978), it would be expected that similarly 
sized in<j;reases in NA on acute treatment would 
result in similar chronic compensatory effects. A 
similar en)iancement of anorexia was seen at low 
and high doses of DM I and iprindole. However, 
only the high doses caused the subsequent 
amelioration and reversal of this effect. Secondly, 
although mianserin is more potent that iprindolb 
in blocking aj-receptors, and thereby enhancing 
N A  release (Baumann and Maitre, 1975), iprindole 
did enhance anorexia, whereas mianserin did not. 
An alternative hypothesis to explain the acute 
enhancement of anorexia by DM I and iprindole, 
bu t not mianserin, is that, like stereotypy, the 
enhancement of anorexia results from the meta­
bolic artefact described above. This possibility has
previously been discounted (Willner and Mont­
gomery, 1981), on the grounds that typically, the 
inhibition of amphetamine metabolism results 
primarily in a prolongation of the effects of 
amphetamine, which did not appear to be the case 
for the enhancement of anorexia. However, this 
conclusion of our previous study now appears to 
have arisen from the use of an inappropriate 
method: the results of expt. 8 show clearly that 
amphetamine anorexia was not only increased, but 
also prolonged by DM I pretreatment. The hy­
pothesis that the enhancement of amphetamine 
anorexia by acute antidepressant administration is 
primarily a metabolic artefact is supported by a 
further observation: potentiation of anorexia by 
DM I was minimal when amphetamine was applied 
directly to the perifomical hypothalamus (Towell 
and Willner, in preparation).
The most parsimonious account of the present 
results would therefore appear to be that both the 
acute components of the model shown in fig. 4 are 
artefactual, whilst the chronic components repre­
sent an increase in DA function (stereotypy) and a 
decrease in /3-adrenergic function (anorexia). If it 
is accepted that the acute effects on amphetamine- 
induced anorexia are artefactual, it may be con­
cluded that during the course of two to three 
weeks treatment at high but not low doses, DMI, 
iprindole and mianserin all reduced amphetamine 
anorexia. The results are therefore consistent with 
the hypothesis that chronic antidepressant treat­
ment may cause a net reduction in the output of 
the relevant /8-adrenergic synapses. A similar con­
clusion was reached by studies which have ad­
dressed the problem electrophysiologically, by re­
cording the activity of cells in hippocampus and 
cerebellum which receive a /8-adrenergic input 
(Bloom et al., 1979; Huang, 1979; Huang et al.,
1980). The relevance of these findings to the clini­
cal effect of antidepressants is, of course, another 
question.
Clearly, the results obtained in these experi­
ments provide very indirect and inferential evi­
dence concerning brain function, which could be 
subject to a number of alternative explanations. 
The interpretation presented here is offered as a 
parsimonious explanation, which is consistent with 
the literature. Further, more direct, insight into
whether chronic antidepressants produce a net de­
crease in /8-adrenergic function should be forth­
coming from experiments employing intracranial 
amphetamine administration, which are currently 
in progress.
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